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Summary 
Huntington’s disease (HD) is a progressive neurodegenerative disorder 
characterized by motor and psychiatric disturbances and cognitive decline, largely 
affecting the striatum. HD is a polyglutamine expansion disorder caused by a CAG 
expansion in the HTT gene, leading to the expression of mutant huntingtin (mHtt). 
Themutant protein has been linked to several pathological mechanisms, including 
transcriptional deregulation, mitochondrial dysfunction and oxidative stress, which may 
result from impaired mitochondrial function and/or imbalanced levels of antioxidants. In 
this respect, several compounds used in HD clinical trials present antioxidant activity, 
including creatine and cystamine. Also, insulin-like growth factor 1 (IGF-1) was 
previously shown to protect HD cells, whereas insulin prevented neuronal oxidative 
stress. However, the role of IGF-1/Akt pathway in HD remains controversial. 
The main objective of this thesis was to clarify the redox imbalance pathways 
following expression of full-length mHtt. We aimed to detail the changes in the 
antioxidant status, namely the glutathione redox system, and the efficacy of compounds 
with potential antioxidant activity used in clinical trials, as well as the role of insulin/IGF-
1 pathway on oxidative stress in HD. Thus, we used striatal cells derived from HD knock-
in mice expressing full-length mHtt with 111 glutamines (STHdh
Q111/Q111
; mutant cells)
versus wild-type striatal cells (STHdh
Q7/Q7
).
In the first part of this work we detailed the changes in the glutathione antioxidant 
system by determining the activity and expression of proteins involved in the regulation 
of glutathione levels in HD striatal cells. Mutant cells showed increased reactive oxygen 
species (ROS) and caspase-3 activation. Interestingly, HD cells exhibited an increase in 
intracellular levels of both reduced and oxidized glutathione (GSH, GSSG), and enhanced 
activities of glutathione-related enzymes. Nevertheless, glutamate-cysteine ligase (GCL) 
and glutathione synthetase activities and levels of GCL catalytic subunit were decreased 
in mutant cells, suggesting decreased de novo synthesis of GSH. Enhanced intracellular 
total glutathione, despite decreased synthesis, could be explained by decreased 
glutathione export in mutant cells. Concordantly, we observed decreased mRNA 
expression levels and activity of the multidrug resistance-associated protein 1 (Mrp1). 
Data suggested that full-length mHtt affects the export of glutathione by decreasing the 
expression of Mrp1. Moreover, boosting GSH-related antioxidant defence mechanisms 
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induced by full-length mHtt was apparently insufficient to counterbalance increased ROS 
formation and emergent apoptotic features in HD striatal cells. 
In the second part of the work we analysed the cellular antioxidant profile 
following hydrogen peroxide (H2O2) and staurosporine (STS) exposure, and further tested 
the protective effect of cystamine and creatine in striatal cells. Mutant cells displayed 
increased mitochondrial ROS production and decreased NADPH oxidase and xanthine 
oxidase (XO) activities, reflecting lower cytosolic superoxide anion generation, along 
with increased superoxide dismutases (SODs) and components of glutathione redox 
cycle. Exposure to H2O2 and STS enhanced ROS in mutant cells and largely increased 
XO activity. STS further boosted mitochondrial ROS and caspase-3 activity. Both stimuli 
slightly increased SOD1 activity, and decreased GRed, with a consequent rise in GSSG in 
mutant cells, whereas H2O2 only increased GPx activity. These results indicated that 
elevation of antioxidant levels accompanies mitochondrial-driven ROS generation in 
mutant striatal cells and that exposure to noxious stimuli induces a higher susceptibility to 
oxidative stress by increasing XO activity and lowering the antioxidant response. 
Additionally, creatine and cystamine increased mutant cells viability and prevented ROS 
formation in HD striatal cells subjected to H2O2 and STS. In the third part of this work we 
analysed the role of insulin/IGF-1 in HD striatal cells against ROS production and related 
antioxidant and signaling pathways. Insulin and IGF-1 decreased mitochondrial-driven 
ROS formation induced by mHtt, without changing SOD2 activity or glutathione levels. 
Insulin and IGF-1 promoted Akt and extracellular signal-regulated kinase (Erk) 
phosphorylation, respectively, and increased nuclear levels of phosphorylated nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2), which regulates the expression of detoxifying 
and antioxidant genes; however, this was not correlated with Nrf2 transcriptional activity 
or changes in mRNA levels of some Nrf2 target genes. Insulin and IGF-1 treatment also 
ameliorated mitochondrial function in HD cells. In the case of insulin, this occurred in a 
phosphatidylinositol 3-kinase (PI-3K)/Akt-dependent manner, concomitantly with 
reduced caspase-3 activation evoked by mHtt. Hence, insulin and IGF-1 improved 
mitochondrial function and reduced mitochondrial-driven ROS induced by mHtt, along 
with differential stimulation of Akt and Erk, in a process independent of Nrf2 
transcriptional activity.  
The present work defined the changes in antioxidant profile and cellular signaling 
following expression of full-length mHtt in mice striatal cells, demonstrating a higher 
susceptibility of these cells to stress and apoptotic cell death, thus revealing possible 
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targets for therapeutic intervention in HD. Importantly, treatment with cystamine and 
creatine rescued oxidative stress caused by stress stimuli, whereas activation of insulin or 
IGF-1 receptor-mediated kinase cascades reduced mitochondrial-driven oxidative stress 
through Nrf2-independent pathway in HD knock-in striatal cells, thus potentially delaying 
disease progression. 
Keywords: Huntington’s disease, mutant huntingtin, oxidative stress, glutathione redox 
system, insulin/IGF-1 signaling, reactive oxygen species, antioxidant response.   
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Resumo 
A doença de Huntington (DH) é uma doença neurodegenerativa progressiva 
caracterizada por distúrbios motores e psíquicos e declínio cognitivo, afectando o 
estriado. A DH é umadoença de poliglutaminas causada por uma expansão de CAGs no 
gene HTT, conduzindo à expressão de huntingtina mutante (Httm). A proteína mutante 
tem sido associada a vários mecanismos patológicos, incluindo a desregulação da 
transcrição, disfunção mitocondrial e stresse oxidativo, que poderá resultar da 
desregulação da função mitocondrial e/ou do défice de antioxidantes. Neste contexto, o 
tratamento com compostos utilizados em ensaios clínicos da DH apresentaram actividade 
antioxidante. Por outro lado, o factor de crescimento semelhante à insulina tipo 1 (IGF-1) 
protegeu as células DH, enquanto a insulina preveniu o stresse oxidativo neuronal. 
Contudo, o papel da via IGF-1/Akt na DH permanence controverso.  
O principal objectivo desta tese foi clarificar os mecanismos de (des)regulação 
redox após expressão da forma completa da Httm. Pretendemos avaliar as alterações de 
antioxidantes, nomeadamente o sistema redox da glutationa, assim como a eficácia de 
compostos usados em clínica (creatina e cistamina) com potencial actividade 
antioxidante, e o papel da insulina/IGF na regulação do stresse oxidativo na DH. Para tal, 
utilizámos células do estriado derivadas de murganhos knock-in para a DH, que 
expressam a Httm com 111 glutaminas (STHdh
Q111/Q111
; células mutantes) versus células
wild-type (STHdh
Q7/Q7
).
Na primeira parte deste trabalho determinámos as alterações do sistema redox da 
glutationa através da análise da actividade e expressão de proteínas envolvidas na 
regulação dos níveis de glutationa em células estriatais DH. As células mutantes 
mostraram um aumento de espécies reactivas de oxigénio (ROS) e da actividade da 
caspase-3. Surpreendentemente, as células mutantes exibiram um aumento dos níveis 
intracelulares de glutationa reduzida e oxidada (GSH, GSSG), e um aumento das 
actividades de enzimas relacionadas com a glutationa. No entanto, as actividades da 
glutamato-cisteína ligase (GCL) e da glutationa sintetase e os níveis da subunidade 
catalítica da GCL diminuíram em células DH, sugerindo uma diminuição da síntese de 
novo da glutationa. Um aumento dos níveis totais intracelulares de glutationa, apesar da 
diminuição da síntese, foi explicado pela redução da exportação da glutationa em células 
mutantes. De facto, observou-se um decréscimo da expressão de mRNA e actividade da 
proteína-1 associada à resistência a múltiplas drogas (Mrp1). Estes resultados sugeriram 
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que a Httm afecta a exportação da glutationa através do decréscimo da expressão do 
Mrp1. Por outro lado, o aumento dos mecanismos de defesa antioxidante induzidos pela 
Httm não foi suficiente para contrabalançar a formação de ROS e as características 
apoptóticas em células estriatais de DH. 
Na segunda parte do trabalho analisámos o perfil antioxidante celular após a 
exposição a péroxido de hidrogénio (H2O2) e estaurosporina (STS), e testámos o efeito 
protector da cistamina e creatina em células do estriado. As células mutantes mostraram 
um aumento da produção de ROS mitocondriais e uma diminuição das actividades da 
NADPH oxidase e da xantina oxidase (XO), reflectindo baixos níveis de anião 
superóxido citosólico, assim como um aumento da actividade das superóxido dismutases 
(SODs) e componentes do ciclo redox da glutationa. A exposição ao H2O2 e à STS 
aumentou os níveis de ROS em células mutantes e aumentou largamente a actividade da 
XO; a STS aumentou também a geração de ROS mitocondriais e a actividade da caspase-
3. Ambos os estímulos aumentaram ligeiramente a actividade da SOD1 (Cu/Zn-SOD), e
diminuíram a actividade da GRed, com um aumento consecutivo da GSSG em células 
mutantes, enquanto que o H2O2 apenas aumentou a actividade da GPx. Estes resultados 
indicaram que a geração de ROS mitocondriais é acompanhada pelo aumento de 
actividade do sistema antioxidante em células do estriado mutantes e que a exposição a 
estímulos nocivos induz um aumento da susceptibilidade ao stresse oxidativo através do 
aumento da actividade da XO e da diminuição da resposta antioxidante. Adicionalmente, 
a creatina e a cistamina aumentaram a viabilidade celular e preveniram a formação de 
ROS em células DH submetidas a H2O2 e STS. 
Na terceira e última parte deste trabalho analisámos o papel da insulina/IGF-1 em 
células do estriado DH contra a produção de ROS e os mecanismos antioxidantes e de 
sinalização intracelular relacionados. A insulina e o IGF-1 diminuiram a formação de 
ROS derivados da mitocôndria induzidos pela Httm, sem alterarem a actividade da SOD2 
ou os níveis de glutationa. A insulina e o IGF-1 promoveram a fosforilação do Akt e da 
cinase regulada por sinais extracelulares (Erk), respectivamente, e aumentaram os níveis 
nucleares do factor de transcrição nuclear Nrf2fosforilado, que regula a expressão de 
genes antioxidantes e de destoxificação celular; contudo, este resultado não foi 
relacionado com a actividade transcripcional do Nrf2 ou com alterações nos níveis de 
mRNA de genes alvo do Nrf2. O tratamento com insulina e IGF-1 também melhorou a 
função mitocondrial de células DH. No caso da insulina, este mecanismo ocorreu de 
forma dependente da via fosfoinositol 3-cinase (PI-3K)/Akt, em simultâneo com um 
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decréscimo da activação da caspase-3 induzida pela Httm. Assim, a insulina e o IGF-1 
melhoraram a função mitocondrial e reduziram a formação de ROS mitocondriais 
induzidos pela Httm, e estimularam diferencialmente Akt e ErK, num processo 
independente da actividade transcripcional do Nrf2. 
O trabalho apresentado nesta tese ajudou a clarificar a desregulação do perfil 
antioxidante e a sinalização celular que ocorre após a expressão da Httm em células 
estriatais. Para além disso, demonstrou-se uma maior susceptibilidade destas células ao 
stresse e à morte celular por apoptose, que poderá ser melhorada após o tratamento com 
citamina ou creatina, e após estimulação da cascata de cinases pela insulina ou IGF-1. 
Desta forma, este trabalho contribuiu para definir possíveis alvos de intervenção 
terapêutica que poderão reduzir a progressão da doença e melhorar os sintomas da DH. 
Palavras-Chave: Doença de Huntington, huntingtina mutante, stresse oxidativo, sistema 
redox da glutationa, sinalização da insulina/IGF-1, espécies reactivas de oxigénio, 
resposta antioxidante. 

Chapter 1 – Introduction 
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1.1 Huntington’s disease 
1.1.1 Huntington’s disease: an overview and historical facts 
“... in riding with my father on his professional rounds, I 
saw my first cases of ‘that disorder.’... It made a most enduring 
impression upon my young mind ... an impression which was the 
very first impulse to my choosing chorea as my virgin 
contribution to medical lore. Driving with my father through a 
wooded road leading from Easthampton to Amagansett, we 
suddenly came upon two women, mother and daughter, both 
bowing, twisting, grimacing. I stared in wonderment, almost in 
fear. What could it mean? My father paused to speak with them, 
and we passed on. Then my Gamaliel-like instruction began; my 
medical education had its inception. From this point, my interest 
in the disease has never wholly ceased.” (Huntington, 1910).  
“The hereditary chorea ... is confined to certain and 
fortunately a few families…hardly ever manifesting itself until 
adult or middle life... The tendency to insanity, and sometimes 
that form of insanity which leads to suicide, is marked... As the 
disease progresses the mind becomes more or less impaired... I 
have never known a recovery or even an amelioration of 
symptoms in this form of chorea; when once it begins it clings to 
the bitter end...” (Huntington, 1872). 
George Huntington (1850-1916) first encountered victims of hereditary chorea (a 
motor symptom characterized by abnormal and involuntary “dance-like” movementsand 
published in Medical and Surgical Reporter of Philadelphia (1872) at the age of 21 the 
main clinical aspects of the disease that had already been noted since the seventeen 
century by other physicians, including his father and grandfather. However, it was only 
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after the detailed and clear clinical descriptions given by George Huntington that the 
hereditary chorea was distinguished from other forms of chorea. After this description, 
other authors named the disease Huntington’s chorea, and later it was identified as 
Huntington’s disease (HD) because not all patients develop chorea, and due to the 
presence of cognitive and behavioral symptoms (Lanska, 2000).  
In the decade from 1983 to 1993, HD was sequentially linked to a polymorphic 
DNA marker that maps to human chromosome 4 (Gusella et al., 1983), located in the p16 
region at the short arm of chromosome 4 (Gusella et al., 1985; Landegent et al., 1986), 
and was included in the group of the nine inherited autosomal dominant (spinocerebellar 
ataxias (SCA) 1, 2, 3, 6, 7, 17, and dentatorubral-pallidoluysian atrophy (DRPLA)) or X-
linked (spinal and bulbar muscular atrophy (SBMA)) polyglutamine (polyQ) 
neurodegenerative disorders, due to the discovery of an expanded trinucleotide CAG 
repeat (>36) in the exon 1 of the IT15 (“interesting transcript 15”), currently recognized 
as the huntingtin (HTT) or HD gene (Huntington’s Disease Collaborative Research 
Group, 1993) (Table 1.1). These genetic disorders have in common the expansion of 
polyQ residues in different affected proteins. This modification alters the properties and 
activity of each one of the affected proteins and leads to a gain and/or a loss of function, 
as well as the accumulation of protein aggregates in the cytoplasm and/or in the nucleus. 
The number of CAG repeats is dynamic and can expand or contract from generation to 
generation; in the majority of polyQ diseases high CAG expansion result from paternal 
transmission (anticipation) (Pasternak, 2005), whereas most maternal transmissions show 
no change or a decrease in repeat number. In general, the severity of disease symptoms 
correlates with the number of CAG repeats in the affected protein, whereas the age of 
onset has an inverse correlation with the number of CAG repeats. Although the affected 
protein in the disease is ubiquitously expressed, specific brain regions are affected (Havel 
et al., 2009) as shown in Table 1.1.  
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Table 1.1 – Summary of the polyQ disorders genetic features, affected protein and brain regions. 
1 Driver-Dunckley and Caviness, 2007; Sharon et al., 2010; Warby et al., 2011. 
2 Finsterer, 2009; La Spada, 1999; 2011; Rhodes et al., 2009; Rocchi and Pennuto, 2013. 
3 Matilla-Dueñas et al., 2008; Orr, 2012; Subramony and Ashizawa, 1998; 2011; Whaley et al., 2011. 
PolyQ 
disorder 
Chromosomal 
locus 
Mutated gene 
Expanded 
exon 
Pathological 
CAG repeat 
number 
Affected protein 
Normal 
subcellular 
localization 
Putative function 
Affected brain 
regions 
HD
1
 4p16.3 HTT 1 >36 Huntingtin Cytoplasm 
Anti-apoptotic, 
signaling, 
transport, 
transcription 
Striatum and 
cortex 
SBMA
2
 Xq11-12 AR 1 >35 
Androgen 
receptor 
Nuclear and 
cytoplasmic 
Transcription Motor neurons 
SCA1
3
 6p22.3 ATXN1 8 >40 Ataxin-1 
Nuclear and 
cytoplasmic 
Transcription 
Purkinje cells in 
the cerebellum;  
brainstem nuclei 
and  cerebellar 
dentate nuclei 
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4 Kasumu and Bezprozvanny, 2012; Laffita-Mesa et al., 2012; Lastres-Becker, 2008; Pulst, 1998; 2013. 
5 Bettencourt and Lima, 2011; Colomer Gould, 2012; Costa and Paulson, 2012; Paulson, 1998; 2012. 
6 Bunn et al., 2012; Craig et al., 2004;  Fujioka et al., 2013; Gomez, 1998; 2013; Unno et al., 2012. 
SCA2
4
 12q24.1 ATXN2 1 >31 Ataxin-2 Cytoplasmic RNA metabolism 
Cerebellar 
Purkinje cells 
SCA3
5
 14q32.12 ATXN3 10 >52 Ataxin-3 
Nuclear and 
cytoplasmic 
De-ubiquitylating 
activity 
Cerebellum, 
brainstem, and 
substantia nigra 
SCA6
6
 19p13.2 CACNA1A 47 20 to 33 
Voltage-
dependent P/Q-
type calcium 
channel subunit 
alpha-1A 
Membrane 
associated 
P/Q-type alpha1A 
Ca
2+
 channel 
subunit 
Cerebellar 
Purkinje cells 
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7 Garden, 1998; 2012; Garden and La Spada, 2008; Horton et al., 2013. 
8 Gao et al., 2008; Toyoshima et al., 2005; 2012. 
9 Tsuji, 1999; 2010; 2012. 
SCA7
7
 3p14.1 ATXN7 3 >36 Ataxin-7 
Nuclear and 
cytoplasmic 
Transcription 
Cerebellar 
Purkinje cells, 
brainstem, spinal 
cord 
SCA17
8
 6q27 TBP 3 
> 45 
CAG/CAA 
TATA Box 
Binding Protein 
Nuclear Transcription 
Cerebellar 
Purkinje cells, 
Cortex, Striatum 
DRPLA
9
 12p13.31 ATN1 5 48 to 93 Atrophin-1 
Nuclear and 
cytoplasmic 
Transcription 
Dentatorubral and 
pallidoluysian 
systems 
8 
1.1.2 Huntington’s disease genetics and prevalence 
HD is the most prevalent polyQ disorder with a worldwide prevalence of 5-10 
cases per 100,000 persons (Table 1.2) but varies geographically as a result of ethnicity, 
local migration and past immigration patterns, and HTT gene haplotypes with no 
differences of prevalence between men and women. The identity of the genetic change 
responsible for HD was first described in individuals living in the Lake Maracaibo region 
of Venezuela, which is believed to have the highest prevalence of HD in the world where 
HD affects up to 700 per 100,000 persons (Table 1.2). In fact, the rate of occurrence is 
highest in individuals of Western European descent, and is less frequently in Japan, 
China, and Finland, and among African descents. A epidemiological study of the 
prevalence of HD in the UK between 1990 and 2010 found that the average prevalence 
for the UK was 12.3 per 100,000, whereas the frequency of HD in Japan has been 
estimated between 0.1 and 0.38 per 100,000 (Evans et al., 2013; Pringsheim et al., 2012; 
Warby et al., 2011) (Table 1.2). 
HD is inherited in a dominant fashion and a single HD-causing allele is sufficient 
to cause the disease. Unaffected alleles have CAG repeat size ranging from 10 to 35. 
With a median size of 18, the most common alleles in all populations contain repeats of 
15-20 CAGs (Warby et al., 2009). HD-causing alleles are classified as: 1) Reduced-
penetrance HD-causing alleles with 36-39 CAG repeats. An individual with an allele in 
this range is at risk for HD but may not develop symptoms (Langbehn et al., 2004). 2) 
Full-penetrance HD-causing alleles with 40 or more CAG repeats. Alleles of this size are 
associated with development of HD with great certainty (Warby et al., 1998; 2010). 
Individuals with adult-onset HD usually have a CAG expansion from 40 to 55. In that 
range, 50-70% of age of symptom onset appears to be explained by the length of the 
polyQ stretch, whereas the remainder is determined by other modifying genes and 
environmental factors (Wexler et al. 2004). For longer polyQ stretches, a greater 
proportion of age of symptom onset is explained by the length of the polyQ stretch. Like 
other polyQ disorders, there is an inverse correlation between the length of CAG repeats 
and the age of onset. Thus, the longer the CAG stretch, the earlier symptoms typically 
appear. HD juvenile onset cases have CAG expansions greater than 60 that are often 
inherited from the father (paternal transmission) (Warby et al., 2011). 
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1.1.3 Huntington’s disease symptoms 
HD symptoms onset usually occurs between 30-50 years of age (Table 1.2). 
Although each person with HD is clinically unique, chorea is the most prevalent and 
manifested symptom in HD. Chorea is derived from the Greek word meaning “dance”, 
and is characterized by abnormal and involuntary rapid “dance-like” movements of hands 
or feet with an extension to other parts of the body as the disease progresses. Generally, 
involuntary movements of face, fingers, feet or thorax and saccades, or abnormal fast 
movements of the eyes, are an early manifestation of the disease (Berardelli et al., 1999; 
Lasker et al., 1987; Penney et al., 1990). The treatment for chorea normally requires 
dopamine-depleting drugs, such as tetrabenazine, the only drug so far approved by the 
Food and Drug Administration (FDA) for the treatment of HD. Other antichoreic agents 
include haloperidol, a dopamine antagonist and antipsychotic drug (Killoran and Biglan, 
2012). Slowness of movements (bradykinesia), rigidity and the involuntary contraction of 
muscles (dystonia) progressively appear and normally dictate the final stage of the 
disease, in which the patient will become severely rigid, grossly akinetic and dysphagic. 
Also, ataxia and abnormal postural are common in advance stages of HD (Berardelli et 
al., 1999; Penney et al., 1990; Louis et al., 2000); abnormal facial expression and 
difficulties in chewing, swallowing and speaking (Walker, 2007), weight loss and 
malnutrition (in advanced stages of HD) (Aziz et al., 2008) and sleep disturbances 
(Gagnon et al., 2008) are also frequent symptoms.  
Emotional disturbances, including depression, dysphoria, agitation, irritability, 
anxiety, apathy, and delusional behavior are common in HD patients (Caine and 
Shoulson, 1983; Paulsen et al., 2001), which progressively aggravate with the course of 
disease. Psychosis and paranoia are also manifested in HD patients (Josiassen et al., 
1983). Some behavioral symptoms may occur before the diagnosis, which can include 
irritability, depression, and obsessive-compulsive behaviour (Duff et al., 2007; Kirkwood 
et al., 2002). Between 30-50% of HD patients develop depressive symptoms in the course 
of disease and can lead to personality changes in early stages. Moreover, the incidence of 
suicide is high in HD patients (Sorensen and Fenger, 1992).  
Early manifestations of the disease includes deficits in cognition, which 
progressively worse and are related with progressive caudate nucleus (CN) atrophy 
(Aylward, 2000; 2007; Montoya et al., 2006). In the early stages, HD patients often 
experience impaired problem-solving abilities, visuospatial skills difficulties, attention 
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deficit, difficulties in planning, and cognitive inflexibility, which can lead to a decline in 
performance at work. Although memory in general is relatively preserved, deficits in 
episodic, procedural and working memory can manifest in the course of disease, leading 
to subcortical dementia syndrome (Ho et al., 2003; Montoya et al., 2006; Paulsen et al., 
1995; Rohrer et al., 1999).  
The juvenile form of HD is a distinct clinical variant of HD, also called the 
“Westphal variant” of HD and accounts for 5-10% of HD cases. As described earlier, it 
affects individuals before age 20 and occurs when the length of CAG repeats is greater 
than 60. The disease progression is faster and the symptoms are more severe in juvenile 
cases. Bradykinesia without chorea, rigidity and spasticity, dystonia, epileptic seizures 
and deficits in cognition are the most manifested symptoms (Telenius et al., 1993; Warby 
et al., 1998; 2010).  
The death of the HD patients occurs 15-20 years after the symptoms onset and 
may result from complications such as heart failure, physical injuries provoked by falls, 
inanition, dysphagia, or aspiration pneumonia (Walker, 2007). 
1
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Table 1.2 – Summary of the polyQ disorders prevalence and clinical features. 
10 Driver-Dunckley and Caviness, 2007; Sharon et al., 2010; Warby et al., 2011. 
11 Finsterer, 2009; La Spada, 1999; 2011; Rhodes et al., 2009; Rocchi and Pennuto, 2013. 
12 Matilla-Dueñas et al., 2008; Orr, 2012; Subramony and Ashizawa, 2011; Whaley et al., 2011. 
PolyQ 
disorder 
Estimated 
worldwide  mean  
prevalence 
Highest prevalence 
Lowest 
prevalence 
Mean age of 
symptoms onset 
(range in years) 
Average duration 
(range in years) 
Major Clinical Features 
HD
10
 5-7.5 per 100,000 
700 per 100,000 
(Maracaibo region 
of Venezuela) 
0.1-0.38 per 
100,000 (Japan) 
30-50 15-20 Motor, cognitive decline, psychiatric triad 
SBMA
11
 1-2 per 100,000 
15 per 100,000 
(Vaasa region in 
Western Finland) 
- 20-50 
Normal life 
expectancy but 
wheelchair dependent 
20-30 years after 
onset 
Slowly progressive weakness, atrophy, and 
fasciculations of bulbar, facial and limb 
muscles  associated with mild androgen 
insensitivity 
SCA1
12
 1-2 per 100,000 - - 30-50 10-28 
Cerebellar ataxia, dysarthria, and eventual 
deterioration of bulbar functions 
1
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13 Kasumu and Bezprozvanny, 2012; Laffita-Mesa et al., 2012; Lastres-Becker, 2008; Pulst, 1998; 2013. 
14 Bettencourt and Lima, 2011; Colomer Gould, 2012; Costa and Paulson, 2012; Paulson, 1998; 2012. 
15 Bunn et al., 2012; Craig et al., 2004;  Fujioka et al., 2013; Gomez, 1998; 2013; Unno et al., 2012. 
SCA2
13
 1-2 per 100,000 
43 per 100,000 
(Holguin region in 
Cuba) 
- 30-50 10-15 
Progressive cerebellar syndrome 
characterized by ataxic gait, cerebellar 
dysarthria, dysmetria and 
dysdiadochokinesia. 
SCA3
14
 1-2 per 100,000 
1 per 239 (Flores 
island, Azores) 
- 20-50 7-29 
Ataxia, brainstem dysfunction, dystonia, 
parkinsonism 
SCA6
15
 >1 per 100,000 
5.21 per 100,000 
(UK) 
- 43-52 >25 
Slowly progressive cerebellar ataxia, 
dysarthria, and nystagmus 
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16 Garden, 1998; 2012; Garden and La Spada, 2008; Horton et al., 2013. 
17 Gao et al., 2008; Toyoshima et al., 2005; 2012. 
18 Tsuji, 1999; 2010; 2012. 
SCA7
16
 >1 per 100,000 - - 
3rd-4th decade 
(0.5-60) 
20 (1-45) 
Progressive cerebellar ataxia, including 
dysarthria and dysphagia, and cone-rod 
and retinal dystrophy with progressive 
central visual loss resulting in blindness in 
affected adults 
SCA17
17
 >100 families 
0.16 per 100,000 ( 
North-East 
England) 
0.47 per 
1,000,000 
(Japan) 
34.6 (3-75) 19 (10-28) 
Ataxia, chorea, brainstem dysfunction, 
dystonia, dementia 
DRPLA
18
 >1 per 100,000 
0.48 per 100,000 
(Japan) 
- 28.8 (1-60) 13 
Ataxia, chorea, seizures, dementia, 
myoclonus 
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1.1.4 Huntington’s disease protein and neuropathological features 
Althought HD pathology has been observed in peripheral tissues (Björkqvist et al., 
2008, van der Burg et al., 2009), like other polyQ disorders, HD is predominantly a 
central nervous system (CNS) disorder, characterized by cell loss and atrophy 
(Sathasivam et al., 1999), classified in five grades (0–4) designated in ascending order of 
severity (Vonsattel et al., 1985).  
Within the brain, atrophy of the striatum (the largest component of the basal 
ganglia system) is the most prominent (Vonsattel and DiFiglia, 1998), which primarily 
include a selective degeneration of medium spiny projection neurons (which represent 
about 96% of striatal neurons, and receive synaptic input primarily from the cortex) in the 
CN and putamen, while aspiny interneurons (which represent around 2% of the striatal 
neurons) of the striatum are generally spared (Cowan and Raymond, 2006; Ferrante et al., 
1985; 1987a,b). Counts of neurons in the CN revealed that 50% are lost in grade 1 and 
that 95% are lost in grade 4 (Vonsattel et al., 1985). However, progressive degeneration 
within medium spiny projection neurons in the CN and putamen appears to be different. 
Early in the course of HD, striato-globus pallidus (GP) internal segments (GPi) medium 
spiny projection neurons (which express substance P/gamma-aminobutyric acid (GABA) 
and projects to and inhibit GPi resulting in thalamus desinhibition and consequent 
excitation of upper motor neurons in the motor areas of the cortex, which increase 
movement (direct pathway)) are relatively spared, whereas striato-GP external segments 
(GPe) (which express enkephalins and projects to and inhibit GPe resulting in 
subthalamic nucleus inhibition and consequent less inhibition of substantia nigra (SN) 
pars reticulata (SNr) and GPi which inhibits thalamus resulting in the inhibition of upper 
motor neurons; thus decreasing movement (indirect pathway)) and striato-SNr (which 
express substance P/GABA and projects to and inhibit SNr (direct pathway)) medium 
spiny projection neurons degenerate (Reiner et al., 1988; Richfield et al., 1995a,b); loss of 
striato-GPe neurons was also demonstrated in presymptomatic HD (Albin et al., 1992). 
The early and relatively selective loss of striato-GPe and striato-SNr neurons was 
suggested to be a plausible explanation for the chorea and oculomotor abnormalities that 
are prominent clinical features of early HD (Albin, 1995). However, in later stages of 
adult HD, both populations of striatal projection neurons are affected, with concomitant 
loss of markers of the direct pathway (substance P/GABA-containing neurons), including 
dopamine D1 receptors and substance P (Reiner et al., 1988; Richfield et al., 1991). Also, 
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in juvenile HD cases, degeneration of both direct and indirect pathway striatal neurons 
was observed (Albin et al., 1990). Thus, the degeneration of both the direct and indirect 
pathways was suggested to be functional correlated with bradykinetic rigid phenotype 
observed in late stage and juvenile HD (Albin et al., 1990). Also, within the spared aspiny 
interneurons in HD there appears to be a differential level of vulnerability. Aspiny 
interneurons projection arbors are restricted to the striatum, and comprises: a) large 
cholinergic aspiny interneurons; b) medium somatostatin (SS)/neuropeptide Y 
(NPY)/diaphorase or nitric oxide synthase (NOS)-positive aspiny interneurons; and c) 
medium GABAergic-containing/parvalbumin-positive aspiny interneurons). Striatal 
SS/NPY/NOS neurons are relatively spared in HD (Ferrante et al., 1985; Dawbarn et al., 
1985). Although markers of striatal cholinergic function decline in HD, striatal 
cholinergic aspiny interneurons are preserved, indicating functional impairment but not 
degeneration of striatal cholinergic aspiny interneurons (Hirsch et al., 1989). Moreover, it 
was suggested that striatal GABA/parvalbumin-containing interneurons are preserved 
early in the course of HD, but degenerate with disease progression (Albin, 1995; 
Harrington and Kowall, 1991).  
On the other hand, non-striatal brain regions can also be affected, particularly in 
latter stages of the disease, and can include the SN, hippocampus, and mostly various 
regions of the cortex (Van Raamsdonk et al., 2005), whereas pyramidal neurons of deeper 
cortical layers appear to be more affected in HD, which can be correlated with dementia 
and personality changes in HD patients (Vonsattel, 2008). 
The reason why there is selective brain degeneration in HD is not known. 
However, it might be due to the role and importance of the protein that is affected in HD 
might have in the brain. The HTT gene encodes a polymorphic stretch of glutamines (Q) 
within the N-terminal of a high molecular weight protein, with approximately 3144 amino 
acids (~348 kDa), known as huntingtin (Htt) (Hoogeveen et al., 1993; Huntington’s 
Disease Collaborative Research Group, 1993) (Figure 1.1). Htt polyQ tract begins at the 
18 amino acid and is followed by a proline rich sequence (polyP) composed by 38 amino 
acids, which is thought to be important in Htt solubility (Steffan et al., 2004) (Figure 1.1). 
The first 17 amino acids of Htt are important for nuclear shuttling since they interact with 
TPR (translocated promoter region), a protein of the nuclear pore that actively exports 
proteins from the nucleus. When the first 17 amino acids were eliminated, Htt nuclear 
accumulation was observed (Cornett et al., 2005). Htt also contains multiple regions of 
so-called HEAT (Huntingtin, Elongation factor 3, a subunit of protein phosphatase 2A 
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and the lipid kinase TOR) repeats, a sequence of ~40 amino acids named after the first 
four proteins in which it was discovered (Andrade and Bork, 1995; Neuwald and Hirano, 
2000). Although the exact function of HEAT repeats are currently unclear, studies have 
suggested that these domains play a role in a variety of interactions between proteins, 
including transportation in the cytoplasm and nucleus, microtubule dynamics and 
chromosome segregation (Neuwald and Hirano, 2000).  
Figure 1.1 – Huntingtin protein structure. The CAG expansion which occurs in the exon-1 of 
HTT gene is translated into an expansion of glutamines (Q) in a region of the N-terminal Htt 
protein, which is composed by ~3144 aminoacids (aa). The polyQ region is preceded by 17 
aminoacids (N17) and followed by a polyproline (polyP) rich region. The polyQ region comprised 
by 10 to 35Q is present in normal individuals. Between 36 to 39Q, individuals may not develop 
symptoms but are at risk to develop HD. Above 39Q, individuals develop HD symptoms, which 
are more severe with increased Q number. 
Htt mRNA and protein are ubiquitously expressed throughout the development 
and in the adult, in a variety of cells and peripheral tissues, and homogenously throughout 
the brain where it has its higher expression, with a predominance of neuronal over glial 
expression (Landwehrmeyer et al., 1995; Li et al., 1993; Sharp et al., 1995; Strong et al., 
1993). In the brain, Htt mRNA was detected in both grey and white matter (lowest 
expression levels), and the highest expression levels of Htt were found in the cortex (with 
differential expression between cortical layers), hippocampus, SN and cerebellum, 
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followed by the striatum (Landwehrmeyer et al., 1995; Li et al., 1993; Strong et al., 
1993), with no differences in the distribution and levels of Htt mRNA between 
symptomatic HD patients and control individuals, except in the striatum where the 
intensity of labeling was significantly reduced (Landwehrmeyer et al., 1995). However, 
presymptomatic HD brains revealed a striatal expression similar to controls and surviving 
striatal neurons in more advanced HD had an expression of Htt mRNA within normal 
limits. Thus, HD brain selective degeneration does not seem to result from altered Htt 
mRNA expression (Landwehrmeyer et al., 1995).  
Wild-type Htt protein within neurons can be found in the cytoplasm, neurites and 
synapses, and associates with various organelles and structures, such as microtubules, 
plasma membrane, endosomal and endoplasmic compartments, clathrin-coated vesicles 
and mitochondria (DiFiglia et al., 1995; Gutekunst et al., 1995; Kegel et al., 2005; 
Trottier et al., 1995). Although mostly located in the cytoplasm, Htt is also detected in the 
nucleus (Hoogeveen et al., 1993; Kegel et al., 2002). Due to its subcellular localization 
Htt interacts with numerous proteins involved in gene expression, intracellular transport, 
signaling and metabolism (Borrell-Pages et al., 2006a,b; Harjes and Wanker, 2003; Li and 
Li, 2004a,b). However, the normal function of Htt is not completely known. On the other 
hand, it was shown that wild-type Htt is involved in embryonic development, since 
homozygous HTT locus knockout mice are lethally affected at early embryonic 
development stages (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). On the 
other hand, the presence of one fully functional allele (at least 50% Htt expression) is 
compatible with life in humans and HD is not caused by a simple loss of function of the 
HTT gene (Cattaneo et al., 2005). In fact, patients with Wolf-Hirshhorn syndrome, having 
a partial deletion of chromosome 4 that comprises the CAG triplet repeats region and 
therefore have only one copy of the HTT gene, are born and do not develop HD (Gusella 
et al., 1985). Also, conditional inactivation of wild-type Htt, to avoid early embryonic 
lethality of homozygous knockout mice, in which Htt levels were reduced to below 50% 
of normal presented defects in the epiblast (the structure that will give rise to the neural 
tube), which led to reduced neurogenesis and profound malformations of the cortex and 
striatum, thus indicating that Htt plays a role in neurogenesis (Dragatsis et al., 2000; 
White et al., 1997). Other evidences suggest that wild-type Htt has an anti-apoptotic 
function in a gene and protein-dependent manner (Leavitt et al., 2006). Wild-type Htt acts 
downstream mitochondrial cytochrome c release (a protein at the mitochondrial 
intermembrane space that when released from mitochondria can bind to caspases to 
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activate the cell death process), preventing the activation of both caspase-9 (Rigamonti et 
al., 2001) and -3 (Rigamonti et al., 2000). Moreover, wild-type Htt physically interacts 
with active caspase-3 and inhibits its activity (Zhang et al., 2006). Furthermore, Htt 
appears to act as an activator or enhancer of gene transcription. Particularly, Htt was 
shown to regulate the gene transcription of brain-derived neurotrophic factor protein 
(BDNF), a neurotrophin essential for striatal neuronal survival and for the activity of 
cortico-striatal synapses, by binding and trapping in the cytoplasm (inhibit) the BDNF 
transcriptional repressor REST/NRSF (RE-1 silencing transcription factor/neuron-
restrictive silencer factor) (Gauthier et al., 2004; Zuccato et al., 2001; 2003; 2007). 
Expanded polyQ Htt (mutant Htt; mHtt) appears to possess at least certain 
properties of wild-type Htt. In fact, mHtt can rescue the embryonic lethal phenotype seen 
in Htt-null knockout mice (Hodgson et al., 1996; Dragatsis et al., 1998). However, it is 
still not clear if neuronal cytotoxicity in HD is due to a loss or a novel gain of Htt 
function or both. The proteolytic cleavage of mHtt into N-terminal fragments containing 
the polyQ stretch and their subsequent translocation to the nucleus, and formation of 
intranuclear aggregates (DiFiglia et al., 1997; 2002; Goldberg et al., 1996), is a hallmark 
of the disease detected in post-mortem HD human brains. The aggregates can be found 
before the onset of the first symptoms (DiFiglia et al., 1997; Weiss et al., 2008), and the 
rate of aggregate formation was shown to correlate with the length of the polyQ repeat 
(Legleiter et al., 2010). However, the toxicity of mHtt nuclear inclusions remains 
controversial, since their formation is correlated with disease progression, but is not 
linked with neuronal degeneration. In fact, some studies have shown that mHtt inclusions 
are protective against mHtt-induced toxicity in cultured cells (Arrasate et al., 2004; 
Davies et al., 1997; Saudou et al., 1998). Exposure of mHtt-transfected striatal neurons to 
conditions in which nuclear localization of mHtt was blocked and consequently, 
suppressing its ability to form intranuclear inclusions, resulted in increased cell death, 
suggesting that the formation of intranuclear inclusions might reflect a cellular 
mechanism to protect against mHtt-induced cell death (Saudou et al., 1998). On the other 
hand, the decrease of proteolytic cleavage of mHtt reduced its toxicity and slowed disease 
progression (Gafni et al., 2004; Wellington and Hayden, 2000). In addition, expression of 
smaller N-terminal mHtt fragments resulted in increased toxicity in cultured cells 
(Hackam et al., 1998) and transgenic animals (Davies et al., 1997; Schilling et al., 1999; 
Yu et al., 2003), when compared to the full-length mHtt expression with the same polyQ 
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expansion. This result suggested that the susceptibility to neuronal death is greater with 
decreased protein length and increased polyQ size.  
Therefore, several HD models have been generated to mimic the 
neuropathological features that occur in Humans. These models express only a fragment 
or a full-length mHtt to study the cellular and molecular mechanisms of mHtt-induce 
neurodegeneration. 
1.1.4.1 Huntington’s disease models 
1.1.4.1.1 Knock-in models 
Knock-in HD models were generated by targeting an expanded polyQ repeat 
and/or adjacent human mHtt exon 1 sequences (including the polyP region) to replace the 
corresponding sequences in the endogenous murine HD homologue gene (Hdh), thus 
expressing mHtt from the endogenous Hdh locus in a similar manner to the expression in 
HD patients. Therefore, Hdh knock-in mice are commonly considered as one of the most 
precise genetic HD mouse models (Gusella and Macdonald, 2006). When compared to N-
terminal mHtt fragments expressing models, Hdh knock-in mice display slow progression 
and moderately mild phenotypes, and their lifespan is usually normal. These mouse 
models are important to evaluate early pathological processes induced by mHtt in 
humans. Originally, knock-in models were disappointing because the first mice generated 
with an extended stretch of 50 or 80 CAG repeats into the endogenous mouse Hdh gene 
(HdhQ50; HdhQ80) presented no behavioural phenotypes or abnormalities, or mHtt 
aggregates (Shelbourne et al., 1999; White et al., 1997). Therefore, other knock-in models 
that represented better the human pathology were developed. 
1.1.4.1.1.1 HdhQ111 
The HdhQ111 model is a knock-in mouse model of HD with an insertion of a 
chimeric murine Hdh/human mHtt exon 1 into the endogenous Hdh locus; the human 
mHtt portion includes 111 CAG repeats and a polyP region (Wheeler et al., 1999). The 
behavioral phenotypes of HdhQ111 are very mild and slowly progressive. Rotarod, 
clasping or open field abnormalities were not detected in heterozygous or homozygous 
HdhQ111 mice until 17 months of age, and gait abnormalities were detected only at 24 
months of age  (Wheeler et al., 2002). HdhQ111 homozygous mice show selective and 
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progressive accumulation of nuclear mHtt at 2.5 months of age (Wheeler et al., 2000), 
nuclear inclusion formation at 10 months of age, and reactive gliosis in the striatum at 24 
months of age (Wheeler et al., 2000, 2002).  
1.1.4.1.1.2 CAG140 
The CAG140 HD knock-in mice model was developed with a replacement of the 
endogenous murine Hdh exon 1 with a chimeric mouse and human exon 1 with 140 CAG 
repeats. CAG140 HD mice display early hyperactivity at 1 month of age, followed by 
hypoactivity at 4 months of age, gait abnormality at 12 months of age, with nuclear mHtt 
microaggregates in the striatum and cortex, and nuclear inclusions in the striatum at 4 
months of age and in the cortex at 6 months. However, nuclear microaggregates were also 
observed at 6 months of age in the cerebellum, a relatively spared region in human HD 
brain, but presented no cell loss or brain atrophy (Menalled et al., 2003).  
1.1.4.1.1.3 Hdh(CAG)150 
Hdh(CAG)150 HD knock-in mice was developed by a replacement of the short 
CAG repeat in the murine Hdh exon 1 with a stretch of 150 CAG repeats (Lin et al., 
2001). Homozygous Hdh(CAG)150 mice revealed several slowly progressive motor 
abnormalities (Heng et al., 2007; Woodman et al., 2007). Homozygous HdhCAG(150) 
mice display progressive rotarod deficits at 18 months of age and mHtt aggregates in the 
striatum and hippocampus at 6 months and widespread in the brain at 10 months of age 
(Tallaksen-Greene et al., 2005). Striatal neuronal loss is observed at 100 week-old (Heng 
et al., 2007).  
1.1.4.1.2 Transgenic models 
In transgenic mouse models, full-length or a fragment of the mutant HTT gene is 
inserted randomly into the mouse genome, leading to the expression of a mutant protein 
in addition to the endogenous Htt. Thus, transgenic mouse models of HD express N-
terminal mHtt fragments or full-length human HTT gene with an expanded polyQ tract.  
1.1.4.1.2.1 N-terminal huntingtin transgenic models 
The first transgenic mice models of HD include the insertion of a fragment of the 
human HTT gene. R6/2 HD mice contain a mutant N-terminal segment of the exon 1 of 
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the human HTT gene with 144 CAG repeats (Mangiarini et al., 1996). These mice display 
choreiform-like movements, inclusion formation at 4-5 weeks, followed by an early death 
around 12-14 weeks, but with minimal neuronal death when compared to human HD 
patients (Hersch and Ferrante, 2004; Li et al., 2005; Mangiarini et al., 1996). Another 
transgenic model developed is the R6/1 HD mice that express a truncated HTT gene with 
around 115 CAG repeats, and exhibit a more progressive pathology and lower expression 
of the mutant transgene, a marked decline in rotarod performance develops at 13-20 
weeks, correlating with the numbers of striatal neurons exhibiting intranuclear inclusions 
of mHtt, and with death occurring within 4-5 months of age (Davies et al., 1997; Hansson 
et al., 2001a,b). The N171-82Q mouse model of HD contains a longer N-terminal 
fragment of mHtt (exon 1 and exon 2) with 82 CAG repeats. The lifespan of the N171-
82Q HD is ∼17-20 weeks with HD-like symptoms beginning at 10-12 weeks of age. In 
these mice, neuropathological features are more similar to human HD, so that 
neurodegeneration is more prominent and seems more selective for the striatum (Duan et 
al., 2003; Hersch and Ferrante, 2004; Schilling et al., 1999).  
1.1.4.1.2.2 Full-lenght huntingtin transgenic models 
Two genomic transgenic models expressing full-length mHtt from the human 
genomic locus on a yeast artificial chromosome (YAC) (Hodgson et al., 1999; Slow et al., 
2003; Van Raamsdonk et al., 2007a,b) or on a bacterial artificial chromosome (BAC) 
(Gray et al., 2008) were generated. A series of YAC transgenic models of HD expressing 
full-length human mHtt with 18, 46, 72, and 128 CAG repeats (i.e., YAC18, YAC46, 
YAC72, and YAC128) were generated after microinjection of YAC DNA construct into 
the friend leukemia virus B strain (FVB/N) pronuclei and maintained on the inbred mouse 
FVB/N background strain; in contrast to the C57BL/6 background strain common to most 
HD mouse models, the FVB/N strain shows higher neuronal loss when exposed to 
excitotoxic stress after injection of kainic acid or quinolinic acid (QA) (Hodgson et al., 
1999; Slow et al., 2003; Van Raamsdonk et al., 2007a,b). YAC128 mice are the latest of 
the series and exhibit by far the most robust phenotypes among all the YAC models; 
therefore, YAC128 is used as a preclinical model in HD (Slow et al., 2003). At the 
protein level, the YAC128 line expresses human mHtt at about 75% of the level of the 
endogenous murine Hdh (Slow et al., 2003). YAC128 mice exhibit hyperactivity at 2 
months of age and hypoactivity at 8–12 months of age. They also exhibit rotarod deficits 
at 4 months of age, which become more prominent at 6 months of age (Graham et al., 
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2006; Van Raamsdonk et al., 2005a,b). mHtt nuclear localization is detected in the 
striatum at 1-2 months and in the cortex and hippocampus at 3 months of age. Nuclear 
inclusions are detected only at 18 months in the striatum. As in humans, selective atrophy 
in the striatum and cortex, but not in cerebellum is detected (Van Raamsdonk et al., 
2005a,b). BACHD is a more recent generated transgenic mouse model of HD maintained 
in the FVB/N background strain. BACHD mice exhibit mild rotarod deficits at 2 months, 
with progressive deficits and hypoactivity at 6 months of age. At 12 months of age, 
cortical and striatal atrophy is detected, but no early nuclear mHtt localization is detected 
(Gray et al., 2008; Menalled et al., 2009).  
1.1.4.1.3 Toxic lesion models 
Taking into account the reduced activity of mitochondrial respiratory complex II 
(succinate dehydrogenase) in the CN and putamen of symptomatic HD patients, and the 
report that accidental ingestion of the mitochondrial toxin 3-nitropropionic acid (3-NP, an 
irreversible complex II inhibitor) produced preferential degeneration of the putamen and 
CN associated with severe neurological symptoms in humans, pharmacologic inhibitors 
of mitochondrial complex II (3-NP and malonate, the latter a reversible inhibitor) were 
tested in a tentative to reproduce HD features. They have been found to induce striatal 
damage and motor phenotypes in animals, closely resembling the symptoms seen in HD 
patients (Brouillet et al., 2005; Kumar et al., 2010). The main advantage of 3-NP is that 
HD symptoms develop spontaneously after its systemic administration (Reynolds et al., 
1998). This model has been extended to non-human primates in which chronic systemic 
administration of 3-NP mimics behavioural, histological and neurochemical features of 
HD (Brouillet et al., 1995; Brouillet and Hantraye, 1995). Malonate was shown to cause 
motor impairments and neuronal pathology resembling HD after intrastriatal 
administration (as malonate does not cross the blood-brain barrier) in rodents. Similar to 
3-NP, malonate produces age-dependent striatal lesions that can be attenuated by N-
methyl-D-aspartate (NMDA) receptor (NMDAR) antagonists. Further indirect evidence 
contributes to malonate-induced neurodegeneration (Kumar et al., 2010). 
There is increased evidence of excitotoxicity in HD, a pathological process that 
occurs due to excessive stimulation of ionotropic glutamate receptors such as the NMDA, 
in particular, and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors (AMPAR) by the excitatory neurotransmitter glutamate leading to neuronal 
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damaged and death (Dong et al., 2009). Indeed, the excitotoxin QA-induced striatal 
lesions closely resembling those of HD, as they result in marked depletion of both GABA 
and substance P, selectively sparing SS/NPY neurons (Beal et al., 1986). Thus, QA was 
proposed as a model to replicate the neurochemical characteristics of HD. QA is an 
extensively studied endogenous metabolite of the tryptophan degradation pathway, also 
known as the kynurenine pathway. QA is a NMDA receptor agonist, preferentially acting 
on discrete populations of these receptors containing GluN2A and GluN2B subunits. QA 
exerts excessive excitation of NMDA receptors and recruits enhanced cytoplasmic Ca
2+
concentrations, mitochondrial dysfunction, decreased ATP levels, cytochrome c release, 
selective loss of GABAergic and cholinergic neurons, and oxidative stress. The 
intrastriatal injection of QA reproduces striatal lesions observed in HD by targeting a 
subset of medium spiny neurons - the GABAergic and substance P medium spiny 
neurons. The QA model has been successfully tested in primates, exhibiting similar 
neuropathological lesions (Beal et al., 1986; Ferrante et al., 1993; Lugo-Huitrón et al., 
2013; Pérez-De La Cruz et al., 2012; Schwarcz and Kohler, 1983). 
1.1.4.1.4 Invertebrate models 
In a tentative to overcome the limitations of human genetic studies, models 
ranging from yeast, the fruit fly Drosophila melanogaster, and the nematode 
Caenorhabditis elegans to mammals and human cell culture systems, have been used to 
study specific functional aspects of the genes/proteins identified in neurodegenerative 
diseases.  
Drug development is an expensive and time-consuming process which has to be 
proofed by clinical trials. In this respect, genetic studies performed during the past decade 
in invertebrate models such as Drosophila and C. elegans provided new strategies and 
rationales for the development of neuroprotective drugs. The “low-cost” and the rapid 
drug screening that Drosophila and C. elegans provide, have allowed the pre-selection of 
candidate drugs for neuroprotection, and enabled the identification and study of key 
modulators of conserved biological processes, in advance of their discovery and study in 
more complex mammalian. Also, they are good model systems to study in vivo how 
postmitotic cells may respond to the stress produced by disease proteins during 
developmental and adult life, and represent an attractive intermediate by combining 
sufficient complexity to allow investigation of both cellular and behavioral phenotypes 
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with simplicity that facilitates rapid, high‐throughput testing of hypotheses. In fact, under 
normal conditions, C. elegans development to adult stage is completed in approximately 3 
days with a lifespan of approximately 2 weeks, thus allowing experiments to be designed 
and carried out quite rapidly compared with other animal models. Also, Drosophila has a 
short life span ranging from 40 to 120 days depending on diet and stress, and it shows 
complex behaviour, including learning and memory, driven by a sophisticated brain and 
nervous system. At least 50% of fly genes display homology to human genes, and among 
human diseased genes ~75% have a Drosophila ortholog, including HTT. However, 
despite a high level of genetic conservation for numerous essential pathways involved in 
development and/or cell maintenance, nematodes and flies are physiologically distantly 
related to humans. Notwithstanding the limitations, expression of polyQ-containing 
proteins was shown to be neurotoxic in both Drosophila retinal neurons and C. elegans 
chemosensory or mechanosensory neurons (Brignull et al., 2006; Hirth, 2010; Neri, 
2011). 
1.1.4.1.5 In Vitro Models 
Several cell lines have been used to model the pathological features of HD, such as 
the non-neuronal human HeLa cells, the human embryonic (HEK293T) and monkey 
kidney fibroblast cell lines (COS-7), as well as the Neuro2a (N2a) neuroblastoma 
(mouse) and neuron-like PC12 (rat) cells, ST14A (derived from embryonic day 14 rat 
striatal primordia by retroviral transduction of the temperature-sensitive SV40 large T 
antigen), SK-N-SH and SH-SY5Y (human neuroblastoma), rat and mouse primary striatal 
neurons, STHdh
Q111/ Q111
 striatal cells, and HD cybrids (Cisbani and Cicchetti, 2012).
These cell lines have been widely used and provide a cost and time-effective model 
to investigate pathways associated with HD. In this section we will focus and resume 
some described features of STHdh
Q111/ Q111
 striatal cells.
1.1.4.1.5.1 STHdhQ111/ Q111 striatal cells 
The long polyQ segments in the precise genetic models of juvenile HD, HdhQ92 
and HdhQ111 knock-in mice, altered mHtt physical properties, producing HD-like in vivo 
brain pathology specifically in the striatum; this  included nuclear localization of mHtt 
predominantly in medium spiny neurons, and subsequent formation of N-terminal 
inclusions and insoluble aggregate (Wheeler et al., 2000). Thus, immortalized wild-type 
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or homozygous mutant progenitor striatal cells that express endogenous normal/wild-type 
Htt (Q7) or mHtt with 111 Q (Q111) derived from E14 striatal primordia of wild-type or 
HdhQ111 knock-in mice, respectively, were developed. The cells represent early phases 
of HD pathogenesis because they show no visible Htt aggregates, no toxicity occurs under 
non-stimulated conditions, and also because they are derived from the embryonic phase 
of the Hdh knock-in mice (Trettel et al., 2000). Moreover, STHdh
Q111
 cells are selectively
vulnerable to 3-NP. The 3-NP treatment caused significantly greater cell death in mutant 
striatal cells, compared with wild-type cells (Ruan et al., 2004). Also, mitochondrial 
respiration and ATP production were significantly reduced in STHdh
Q111 
cells (Milakovic
and Johnson, 2005). Furthermore, in a recent study, STHdh
Q111/Q111
 cells displayed more
fragmented mitochondria compared to STHdh
Q7/Q7
, correlating with decreased dynamin
related protein 1 (Drp1) and optic atrophy 1 (autosomal dominant) (Opa1) protein levels, 
key regulators of mitochondrial fission and fusion, respectively. In fact, STHdh
Q111/Q111
cells presented significantly decreased mitochondrial fusion and hydrogen peroxide 
(H2O2)-induced increased swollen mitochondria, which correlated with increased 
mitochondrial oxidized state (Jin et al., 2013). Indeed, mtDNA damage was associated 
with reduced mitochondrial bioenergetics in STHdh
Q111/Q111
 cells (Siddiqui et al., 2012).
STHdh
Q111/Q111
 cells also showed higher basal levels of mitochondrial-generated ROS and
mitochondrial DNA (mtDNA) lesions and a lower spare respiratory capacity (Siddiqui et 
al., 2012). Therefore, STHdh
Q111/Q111
 striatal cells represent a highly accurate model of
HD, providing a reliable tool for the study of mHtt-induced cytotoxicity in the striatum in 
the early phases of the disease. 
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1.2 Mechanisms of cytotoxicity induced by mutant huntingtin 
The expanded polyQ stretch in the protein Htt results in a conformational change 
leading to the deregulation of several cellular processes, such as transcription, 
mitochondrial function and energy homeostasis, reactive oxygen species (ROS) 
production, and/or modified intracellular signaling pathways, which can be originated 
from and/or enhance apoptotic cell death (Figure 1.2) as discussed in the next sections. 
Figure 1.2 – Mutant huntingtin-induced deregulation of several cellular processes. Mutant 
huntingtin (mHtt) has been described to induce apoptotic cell death by activating caspases 
cascade, namely caspase-3 (Casp3). The formation of cytosolic aggregates and nuclear inclusions 
of mHtt fragments composed by the N-terminal Htt (N) recruits other proteins leading to their 
inactivation, many of these proteins are transcription factors which results in transcriptional 
deregulation. mHtt fragments also have been linked to increased reactive oxygen species (ROS) 
production and to interact with mitochondrial components resulting in mitochondrial dysfunction 
and energy deregulation. Signaling pathways have been also described to be deregulated in HD. 
Indeed mHtt appears to reduce kinases activity leading to reduced target proteins phosphorylation. 
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1.2.1 Mutant huntingtin induces apoptotic cell death 
Several proteases were shown to cleave Htt in vitro and in vivo, and the 
corresponding cleavage products have been found in the brain of patients and murine 
models (Mende-Mueller et al., 2001). These proteases include caspase-1, -2, -3 and -6 
(Goldberg et al., 1996; Graham et al., 2006; Hermel et al., 2004; Wellington et al., 1998; 
2000; 2002), calpains (Bizat et al., 2003; Gafni and Ellerby, 2002; Goffredo et al., 2002) 
and aspartic proteases (Lunkes et al., 2002). Both normal and mHtt are substrates for 
caspase-3 activity, suggesting that the proteolytic cleavage is a physiologic event in the 
cell. However, the abnormal polyQ tract of truncated mHtt changes the conformation of 
the native structural protein, which renders it the preferred enzymatic substrate, in respect 
to normal Htt, and consequently induces the formation of insoluble aggregates (Davies et 
al., 1997; Scherzinger et al., 1997). mHtt fragments within the striatum of HD brains 
clearly differ from those of control brains (Mende-Mueller et al., 2001) and HD mice 
expressing mHtt resistant to cleavage by caspase-6 but not caspase-3 maintained normal 
neuronal function and did not develop striatal neurodegeneration, and protected against 
neurotoxicity induced by NMDA, QA, and staurosporine (STS), suggesting that the 
proteolytic cleavage of mHtt by caspase-6 is necessary to induce neurodegeneration 
(Graham et al., 2006). Moreover, mHtt has been shown to induce the activation of the 
intrinsic apoptotic pathway. Expression and Mitochondrial cytochrome c release were 
found to be increased in HD striatal neurons (Kiechle et al., 2002; Wellington et al., 
1998) and in excitotoxic lesion models of HD (Antonawich et al., 2002; Bizat et al., 2003; 
Vis et al., 2001), which may be associated with increased activation of caspase-1, -2, -3, -
6, -7, -8 and -9 verified in HD mouse models and HD human brain (Hermel et al., 2004; 
Kiechle et al., 2002; Maglione et al., 2006; Ona et al., 1999; Sanchez et al., 1999; 
Wellington et al., 1998). In this respect, mHtt was also found to bind and enhanced the 
pro-apoptotic factor p53 activation, which concomitantly increased caspase-6 activation 
in skeletal muscle, and in the brain from HD patients and mouse models (Bae et al., 2005; 
Ehrnhoefer et al., 2013; Steffan et al., 2000). Interestingly, p53 activation was found to 
regulate Htt expression at transcriptional level, both in vitro and in vivo, in the striatum 
and cortex of HD mouse brain, suggesting that a p53 stress response could be a modulator 
of the process of HD (Feng et al., 2006), whereas p53 deficient HdhQ140 HD mice 
resulted in a reduction of mHtt expression in brain and testis, and a significant increase in 
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nuclear aggregate formation in the striatum. The authors suggested a functional rescue of 
at least several aspects of the HD phenotype by a deficiency in p53 (Ryan et al., 2006).  
1.2.2 Mutant huntingtin leads to transcriptional deregulation 
Another consequence of mHtt expression is transcriptional deregulation. Nuclear 
mHtt aggregates interfere with normal transcriptional (Davies et al., 1997; DiFiglia et al., 
1997). Several transcription factors have been reported to interact with mHtt. The mutated 
form of Htt was shown to interact with both the polyQ (Nucifora et al., 2001) and the 
acetyltransferase domains (Steffan et al., 2000; 2001) of CBP ((cyclic adenosine 
monophosphate (cAMP) response element (CRE) binding protein (CREB))-binding 
protein), and with TAF4 (TAF4 RNA Polymerase II, TATA Box Binding Protein (TBP)-
Associated Factor); this factor, together with TBP, which also interacts with mHtt, is 
fundamental for RNA polymerase II activity (Dunah et al., 2002; Schaffar et al., 2004; 
Shimohata, 2002). The interaction of TBP with mHtt leads to the sequestration of TBP 
into mHtt aggregates, preventing the binding of TBP to DNA promoters (Friedman et al., 
2008; Huang et al., 1998). CRE-mediated transcription is regulated by TAF4, which is 
part of the basal transcriptional machinery and can abnormally interact with mHtt, 
rendering the transcriptional complex ineffective (Dunah et al., 2002). mHtt can also alter 
CRE-mediated transcription through inhibition of CBP transcriptional activities. CBP 
plays a role in histone acetylation by acting as an acetyltransferase, opening the chromatin 
structure and exposing the DNA to transcription factors such as TAF4, thus enhancing 
CRE-mediated transcription. In the presence of mHtt, the interaction between the mutant 
protein and CBP is enhanced, leading to histone hypoacetylation and inhibition of CBP-
mediated transcription (Cong et al., 2005; Steffan et al., 2000). Also, in the presence of 
mHtt, CBP becomes abnormally ubiquitinated resulting in its higher degradation and in 
reduced transcriptional expression of CREB-controlled genes (Jiang et al., 2003). 
Concordantly, deletion of CREB in the brain causes selective neurodegeneration in the 
hippocampus and striatum (Mantamadiotis et al., 2002).  
Specificity protein 1 (Sp1) transcription factor involved in many cellular 
processes, including cell differentiation, cell growth, apoptosis, immune responses, 
response to DNA damage, and chromatin remodeling, was also shown to interact with the 
soluble form of mHtt, which inhibited Sp1 binding to DNA and suppressed its 
transcriptional activity in post-mortem brain tissues of both presymptomatic and affected 
29 
HD patients, and in the brain of R6/2 HD mice, in a polyQ-dependent manner, whereas 
overexpression of Sp1 and the coactivator TAF4 reduced the cellular toxicity, the neuritic 
extension defects, and the transcriptional inhibition caused by intranuclear mHtt (Dunah 
et al., 2002; Li et al., 2002; Zhai et al., 2005). Interestingly, genes whose mRNA levels 
were decreased in HD had abnormal Sp1-DNA binding, whereas genes with unchanged 
mRNA levels had normal levels of Sp1 association, suggesting that mHtt dissociates Sp1 
from target promoters, inhibiting transcription of specific genes (Chen-Plotkin et al., 
2006). More recently, Sp1 was found to regulate human HTT gene expression. The 
expression of Sp1 enhanced HTT gene transcription and the inhibition of Sp1-mediated 
transcriptional activation reduced HTT gene expression, suggesting that the dysregulation 
of Sp1-mediated Htt transcription, combining with mHtt detrimental effect on other Sp1-
mediated downstream gene function, may contribute to the pathogenesis of HD (Wang et 
al., 2012). 
1.2.3 Mutant huntingtin promotes mitochondrial dysfunction and 
dysregulation of energy metabolism 
1.2.3.1 Glucose transport, uptake and metabolism in HD 
The normal function of the brain requires high amounts of energy which is 
provided mainly through the glucose metabolism within cells (Siegel et al., 1999). When 
glucose metabolism is reduced, several dysfunctions in the brain may occur. The first 
evidence that energy metabolism has an important role in HD pathogenesis came from the 
observation that HD patients exhibit prominent weight loss, despite sustained caloric 
intake (O’Brien et al., 1990). Indeed, glucose hypometabolism appears to be present in 
HD and was demonstrated to begin in the asymptomatic phase of the disease, and in 
degenerating regions of HD, striatum and cortex (Andrews and Brooks, 1998; Kuwert et 
al., 1990). However, more recently, a study suggested that hypothalamus, but not the 
basal ganglia, is the brain region responsible for metabolic impairments in HD, since the 
selective hypothalamic expression of a short fragment of mHtt in BACHD mice was 
sufficient to recapitulate the glucose metabolic disturbances that occur in HD patients, 
whereas the selective hypothalamic inactivation of the expanded HTT gene prevented the 
development of the metabolic phenotype (Hult et al., 2011). An essential step for glucose 
consumption by cells is its transportation across plasma membrane, which is facilitated 
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via several glucose transporters (GLUT). Thus, a dysregulation in these proteins may 
reflect a lower cellular capacity to use glucose. Although no differences were observed at 
earlier HD stages (grade 1), in advanced stages (grade 3) GLUT1 and -3 protein levels 
were decreased by three- and four-fold, respectively, in the CN of post-mortem HD 
patients (Gamberino and Brennan, 1994), suggesting reduced glucose transport by striatal 
cells. In fact, a significant decrease in glucose uptake in the cortex and striatum of both 
pre-symptomatic and symptomatic HD patients was verified (Antonini et al., 1996; 
Ciarmiello et al., 2006). Also, GLUT1 and -4 gene expression were downregulated in 
COS-7 and SK-N-SH cells expressing N-terminal (exon-1) mHtt with 74Q, and in the 
muscle of 11- and 15-week-old R6/2 HD mice, respectively, whereas GLUT1 
overexpression or treatment with glucose decreased mHtt aggregation and cell death (Kita 
et al., 2002; Ravikumar et al., 2003; Strand et al., 2005),  indicating a protective role of 
GLUT1 against mHtt-induced degeneration by increasing intracellular glucose 
concentrations.  
When enters the cell, glucose is irreversibly phosphorylated by hexokinase (HK) 
in an ATP-dependent process, resulting in glucose-6-phosphate (G6P) that serves as a 
substrate for both the pentose phosphate pathway and glycolysis (Berg et al., 2006). On 
contrary to the reported decreases in glucose transport and cellular uptake, HK was shown 
to be actively increased in erythrocytes and fibroblasts from HD patients (Cooper et al., 
1998; Zanella et al., 1980), in posterior brain (the posterior part of the striatum, 
hippocampus, thalamus, parietal and occipital cortices) homogenates of advanced 
symptomatic 20-week-old N171-82Q HD mice and 3-NP-treated mice (Oláh et al., 2008), 
suggesting increased glucose phosphorylation and enhanced metabolism in HD. The 
increase in HK activity might reflect increased G6P levels, which can be used by the 
pentose phosphate pathway. In this pathway, β-nicotinamide adenine dinucleotide 2′-
phosphate, reduced (NADPH) is the major cofactor produced by the action of glucose-6-
phosphate dehydrogenase (G6PD) and 6-phophogluconate dehydrogenase (6PGD) and is 
a required cofactor in the regeneration of reduced glutathione (GSH) by glutathione 
reductase (GRed), and for the reductive reactions of lipid biosynthesis (Heales and 
Bolanos, 2002). Indeed, G6PD activity was reported to be increased in erythrocytes from 
HD patients, correlating with increased HK activity (Zanella et al., 1980). However, in 
HD cybrids, G6PD activity was significantly decreased (Ferreira et al., 2011). Thus, it 
might be possible that different tissues or cells in HD have contrary glucose metabolic 
rate or it might be dependent on the stage of the disease. In fact, in the striatum at 4-week-
31 
old R6/2 HD mice, the expression levels of the non-neuronal enolase (ENO1 or enolase 1, 
(alpha), a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate  to 
phosphoenolpyruvate), were significantly increased, whereas in the striatum of 
symptomatic (10 week-old) R6/2 HD mice, enolase activity was significantly decreased, 
which correlated with increased ENO1 and enolase 2 (gamma, neuronal; ENO2) protein 
oxidation (Perluigi et al., 2005), suggesting a decreased glycolytic rate due to increased 
protein oxidation in the striatum along HD progression. Also in the striatum of 
symptomatic (10-week-old) R6/2 HD mice, pharmacological inhibition of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH, a glycolytic enzyme that catalyzes the conversion 
of glyceraldehyde 3-phosphate to D-glycerate 1,3-bisphosphate) induced  decreased 
protein levels of glutamate transporters and enhanced glutamate neurotoxicity (Estrada-
Sánchez et al., 2010), indicating a higher dependence of glycolysis to induce 
neuroprotection. Moreover,  GAPDH has been described to bind  to mHtt polyQ repeats 
(Burke et al., 1996), and to co-localize with mHtt aggregates in a N-terminal polyQ-
region dependent manner (Wu et al., 2007), leading to GAPDH inactivation, which may 
cause a deficit in cerebral energy metabolism (Cooper et al., 1998). Indeed, mHtt 
interaction with GAPDH altered the subcellular localization of GAPDH, increasing its 
nuclear localization and decreasing its glycolytic activity in both fibroblasts from HD 
patients and in neurons from a transgenic HD mouse model expressing full-length mHtt 
carrying 89Qs (Mazzola and Sirover, 2001, 2002; Senatorov et al., 2003). Interestingly, 
GADPH was also shown to induce mHtt nuclear translocation involving a ternary 
complex of mHtt, GAPDH and Siah1, an ubiquitin-E3-ligase thus enhancing cytotoxicity 
(Bae et al., 2006);  conversely GAPDH knockdown in SK-N-SH neuroblastoma cells 
expressing mHtt (exon 1) with 103Qs reduced mHtt aggregation by 45-50% (Lazarev et 
al., 2013), indicating an aggregation-dependent GAPDH process in HD. Importantly, 
GAPDH was recently shown to supply energy, independently of mitochondria, for the 
both anterograde and retrograde fast axonal transport, in a wild-type Htt-dependent 
mechanism (Zala et al., 2013), which might indicate that the fast axonal transport is 
compromised by the expression of mHtt and/or loss of wild-type Htt activity in HD.  
Pyruvate, the glycolytic final product, can be converted into lactate by the 
reversible action of lactate dehydrogenase (LDH) or consumed by pyruvate 
dehydrogenase (PDH) to produce NADH and acetyl-coenzyme A. The latter is used by 
the tricarboxylic acid cycle (TCA, Krebs or citric acid cycle) for production of NADH 
that is required for oxidative phosphorylation to produce high levels of ATP (Nelson and 
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Cox, 2004). In neurons, LDH isoforms are adapted to favor lactate to pyruvate 
conversion, whereas in astrocytes LDH primarily functions to convert pyruvate into 
lactate, which is then released to the extracellular space where it is taken up by neurons 
and converted to pyruvate. Thus, apart from direct glucose utilization, lactate brain levels 
are essential for neuronal activation (O’Brien et al., 2007; Turner and Adamson, 2011). In 
the basal ganglia, striatum and in the cortex of presymptomatic, early manifest and 
advanced stages HD patients, lactate levels and lactate/pyruvate ratio were significantly 
elevated (Jenkins et al., 1993; 1998; Koroshetz et al., 1997; Reynolds et al., 2005). 
Increased lactate/pyruvate ratio was also found in cybrid lines from HD patients (Ferreira 
et al., 2011). However, in a juvenile HD case, an 8-year-old boy with 85 CAG repeats did 
not present significant lactate changes in the basal ganglia (Schapiro et al., 2004), 
whereas a decrease in lactate levels was detected in the cerebrospinal fluid of 
symptomatic adult-onset HD patients (Garseth et al., 2000), which appears to indicate that 
lactate alterations in HD are a region/tissue and/or polyQ length dependent, and also can 
change with disease progression. In fact, decreased lactate levels were detected in cortex, 
cerebellum and brainstem of 4 week-old (presymptomatic) and 8-week-old (early 
symptomatic) R6/2 HD mice, and in the muscle of 8-week-old R6/2 HD mice (Tsang et 
al., 2006). On the other hand, in 12 week-old R6/2 HD mice (symptomatic), lactate levels 
were increased in striatum, cortex, cerebellum and in brainstem and decreased in muscle 
and in urine (Fox et al., 2007; Tsang et al., 2006). Also, a region-selective increase in 
striatal lactate was detected in 3-NP-treated primates and rats (Dautry et al., 1999; 
Matthews et al., 1998). Thus, neuronal consume of lactate might be affected leading to 
reduced pyruvate levels. In fact, administration of pyruvate in rodents significantly 
reduced QA-mediated striatal neuronal degeneration and oxidative damage, whereas 
lactate, was ineffective against oxidative damage and was only partially effective in 
reducing lesions and neuronal degeneration (Ryu et al., 2004), indicating that striatal 
pyruvate production in HD could be diminished or its consume by PDH to produce 
NADH and acetyl-coenzyme A is necessary to offer neuroprotection in HD. In fact, PDH 
complex activities were reduced in CN and putamen of HD patients (Sorbi et al., 1983), 
and decreased PDH activity in basal ganglia was significantly augmented with increasing 
duration of illness, possibly due to a progressive loss of neurons in HD CN (Butterworth 
et al., 1985). Decreased PDH activity along with decreased mitochondrial β-nicotinamide 
adenine dinucleotide, reduced (NADH)/β-nicotinamide adenine dinucleotide (NAD)(t) 
ratio were also observed in HD cybrids, which was correlated with a decrease in PDH 
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E1alpha subunit protein levels (Ferreira et al., 2011). Also, in R6/2 HD mice PDH 
expression levels decreased with age (Perluigi et al., 2005). Therefore, the supply of 
cofactors for the TCA cycle might be compromised in HD. In fact, both the TCA 
enzymes citrate synthase and aconitase activities were decreased in CN, putamen and 
cortex of HD patients (Tabrizi et al., 1999; Sorolla et al., 2008), and in the striatum of 12-
week-old R6/2 HD mice (Tabrizi et al., 2000).  
Thus, the energy production by glycolysis might be affected in HD, which can 
contribute to decreased TCA enzymes activities and consequently less NADH available 
for the oxidative phosphorylations to produce ATP. However, other intracellular systems 
can be an alternative for the energy production, such as the phosphocreatine/creatine 
system. 
1.2.3.2 Phosphocreatine/creatine system and ATP in HD 
The phosphocreatine/creatine system can generate ATP 10 times faster than 
mitochondrial oxidative phosphorylation and 40 times faster than glycolysis (Wallimann 
et al., 1992). Creatine is a substrate of cytosolic and mitochondrial creatine kinases (CK), 
which catalyzes the reversible phosphorylation of creatine, using ATP as a phosphate 
donor to form phosphocreatine and ADP as a by-product. This reaction can be reversible, 
as CK can convert phosphocreatine and ADP into creatine plus ATP (Woznicki and 
Walker, 1979), controlling thereby ATP concentrations through the transfer of high-
energy phosphate from phosphocreatine to ADP (Wyss and Kaddurah-Daouk, 2000). The 
brain expresses high levels of CKs due to the requirement to consume elevated energy 
levels (Wallimann, 2007). Brain-specific cytosolic (BB-CK or CKB) and ubiquitous 
mitochondrial (uMt-CK) are the two isoforms of CK expressed in brain tissues and are an 
easy target of oxidative damage (Zhang et al., 2011). Indeed, oxidation and decreased 
mRNA and protein levels and activity of CKB and uMt-CK were detected in the striatum 
(Crocker et al., 2006; Kim et al., 2010; Perluigi et al., 2005; Sorolla et al., 2008; 2010; 
Zhang et al., 2011) and blood (Kim et al., 2010) of HD patients, and in the striatum of 
R6/2, N171-82Q, and HdhQ111 HD mouse models, in 3-NP-treated rats, and in HD 
STHdh
Q109
 and ST14A 109Q striatal cells (Lagoa et al., 2009; Lin et al., 2013; Zhang et
al., 2011), which might be associated with reduced striatal ATP and creatine levels 
(which correlated with motor and cognitive performance and with the CAG repeat length) 
verified in presymptomatic and symptomatic adult-onset HD patients, in juvenile HD 
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cases (Alcauter-Solórzano et al., 2010; Clarke et al., 1998; Reynolds et al., 2005; 2008; 
Sánchez-Pernaute et al., 1999; Schapiro et al., 2004; van den Bogaard et al., 2011), in 
STHdh
Q111/Q111
 striatal cells (Gines et al., 2003; Milakovic and Johnson, 2005), and in 3-
NP-treated rodents and primates (Dautry et al., 1999; Matthews et al., 1998; Mochel et 
al., 2010). Moreover, mHtt suppressed the activity of the promoter of the CKB gene, 
which contributed to decreased CKB expression in HD, whereas the overexpression of 
CKB rescued ATP depletion, aggregate formation, impaired proteasome activity and 
shortened neurites induced by mHtt (Lin et al., 2013).   
1.2.3.3 Mitochondrial abnormalities in HD 
Under normal conditions, the ATP produced by the mitochondrial respiratory 
chain oxidative phosphorylation (OXPHOS) is responsible, for more than 80% of the 
ATP produced in cells (Papa et al., 2012). However, altered mitochondrial function can 
lead to a disruption of energy balance and consequent neuronal degeneration, which can 
be due to increased mtDNA damage. In fact, in HD patients, decreased activities of 
mitochondrial complexes I, II/III, and IV, were previously detected in striatum CN and 
putamen (Benchoua et al., 2006; Brennan et al., 1985; Browne et al., 1997; Butterworth et 
al., 1985; Gu et al., 1996; Tabrizi et al., 1999), in muscle (Arenas et al., 1998), and 
platelets (Parker et al., 1990; Silva et al., 2013), which can be associated with increased 
mtDNA deletions that were detected in leukocytes, lymphocytes and cortex from HD 
patients (Banoei et al., 2007; Chen et al., 2007; Horton et al., 1995; Liu et al., 2008), 
correlating with CAG repeat length (Liu et al., 2008). Moreover, in symptomatic R6/2 
and N171-82Q HD mouse models, a significant reduction in striatal and cortical activities 
of mitochondrial complexes I, II and IV, and increased striatal mtDNA deletions and 
damage which increased with age, were also observed (Acevedo-Torres et al., 2009; Aidt 
et al., 2013; Benchoua et al., 2006; Chaturvedi et al., 2010; Kim et al., 2011; Oláh et al., 
2008; Tabrizi et al., 2000). Decreased activities of mitochondrial complexes I, IV and V, 
and decreased mtDNA copy number and transcripts and accumulation of mtDNA 
deletions, were further verified in STHdh
Q111/Q111
 striatal cells (Napoli et al., 2013).
Indeed, striatal cells showed higher basal levels of mitochondrial-generated ROS, mtDNA 
lesions and a lower spare respiratory capacity compared to wild-type cells (Siddiqui et al., 
2012). Considering the role of ROS in mtDNA damage, treatment with a synthetic 
mitochondria-specific antioxidant, XJB-5-131, improved mitochondrial function in 
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isolated organelle fractions from HdhQ150 knock-in mice, and restored mtDNA copy 
number in vivo to levels similar to those of the controls (Xun et al., 2012). These results 
suggest that oxidative stress-induces mitochondrial abnormalities that are potentiated 
upon expression of mHtt. 
The replication and transcription of the mitochondrial genome can be effectuated 
by mitochondrial transcription factors and regulators of mitochondrial biogenesis; thus 
maintaining mitochondrial function and energy metabolism, and cell survival (Marín-
García, 2013). Such proteins include the peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), a transcriptional co-activator and a master 
regulator of mitochondrial biogenesis (Puigserver and Spiegelman, 2003). PGC-1α up-
regulates the expression and forms heteromeric complexes with the nuclear respiratory 
factors (NRF)-1 and -2 (Lin et al., 2005; Wu et al., 1999), which in turn regulate the 
expression of many nuclear-encoded mitochondrial genes, such as cytochrome c, and the 
mitochondrial transcription factors A (Tfam) and B (TFB1M, and TFB2M). Importantly, 
Tfam acts on the promoters within the D-loop region of mtDNA and regulates the 
replication and transcription of the mitochondrial genome (Gleyzer et al., 2005; 
Handschin and Spiegelman, 2006; Kelly and Scarpulla, 2004; Scarpulla, 2008a,b). 
Moreover, NRF-1 and -2 were shown to regulate all ten nuclear-encoded subunits of 
complex IV in neurons (Dhar et al., 2008), and several nuclear-encoded subunits of 
complexes I, II, III and V (Marín-García, 2013). The findings that PCG-1α knockout mice 
revealed neurological abnormalities, such as dystonia and clasping and the fact that they 
were lean and presented the most pronounced degeneration in the striatum (Lin et al., 
2004) suggested that PGC-1α could represent a target in HD. In fact, PGC-1α expression 
and activity were reported to be impaired in cell models and transgenic mouse models of 
HD and in brain and muscle tissues from HD patients (Chaturvedi et al., 2009; Cui et al., 
2006; McGill and Beal, 2006; Weydt et al., 2006), whereas overexpression in in vitro 
models of HD and in and N171-82Q HD mice or lentiviral delivery of PGC-1α to the 
striatum of R6/2 HD mice, prevented mHtt protein aggregation, restored mitochondrial 
function, reduced mitochondrial toxicity, completely prevented striatal atrophy at the site 
of PGC-1α injection, rescued HD neurological phenotypes, and neurodegeneration in part 
by attenuating oxidative stress  (Cui et al., 2006; Weydt et al., 2006; Tsunemi et al., 
2012). In a study performed in over 400 German HD patients, polymorphisms in NRF-1, 
Tfam, and PGC-1α showed significant correlation with the age at onset (Taherzadeh-Fard 
et al., 2009; 2011). Also, reductions in Tfam and PGC-1α observed in HD post-mortem 
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brain tissue correlated with reductions in the number of mitochondria (Kim et al., 2010). 
mHtt was also reported to bind to the PGC-1α promoter, causing decreased transcription 
of its mitochondrial target genes (e.g. Tfam and cytochrome c) and impaired 
mitochondrial function (Cui et al., 2006; McGill and Beal, 2006).  
Mitochondrial bioenergetics seems strongly dependent on mitochondrial 
morphology and changes in morphology seem to impact on bioenergetic state. 
Mitochondrial shape is largely determined by a balance between fission and fusion events 
and this equilibrium maintains steady state mitochondrial morphology, mtDNA and 
metabolic integration, bioenergetic functionality and organelle number (Griparic and van 
der Bliek, 2001). Mitochondrial fission is an essential event for the accurate 
rearrangement of mtDNA during cell division and also for the transport of mitochondria 
to new cells during mitosis and meiosis (Hales, 2004; Szabadkai et al., 2004). 
Mitochondrial fission is regulated and maintained by two GTPase genes: mitochondrial 
fission 1 (Fis1) and cytosolic dynamin family member, Drp1. Fis1 is primarily localized 
on the outer mitochondrial membrane and participates in mitochondrial division (Chen 
and Chan, 2005). Drp1 is cytosolic recruited by mitochondrial elongation factors 1 
(Mid51) and 2 (Mid49),  and Mitochondrial Fission Factor (MFF) to mitochondria 
(Elgass et al., 2013), often at sites where mitochondria make contact with the 
endoplasmic reticulum (Friedman et al., 2011) to form spirals around mitochondria that 
constrict to sever both inner and outer membranes (Elgass et al., 2013). In contrast, 
mitochondrial fusion is a two-step process, in which the outer and inner membranes fuse 
by separate events. It is accepted that this event occurs as a way to recover the integrity 
and function of damaged/depolarized membranes, being essential to maintain a 
homogenous organelle population and ensuring inter-complementation of mtDNA (Twig 
et al., 2008a,b). The outer membrane fusion is controlled by two large membrane GTPase 
proteins, mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2), whereas inner membrane fusion is 
controlled by OPA1 (Chen and Chan, 2010). In HD, increased mitochondrial fission and 
decreased fusion has been described. Increased expression of Drp1 and Fis1 and reduced 
expression of Mfn’s and OPA1 was verified in cellular models of HD, and in HD post-
mortem brain tissues. Interestingly, mHtt was shown to bind and increase Drp1 enzymatic 
activity and thus mitochondrial fission (Haun et al., 2013; Kim et al., 2010; Shirendeb et 
al., 2011; 2012; Song et al., 2011; Wang et al., 2009). Moreover, S-nitrosylation of Drp1, 
resulting in increased Drp1 activity, was shown to mediate mHtt-induced mitochondrial 
fragmentation, resulting in dendritic spine loss in both human HD brains and animal 
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models of HD (Haun et al., 2013). Furthermore, mitochondrial fission was described to 
participate in mHtt-induced cell death in HD (Liot et al., 2009). Mitochondrial 
fragmentation, increased vacuolization, disrupted cristae, swollen and also giant 
mitochondria and increased susceptibility towards apoptotic stimuli were also observed in 
in skin fibroblasts and muscle of HD patients, and in HD transgenic mice and cellular 
models (Bayram-Weston et al., 2012; Costa et al., 2010; Squitieri et al., 2010). In 
progenitor and differentiated neuron-like STHdh
Q111/Q111
 cells, changes in mitochondrial
morphology and reduced mitochondrial import of Cys-rich proteins were also observed 
(Napoli et al., 2013). Changes in mitochondrial dynamics and morphology in HD appear 
to be related with the previous observation that mHtt aggregates and/or N-terminal 
fragments of mHtt localize on brain mitochondria of transgenic and knock-in HD models, 
and in human neuroblastoma and STHdh
Q111/Q111 
cells, whereas mHtt-induced
mitochondrial permeability transition (MPT) pore opening contributing for the occurrence 
of intrinsic apoptotic cell death, and impaired vesicular and mitochondrial fast axonal 
trafficking in mammalian neurons in vitro and in whole animals in vivo, which occurred 
early in development prior to the onset of measurable neurological or mitochondrial 
abnormalities (Chang et al., 2006; Choo et al., 2004; Orr et al., 2008; Panov et al., 2002; 
Petrasch-Parwez et al., 2007; Trushina et al., 2004). 
Taken together, these data clearly show that energy metabolism dysregulation and 
mitochondrial dysfunction is present in HD, which could be related to increased oxidative 
stress that will be discussed in the next chapter. 
1.2.4 Mutant huntingtin induces oxidative stress 
Oxidative stress classical definition is the imbalance of pro-oxidants and 
antioxidants in cells, which can result from: 1) an increase in oxidant formation; and/or 2) 
a decrease in antioxidant protection; and/or 3) a failure in the repair of oxidative lesions. 
When the pro-oxidant/antioxidant equilibrium is lost, oxidative stress takes place, altering 
and damaging many intracellular molecules, including DNA, RNA, lipids and proteins 
(Veskoukis et al., 2012). However, the contemporary definition of oxidative stress has 
been refined to account for two different mechanistic outcomes, macromolecular damage, 
and disruption of thiol redox circuits, involving aberrant cell signaling and dysfunctional 
redox control (Jones, 2006; 2008). 
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1.2.4.1 Mutant huntingtin causes increased generation of reactive 
species and oxidative damage 
Damage in cells is induced by free radicals, which are molecules containing one or 
more unpaired electrons in their atomic or molecular orbitals (Halliwell and Gutteridge, 
1999). Reactive species comprise both free radical and non-free radical intermediates and 
can be classified into four groups based on the main atom involved: i) ROS, ii) reactive 
nitrogen species (RNS), iii) reactive sulfur species (RSS) and iv) reactive chloride species 
(RCS) (Sosa et al., 2013). Oxygen-derived reactive species are the major secondary 
products formed in cells of aerobic organisms and characterize the most important class 
of reactive compounds generated in living systems (Raha and Robinson, 2001). 
Depending on the stability of the molecule, ROS half-lives vary from a few nanoseconds 
to hours, and include superoxide anion (O2
−
), H2O2, hydroxyl radical (

OH), peroxyl
radical (RO2

), alkoxyl radical (RO

), hydroperoxyl radical (HO2

), hypochlorous acid
(HOCl), hypobromous acid (HOBr), singlet oxygen (
1
O2) and ozone (O3) (Dalle-Donne et
al., 2005; Sosa et al., 2013). H2O2 is not a free radical, although it can freely diffuse 
across biological membranes and may cause severe damage to essential macromolecules. 
In the presence of transition metals, such as iron or copper, H2O2 can be converted to 
highly reactive 

OH, which is recognized as one of the most potent oxidants in nature
(Fridovich, 1995). The most abundant RNS is nitric oxide (

NO), which is able to react
with certain ROS; 

NO easily reacts with O2
− to form peroxynitrite anion (ONOO−),
which is an oxidant and nitrating molecule, that can cross cell membranes and damage 
intracellular components. 

NO is also converted into peroxynitrous acid (ONOOH) and
into 

OH and nitrite anion (NO2−) (Sosa et al., 2013). Several enzymatic systems 
contribute to intracellular ROS production, including NADPH oxidase (NOX) (Krause, 
2004), cytochrome P450-dependent oxygenases (Bernhardt, 1996), and xanthine oxidase 
(XO) (Harrison, 2002). Non-enzymatic sources of ROS occur mainly in mitochondria, 
believed to be major intracellular source of ROS. During respiration, electrons released 
from the mitochondrial electron transport chain incompletely reduce O2 to form O2
−
 as
by-product. The site of electron leakage from the electron transport chain to form O2
− is
generally considered to be a semiquinone radical (CoQ10H
•
) or reduced flavin (FMN and
FAD), at coenzyme Q10 (CoQ10)-binding-sites of complexes III and I, respectively 
(Brand, 2010; Murphy, 2009; Poyton et al., 2009; Turrens, 2003). Although 
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mitochondrial complexes I and III are the most studied and believed to be the major 
mitochondrial source of ROS, other mitochondrial enzyme complexes have also been 
reported or demonstrated to produce ROS. Examples include the dihydrolipoamide 
dehydrogenase-containing FAD-linked pyruvate and alpha-ketoglutarate dehydrogenase 
complexes (Starkov et al., 2004), as well as the flavoenzymes alpha-glycerophosphate 
dehydrogenase (Tretter et al., 2007), and the electron-transferring flavoprotein:quinone 
(Q) oxidoreductase (ETFQOR) of fatty acid β-oxidation (St-Pierre et al., 2002). 
Although ROS have some biological positive effects by performing an essential 
physiological role in cell signaling, excessive generation and/or long-term exposure to 
high amounts of ROS can lead to profound toxic effects, by reacting with vital cell 
components and alter intrinsic membrane properties like fluidity, ion transport, loss of 
enzyme activity, protein cross-linking, inhibition of protein synthesis, and DNA damage 
ultimately resulting in apoptotic or necrotic cell death (Fialkow et al., 2007; Koppula et 
al., 2012). The nervous system is particularly vulnerable to ROS. In fact, the brain 
contains high amounts of polyunsaturated fatty acids that are highly susceptible to lipid 
peroxidation, presents high oxygen consumption for energy production and possesses a 
deficit in the antioxidant systems comparatively to other organs (Mariani et al., 2005). 
The striatum, the area that is largely affected in HD, is highly susceptible to dysfunction 
of mitochondrial oxidative phosphorylation (Pickrell et al., 2011), and it is known that 
acute poisoning with mitochondrial toxins (cyanide, sodium azide, and 3-NP) and also 
mitochondrial defects of genetic origins (e.g., mutation or deletion of mtDNA or nuclear 
DNA (nDNA)) can lead to striatal degeneration (Beal, 1992; Brouillet et al., 1999). 
Moreover, the striatum of young rats has been shown to display decreased antioxidant 
capacity compared with the cortex or other brain areas (Balu et al., 2005). Furthermore, 
the brain expresses high levels of NOX and XO, which makes the brain more prone to 
increased ROS production. Activated forms of NOX, which require interaction between 
cytosolic and membrane-bound subunits, and which primary function is to catalyze the 
transfer of electrons across the plasma membrane from NADPH to molecular oxygen via 
their “Nox” catalytic subunit, generating O2
−
 and H2O2, are among the major sources of
ROS in the CNS. Increasing evidence suggests that NOX has important roles in 
neurodegenerative diseases. NOX was shown to mediate striatal neuronal injury after 
transient global cerebral ischemia (Gao et al., 2012; Koppula et al., 2012; Serrano et al., 
2003; Yoshioka et al., 2011). In HD, NOX activity was found to be elevated in human 
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HD post-mortem cortex and striatum and highest in striatum of presymptomatic 
individuals. Synaptosome fractions obtained from cortex and striatum of HD(140Q/140Q) 
mice also showed increased NOX activity at 3 months of age, which was potentiated with 
increased age, compared to controls, correlating with increased ROS and neurite swelling. 
Concordantly, NOX inhibition significantly reduced ROS formation, neurite swelling and 
neuronal cell death. Also, mHtt colocalized at plasma membrane lipid rafts with gp91-
phox, a catalytic subunit for the NOX2 isoform, and HD(140Q/140Q) mice bred to gp91-
phox knock-out mice presented decreased NOX activity and normal ROS levels, as well 
as improved survival (Valencia et al., 2013). Moreover, NOX was involved in striatal 
damage evoked by QA in adult rats (Maldonado et al., 2010). XO is an enzyme involved 
in the purine/adenosine metabolism. While the major role of XO is the conversion of 
hypoxanthine and xanthine to uric acid, an interconvertible form, xanthine 
dehydrogenase, also exists and is responsible for conversion of NAD
+
 to NADH. The
action of these enzymes produces O2
−
 and H2O2 (Zhang et al., 1998), while uric acid is a
potent reducing agent (electron donor) and antioxidant. In blood plasma, over half of the 
antioxidant capacity derives from uric acid (Maxwell et al., 1997). In the brain of patients 
with depression or with schizophrenia were found significant increases in XO activity in 
the thalamus and putamen, and significant decreases in XO activity in the occipital cortex 
and thalamus, respectively, with a significant correlation between treatment with 
chlorpromazine (a dopamine antagonist of the typical antipsychotic class of medications 
for the treatment of schizophrenia) and increased XO activity in the putamen and the 
temporal cortex (Michel et al., 2010; 2011). In this respect, XO was demonstrated to 
actively diminish dopamine transporter function in rat striatum (Fleckenstein et al., 1997). 
Also, an age-related increase in XO activity, which significant correlated with increased 
lipid peroxidation, was found in the cerebral cortex of adult female mice (Vida et al., 
2011). In HD human post-mortem cerebral cortex, uric acid levels were found to be 
reduced (Beal et al., 1992), which suggest that XO activity might be decreased and also 
decreased antioxidant capacity due to low levels of uric acid. On the other hand, treatment 
with allopurinol or oxypurinol, inhibitors of XO activity, blocked peroxide accumulation 
and cell death caused by 3-hydroxykynurenine (3-HK) (a tryptophan metabolite whose 
level in the brain is markedly elevated in HD) in primary neuronal cultures prepared from 
rat striatum, suggesting that XO is involved in 3-HK-induced neurotoxicity in HD (Okuda 
et al., 1996), and that cytosolic ROS production might be enhanced in HD striatum. 
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Nevertheless, mitochondrial ROS formation, including O2
−
, was also verified in
fibroblasts from HD patients (Wang et al., 2013). Increased ROS formation was also 
observed in HD cybrids and potentiated with treatment with 3-NP or to STS, an inducer 
of apoptosis (Ferreira et al., 2010). Increased ROS, including O2
−
 formation, were found
in the brain striatum and cortex of symptomatic R6/1, R6/2, and N171-82Q HD mouse 
models (Ellrichmann et al., 2011; Pérez-Severiano et al., 2004; Sadagurski et al., 2011; 
Stack et al., 2010; Tabrizi et al., 2000), and in YAC128 HD mice embryonic fibroblasts 
(Wang et al., 2013). Furthermore, H2O2 treatment potentiated mHtt-induced increased 
ROS levels and cell death, and induced aggregation of mHtt N-terminal fragments, which 
in turn directly caused ROS production in a polyQ length-dependent manner, preceding 
cell death and impairing proteasomal function in neuronal and non-neuronal cellular 
models (Goswami et al., 2006; Hands et al., 2011; Wyttenbach et al., 2002).  
Since molecular products from oxidative/nitrosative stress are generally more 
stable than oxidants and nitrosants themselves, ROS/RNS measurements often involve 
determining levels of their oxidation target products (Griffiths et al., 2002). Several 
biomarkers are normally used to detect oxidations in proteins, lipids and DNA.  
Oxidative damage to nucleotides causes modification of pyrimidine and purine 
bases and is commonly measured by in the detection of 8-hydroxy-2’-deoxyguanosine (8-
OHdG) adducts (Evans et al., 2004; Kasai, 2002). Particularly, mtDNA is highly 
susceptible to ROS-induced damage because it is located in close proximity to the 
production site of ROS, mtDNA repair mechanisms are limited and lacks histone 
protection. As a result, deletions in mtDNA accumulate, ultimately leading to a decline in 
mitochondrial function and concomitant enhanced ROS production (Lin and Beal, 2006). 
Significant increases in the levels of nuclear and mitochondrial DNA-8-OHdG adducts 
has been shown in the CN, cortex, serum, leukocytes, and in plasma of HD patients 
(Browne et al., 1997; Chen et al., 2007; Polidori et al., 1999; Shirendeb et al., 2011; 
Hersch et al., 2006; Túnez et al., 2011). Also, in HD mouse models, DNA oxidation, 
including mtDNA, was significantly increased in forebrain tissue, cortex, striatum, urine 
and plasma of R6/2 (Acevedo-Torres et al., 2009; Bogdanov et al., 2001; Tabrizi et al., 
2000) with striatum being more vulnerable to damage than cortex (Acevedo-Torres et al., 
2009), in striatal tissues of N171-82Q (Stack et al., 2010), and in embryonic fibroblasts 
from YAC128 (Wang et al., 2013). Moreover, systemic and intrastriatal injections of 3-
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NP or QA in rodents induced striatal increases in DNA oxidation (Acevedo-Torres et al., 
2009; Maldonado et al., 2012). 
Reaction of free radicals with unsaturated lipids may trigger lipid peroxidation 
chain reaction, resulting in the oxidative breakdown of cellular membranes. Usually lipid 
peroxidation is detected using various biomarkers, such as malondialdehyde (MDA), 4-
hydroxynonenal (4-HNE), acrolein and isoprostanes (Dalle-Donne et al., 2006; Mariani et 
al., 2005; Morrow et al., 1999). MDA is a physiologic ketoaldehyde produced by 
peroxidative decomposition of unsaturated lipids as a byproduct of arachidonic acid 
metabolism (Dalle-Donne et al., 2006). Acrolein is the simplest unsaturated aldehyde and 
is formed in vivo by the metal-catalyzed oxidation of polyunsaturated fatty acids, 
including arachidonic acid (Uchida et al., 1998). 4-HNE is a major and toxic aldehyde 
generated by free radical attack on omega-6 polyunsaturated fatty acids (arachidonic, 
linoleic, and linolenic acids) (Uchida, 2003) and is considered a second toxic messenger 
of oxygen free radicals (Esterbauer et al., 1991; Dalle-Donne et al., 2006). Prostaglandin 
F2-like compounds (F2-isoprostanes, F2-IsoPs), are formed in vitro and in vivo (Morrow 
et al., 1990) by free radical-catalyzed peroxidation of phospholipid-bound arachidonic 
acid (Comporti et al., 2008). Due to F2-IsoPs release into the circulation and are less 
reactive that other lipid peroxidation products, they can be detected more easily in plasma 
and urine, and thus are considered the most reliable markers of oxidative stress (Comporti 
et al., 2008; Morrow et al., 1996). MDA, 4-HNE, and F2-IsoPs levels were found to be 
elevated in the striatum, cortex, cerebrospinal fluid, and in blood of HD patients (Browne 
et al., 1999; Chen et al., 2007; Lee et al., 2011; Montine et al., 1999; Stoy et al., 2005), 
with increased MDA levels correlating significantly with disease severity (Chen et al., 
2007). Also, in HD mouse models, increased lipid peroxidation was detected in the 
striatum, cortex and whole brain of symptomatic R6/2, N171-82Q, and CAG140 (Lee et 
al., 2011; Pérez-Severiano et al., 2000; Sadagurski et al., 2011; Tabrizi et al., 2000), co-
localizing with mHtt inclusions (Lee et al., 2011). Furthermore, systemic and intrastriatal 
administration of QA in rats or exposure to 3-NP, QA or 3-NP plus QA in striatal and 
cortical mice or rat synaptosomes and slices, also induced an increase in striatal lipid 
peroxidation (Colle et al., 2012; Herrera-Mundo and Sitges, 2013; Maldonado et al., 
2012; Túnez et al., 2006). Also, increased cellular immunoreactivity for 4-HNE was 
observed in a cell line model of HD regulated by doxycycline, the Tet-mtHtt-Q103-EGFP 
cells, which was enhanced following exposure to H2O2 (Lee et al., 2011).  
43 
Oxidative changes in essential proteins may result in functional loss of proteins. 
Irreversible oxidation in proteins are usually detected by determining the levels of protein 
carbonyl groups and 3-nitrotyrosine (3-NT) and reversible protein oxidations can be 
measured by determining cysteine modification products, which includes sulfenic acid (S-
sulfenation), s-nitrosothiols (S-nitrosylation), s-glutathione (S-glutathionylation) and 
protein disulfides (Cai and Yan, 2013) formation. Protein carbonyl groups (aldehydes and 
ketones) can be formed by oxidation of several amino acid residues, including arginine, 
histidine, lysine, proline, threonine and cysteine (Berlett and Stadtman, 1997; Cai and 
Yan, 2013). 3-NT is a product of nitration of protein tyrosine residues by ONOO− 
(Maruyama et al., 1996), thus representing a biomarker for ONOO−. Furthermore, the 
severe impairment in mitochondrial TCA-cycle enzyme aconitase reported in HD brain, 
has been attributed to Fe–S clusters within the protein, which make it a particularly 
vulnerable target for free radical-mediated oxidative damage (Tabrizi et al., 1999). 
Indeed, loss of aconitase activity and increased 3-NT levels were reported in the striatum 
and cortex of HD patients (Browne et al., 1999; Sorolla et al., 2008; Tabrizi et al., 1999). 
Moreover, aldolase C, glial fibrillary acidic protein (GFAP), tubulin, ENO2, and CKB 
were found to be the targets of oxidative modification in both striatum and cortex from 
HD patients (Sorolla et al., 2008). More recently, it was shown that the oxidation of 
mitochondrial enzymes resulted in decreased catalytic activity in striatal samples of HD 
patients, providing a link to the bioenergetic deficits observed in HD (Sorolla et al., 
2010). Oxidation of the mHtt protein was also reported in cellular models. Cysteine 
oxidation within N-terminal of mHtt promoted oligomerization and delayed the clearance 
of soluble protein (Fox et al., 2011). Oxidation of a methionine residue at position 8 of 
exon 1 mHtt was also shown to occur in vivo and in vitro after mHtt aggregation, creating 
additional interactions among mHtt aggregates and altering overall morphologies of the 
aggregates (Mitomi et al., 2012). Also, in HD mouse models, increased 3-NT, protein 
carbonyl groups, and decreased aconitase activity were detected in whole brain, striatum, 
and cortex of R6/2 and N171-82Q (Sadagurski et al., 2011; Stack et al., 2010; Tabrizi et 
al., 2000; Zourlidou et al., 2007). Moreover, a proteomic analysis in the brain of R6/2 
mice revealed increased oxidation in several proteins, namely CK, aconitase, ENO1 and -
2, heat shock protein (Hsp) 90 and the voltage-dependent anion channel 1 (Perluigi et al., 
2005). 
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1.2.4.2 Mutant huntingtin promotes dysregulation of antioxidant 
systems 
To maintain a physiological redox homeostasis, cells are provided of a vast variety 
of endogenous antioxidant proteins that can be produced and regulated via transcription. 
The promoter antioxidant response element (ARE) is a cis-acting regulatory element that 
regulates the antioxidant protein gene transcription of more than 200 cytoprotective 
genes. The activation of ARE-induced gene transcription is induced through the binding 
of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Itoh et al., 
2003; 2004; Kobayashi and Yamamoto, 2006; Zhang et al., 2013). Under normal 
(unstressed) conditions, Nrf2 half life (~20 min) is regulated by several proteins (Table 
1.3 and 1.4). The most known endogenous inhibitor is Kelch-like ECH associated protein 
1 (Keap1), which in association with cullin 3 (Cul3)-Ring box protein 1 (Rbx1) ubiquitin 
ligase complex binds and maintains Nrf2 in cytoplasm to be ubiquitinated and degraded 
by proteasome. However, under conditions of increased ROS formation, Nrf2 dissociates 
from Keap1 prolonging Nrf2 half-life (100-200 min) (Figure 1.3). Oxidative stress-
induced dephosphorylation of Keap1 at Tyr141 and oxidation of cysteine residues within 
Keap1 domain that binds to the Cul3/Rbx1 ubiquitin ligase complex imposes a 
conformational change that weakens its activity as an E3 ligase adaptor, cause the 
formation of disulfide bonds between cysteines of two Keap1 peptides, and also cause the 
switching of Cul3-dependent ubiquitination from Nrf2 to Keap1 leading to its degradation 
and stabilization of Nrf2 (Dinkova-Kostova et al., 2002; Jain et al., 2008; Zhang et al., 
2004; Zhang and Hannink, 2003; Fourquet et al., 2010). However, modifications of 
cysteine thiol groups of Keap1 are important, but are not sufficient for activation of Nrf2. 
The phosphorylation, acetylation, and the conservation of Nrf2 cysteine residues (with the 
exception of Cys183 oxidation which decreases the nuclear export signal (NES) of Nrf2, 
resulting in increased Nrf2 retention in the nucleus), are necessary for Nrf2 activation, 
nuclear translocation, and ARE activation (He and Ma, 2009; Li et al., 2006; Niture et al., 
2014) (Table 1.3 and 1.4). After phosphorylation, Nrf2 is imported to the nucleus, where 
it is acetylated by CBP and forms heterodimers with the receptor-associated coactivator 3 
(RAC3)/AIB-1/steroid receptor coactivator-3, c-Jun, c-Jun dimerization protein 2 (JDP2), 
and small V-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog(s) (Mafs) 
(MafK, MafG or MafF) proteins for high-affinity binding, leading to increased promoter 
specific DNA binding to ARE, and consequent enhancement of Nrf2-ARE transcription 
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of antioxidant genes (Kim et al., 2013; Sun et al., 2009; Tanigawa et al., 2013; Zhang et 
al., 2013) (Table 1.5). In the late response (post-induction of Nrf2) to oxidative stress, 
Keap1 is deubiquitinated, leading to enhanced Keap1-Cul3-Rbx1 complex formation, 
stability and enzymatic activity, and nuclear importation, whereas Nrf2 is deacetylated 
and dephosphorylated, disrupting its binding to ARE, binds to Keap1-Cul3-Rbx1 
complex and both Nrf2 and Keap1 are phosphorylated at Tyr568 and Tyr85, respectively, 
increasing Nrf2 and Keap1-Cul3-Rbx1 complex interaction with exportin 1 (Exp1), 
leading to Nrf2-Keap1-Cul3-Rbx1 nuclear exportation and consequently Nrf2 
degradation, thereby providing a negative feedback mechanism to switch off Nrf2 
activation and restore normal cellular homeostasis  (Jain and Jaiswal, 2006; Kawai et al., 
2011; Kaspar et al., 2012; Sun et al., 2007; Villeneuve et al., 2013) (Figure 1.4).  
4
6
 
Table 1.3 – Nrf2 cellular endogenous inhibitors. 
Endogenous 
inhibitors 
Interaction Function In HD 
Keap1
19
Nrf2 N-terminus Neh2 domain
20
 interacts with 
the C-terminus Kelch-DC domain of the Keap1, 
which in turn through its N-terminal BTB/POZ 
domain
21
, binds to and function as an adaptor 
for the Cul3
22
-E3 ubiquitin ligase complex with 
Rbx1
23,24
 
Nrf2 ubiquitination and consequent 
proteasomal degradation 
Increased Keap1 mRNA but decreased Keap1 
protein levels in STHdh
Q111/Q111
 cells
25
 
β-TrCP26
Both N-terminus and C-terminus portions of 
Nrf2 Neh6 domain interacts with β-TrCP, which 
acts as a substrate receptor for the Skp1
27
-Cul1-
Rbx1 ubiquitin ligase complex
28
 
Nrf2 ubiquitination and consequent 
proteasomal degradation 
β-TrCP was shown to interact with both wild-type 
and mHtt in primary cultures of striatal neurons from 
wild-type mice or HdhQ111/Q111 knock-in mice 
and in HEK293 cells containing Htt fragments, 
decreasing mHtt-induced neuronal cell death
29
 
GSK3-β30
Nrf2 Neh6 N-terminus portion is 
phosphorylated by GSK3-β, resulting in a 
phosphodegron
31
 for the binding of β-TrCP32 
Nrf2 ubiquitination and consequent 
proteasomal degradation 
GSK3-β was found to be actively increased in the 
striatum and cerebral cortex from N171-82Q and 
YAC128 HD mouse models around the onset of 
behavioral deficits, whereas pharmacological 
19 Kelch-like ECH associated protein 1 (Keap1) 
20 Nrf2-ECH homology 2 (Neh2) domain 
21 Bric-a-brac, tramtrack, broad (BTB)/pox virus and Zinc finger (POZ) domain 
22 Cullin 3 (Cul3) 
23 Ring box protein 1 (Rbx1) 
24 Kaspar and Jaiswal, 2010 
25 Jin et al., 2013 
26 Beta-transducin repeat-containing protein (β-TrCP) 
27 S-phase kinase-associated protein 1 (Skp1) 
28 Chowdhry et al., 2013; Rada et al., 2011; 2012 
29 Godin et al., 2010 
30 Glycogen synthase kinase 3 β (GSK3-β) 
31 A phosphodegron is defined as one or a series of phosphorylated residues on the substrate that directly interact with a protein–protein interaction domain in an E3 Ubiquitin-ligase (e.g. an F-
box protein), thereby linking the substrate to the conjugation machinery (Ang  and Harper, 2005) 
32 Chowdhry et al., 2013; Rada et al., 2011; 2012 
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inhibition GSK3-β activity attenuated symptoms, 
and prolonged survival
33
 
USP15
34
Interacts with Keap1
35
 
Specifically deubiquitinates Keap1 leading 
to enhanced Keap1-Cul3-Rbx1 complex 
formation, stability and enzymatic activity, 
and consequent Nrf2 ubiquitination and 
degradation 
mRNA and protein levels of USP15 were decreased 
in N171-82Q HD mice
36
 
Cav-1
37
Nrf2 Cav-1-binding domain (amino acids 281-
289) interacts with the scaffolding domain of 
Cav-1 (amino acids 82-101)
38
 
Recruits Nrf2 to caveolae plasma 
membranes, blocking its nuclear 
translocation and supressing its 
transcriptional activity 
Cav-1 protein was shown to be increased 
STHdh
Q111/Q111
 cells and to interact with mHtt, 
resulting in an increase of intracellular cholesterol  
levels in the CN of post-mortem HD patient’s brains 
(Vonsattel grade 4), in the striatum of 
HdhQ111/Q111 mice, and in STHdh
Q111/Q111
 cells
39
 
PTMA
40
The nuclear protein PTMA binds to the double 
glycine repeat (DGR)/Kelch domain of Keap1, 
in the late response (post-induction of Nrf2) to 
oxidative stress
41
 
Transports Keap1 in complex with Cul3 
and Rbx1 into the nucleus, presumably to 
regulate nuclear level of Nrf2 and rapidly 
switch off the activation of Nrf2 
downstream gene expression 
PTMA was shown to interact with mHtt, enhancing 
mHtt aggregates but preventing mHtt-induced 
cytotoxicity and cell death in both non-neuronal and 
neuronal cell models expressing N-terminal mHtt 
fragments
42
 
SIRT1
43
Interacts with Nrf2
44
 
Deacetylates Nrf2 decreasing its 
transcriptional activity and enhancing its 
cytoplasmic localization 
SIRT1 was shown to interact with mHtt, resulting in 
loss of SIRT1 deacetylase activity, hyperacetylation 
of SIRT1-target proteins, and decreased 
neuroprotection. However, a phase II clinical trial is 
33 Chiu et al., 2011; Valencia et al., 2010 
34 Ubiquitin specific peptidase 15 (USP15) 
35 Villeneuve et al., 2013 
36 Menzies et al., 2010 
37 Cholesterol-binding protein caveolin-1 (Cav-1) 
38 Li et al., 2012; Volonte et al., 2013 
39 del Toro et al., 2010; Trushina et al., 2006 
40 Prothymosin-alpha (PTMA) 
41 Karapetian et al., 2005; Niture and Jaiswal, 2009; Sun et al., 2007 
42 Dong et al., 2012 
43 Sirtuin 1 (SIRT1) 
44 Kawai et al., 2011 
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being conducted to treat HD with the highly specific 
Sirt1 inhibitor, EX-527
45
 
KPNA6
46 KPNA6 directly interacts with the Kelch domain 
of Keap1
47
 
Facilitates Keap1 nuclear import, 
attenuates Nrf2 signaling, and accelerates 
Nrf2 clearance from the nucleus during the 
post-induction phase, therefore promoting 
cytosolic restoration of Nrf2 
- 
p65
48 Physically interacts in vivo and in vitro with 
Keap1
49
 
Induces Keap1 nuclear translocation, 
inhibiting Nrf2-dependent transcription, 
and enhancing Nrf2 ubiquitination 
Decreased expression and activity of p65 was 
verified in the striatum of HD patients and R6/2 HD 
mice, and in STHdh
Q111/Q111
 cells
50
 
λ-PP51 Interacts with Nrf252 Dephosphorylates Nrf2 - 
Src subfamily of 
tyrosine kinases 
Fyn, Src, Yes and 
Fgr kinases 
Interacts with Nrf2
53
 
Phosphorylates Nrf2 at Tyr568, resulting 
in Nrf2 nuclear export and degradation, 
thereby providing a negative feedback 
mechanism to switch off Nrf2 activation 
and restore normal cellular homeostasis 
- 
45 Arrowsmith et al., 2012; Jeong et al, 2011; Jiang et al, 2012 
46 Importin alpha 7 (karyopherin alpha 6; KPNA6) 
47 Sun et al., 2011 
48 p65, a subunit of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor 
49 Yu et al., 2011 
50 Ghose et al., 2011; Laprairie et al., 2014 
51 Lambda protein phosphatase (λ-PP) 
52 Apopa et al., 2008 
53 Jain and Jaiswal, 2006; Niture et al., 2011 
4
9
 
Table 1.4 – Nrf2 cellular endogenous activators. 
Endogenous 
activators 
Interaction Function In HD 
PI-3K/Akt
54
No direct interaction 
between PI-3K or Akt 
and Nrf2 was reported 
until now 
Activation of PI-3K/Akt results in increased Nrf2 nuclear 
translocation and transactivation, which could be due to its 
direct phosphorylation by Akt or Akt phosphorylation and 
inhibition of GSK3-β, thus preventing Nrf2 phosphorylation 
which results in the binding of β-TrCP and consequent Nrf2 
degradation
55
 
(See targeting insulin/IGF-1/PI-3K/Akt/Erk pathway section) 
PKC
56
PKC interacts with the 
Neh2 domain of Nrf2 
(which Keap1 binds)
57
 
Phosphorylates Nrf2 at Ser40, leading to Keap1-Nrf2 
dissociation and Nrf2 nuclear translocation in response to 
oxidative stress 
PKC isoforms (conventional PKC-α and -β) mRNA and 
protein levels were shown to be significantly reduced in both 
striatum and cortex of symptomatic R6/2 HD mice, and in the 
putamen of HD patients. Also, mHtt was shown to associate 
with three PKC isoforms (conventional PKC-α, novel PKC-δ, 
and atypical PKC-ζ), whereas novel PKC-δ specifically 
accumulated and associated with mHtt intranuclear 
aggregates in brain tissues from symptomatic R6/1 and R6/2 
HD mouse models
58
 
MAPKs (JNK1 
and 2, Erk2, 
p38, MEKK3 
and 4)
59
Interacts with Nrf2
60
 
Phosphorylates Nrf2 at serines 215, 408, and 577, resulting 
only in a moderate contribution for Nrf2 nuclear 
translocation and transactivity 
Activation of JNK and p38 have been demonstrated in several 
HD models and were associated with enhanced neurotoxicity, 
whereas increased Erk activity has been largely associated 
with HD neuroprotection
61
 
CK2
62
 
Interacts with Nrf2 
Neh4 and Neh5 
transcription activation 
Mediates two steps of phosphorylation of Nrf2 within its TA 
domains Neh4 and Neh5, resulting in two forms of Nrf2 
migrating with differing MW at 98 kDa (Nrf2-98), which is 
CK2 phosphorylates mHtt at serines 13 and 16, resulting in 
decreased toxicity and cell death, and altered mHtt subcellular 
localization
64
 
54 Phosphatidylinositol 3-kinase (PI-3K)/Protein kinase B (Akt) 
55 Chowdhry et al., 2013; Lee et al., 2001; Nakaso et al., 2003; Wang et al., 2008 
56 Protein kinase C (PKC) 
57 Huang et al., 2002 
58 Harris et al., 2001; Hashimoto et al., 1992; Rajput et al., 2011; Zemskov et al., 2003a,b 
59 Mitogen-activated protein kinases (MAPKs); c-Jun N-terminal kinase (JNK); extracellular signal-regulated kinase (Erk) 2; mitogen-activated protein kinase 14 (p38); mitogen-activated 
protein kinase kinase kinase (MEKK) 3 and 4  
60 Sun et al., 2009; Xu et al., 2006 
61 Apostol et al., 2006; Gianfriddo et al., 2004; Perrin et al., 2009 
62 Casein kinase 2 (CK2) 
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(TA) domains, and also 
interacts with Keap1
63
 
transcriptional active, and 118 kDa (Nrf2-118), which do not 
bind to ARE, and are more susceptible for degradation. Also, 
CK2 phosphorylates Keap1 at Thr55, leading to dissociation 
of the Keap1-Cul3-Rbx1 complex from Nrf2, and 
consequent activation of Nrf2 
PERK
65
 Interacts with Nrf2
66
 
Phosphorylates Nrf2 during endoplasmic reticulum stress 
response, promoting its dissociation from Keap1, nuclear 
translocation, and transactivation 
PERK inhibition or overexpression was shown to not affect 
mHtt aggregation
67
  
CBP
68
 
When in the nucleus, 
Neh4 and Neh5 TA 
domains of Nrf2 bind 
individually and 
cooperatively to CBP
69
 
After binding to Nrf2 Neh4 and Neh5 TA domains of Nrf2, 
CBP acetylates the Neh1 DNA-binding domain of Nrf2, 
leading to increased Nrf2 promoter-specific DNA binding to 
ARE 
CBP was shown to interact with mHtt, resulting in inhibition 
of CBP acetyltransferase and transcriptional activity, altered 
CBP normal localization, CBP recruitment to mHtt 
aggregates, enhanced CBP ubiquitination and degradation, 
and increased cytotoxicity and cell death
70
 
KPNA1/ 
KPNB1
71
 
Interacts with Nrf2
72
 
KPNA1 and KPNB1 forms a heterodimer nuclear import 
system which facilitates Nrf2 nuclear import 
- 
BRCA1
73 Physically interacts with 
Nrf2
74
 
Promotes Nrf2 stability and transactivation 
The levels of non-phosphorylated BRCA1 were significantly 
decreased whereas the phosphorylated (DNA damage 
responsive form of BRCA1) was significantly increased in 
STHdh
Q111/Q111
 cells and in the striatum of symptomatic R6/2 
HD mice, indicating increased DNA damage in HD
75
. 
p21
76 Physically interacts with 
Nrf2
77
 
Competes with Keap1 for Nrf2 binding, and disrupts Keap1-
dependent Nrf2 ubiquitination, inducing Nrf2 transcriptional 
mHtt exon1 protein repressed the transcription of p21
78
. 
64 Atwal et al., 2011; Fan et al., 2008 
63 Apopa et al., 2008; Niture and Jaiswal, 2010; Pi et al., 2007 
65 Protein kinase RNA-like endoplasmic reticulum kinase (PERK) 
66 Cullinan et al., 2003 
67 Lee et al., 2012 
68 CREB-binding protein (CBP) 
69 Katoh et al., 2001; Sun et al., 2009 
70 Choi et al., 2012; Jiang et al., 2003; 2006; Steffan et al., 2000; 2001; Nucifora et al., 2001 
71 Karyopherin alpha 1 (importin alpha 5) (KPNA1) and karyopherin (importin) beta 1 (KPNB1) 
72 Theodore et al., 2008 
73 Breast cancer 1, early onset (BRCA1) 
74 Gorrini et al., 2013 
75 Jeon et al., 2012 
76 Cyclin-dependent kinase inhibitor 1A (p21, Cip1, Waf1) 
77 Chen et al., 2009 
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activity 
p62
79
Physically interacts with 
the C-terminus Kelch-
DC domain of Keap1
80
 
Competes with the interaction between Nrf2 and Keap1, 
resulting in Nrf2 stabilization and transactivation, and Keap1 
degradation via autophagy 
p62 was shown to interact with mHtt and to co-localize with 
mHtt nuclear inclusions in the striatum and frontal cortex of 
HD patients (Vonsattel grades 3, 3-4 and 4), and in the whole 
brain, in the striatum and hippocampus of symptomatic R6/1 
and R6/2 HD mouse models. Also, increased p62 protein 
levels were found in the striatum of HD patients, and R6/2 
and YAC128 HD mouse models, whereas in in the striatum, 
cortex and hippocampus of early symptomatic 12 week-old 
R6/1 and in STHdh
Q111/Q111 
cells, decreased p62 protein levels 
were verified
81
 
WTX
82
Binds to Keap1
83
 Inhibits Nrf2 ubiquitination and degradation - 
DPP3
84
Binds to Keap1
85
 
Prevents Keap1 association with Nrf2, thus inhibiting Nrf2 
ubiquitination and driving Nrf2-dependent transcription 
- 
78 Steffan et al., 2000 
79 Selective autophagy substrate adaptor sequestosome1 (p62) 
80 Bae et al., 2013; Komatsu et al., 2010; Copple et al., 2010 
81 Jin et al., 2013; Lee et al., 2012; Nagaoka et al., 2004; Rué et al., 2013 
82 APC membrane recruitment protein 1 (Wilms tumor on the X; WTX, AMER1) 
83 Camp et al., 2012 
84 Dipeptidyl-peptidase 3 (DPP3) protein 
85 Hast et al., 2013 
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Table 1.5 – Nrf2/ARE target antioxidant genes. 
System Target genes Function 
Superoxide anion (O2
•–
)  and
hydrogen peroxide (H2O2) 
decomposition 
Superoxide dismutase (SOD) 1-3
86
Catalyzes the dismutation of O2
•–
 into H2O2 and molecular oxygen
Catalase
87
Catalyzes the conversion of H2O2 into water and molecular oxygen 
Glutathione 
Glutathione reductase (GRed)
88
Catalyzes the NADPH-dependent reduction of disulfide-oxidized glutathione 
(GSSG) to thiol-reduced glutathione (GSH) [GSSG + NADPH + H
+
 → 2GSH + 
NADP
+
] 
Glutathione peroxidase (GPx) 1-4
89
Converts 2GSH and H2O2 into GSSG and H2O 
Glutathione S-transferase (GST)
90 Catalyzes the conjugation of various electrophiles, reactive alkenals, and numerous 
other xenobiotic to GSH 
Glutamate-cysteine ligase (GCL) catalytic 
(GCLc) and modifier (GCLm) subunits
91
Catalyzes the first step of the synthesis of GSH, involving the ligation of glutamate 
to L-cysteine, in an ATP-dependent manner, producing gamma-glutamylcysteine 
(γ-GC) 
Glutathione synthetase (GS)
92 Catalyzes the second step of GSH synthesis, involving the conversion of γ-GC  and 
glycine, in an ATP-dependent manner, into GSH 
Multidrug resistance-associated protein 1 
(Mrp1)
93
Catalyzes the exportation of glutathione-S conjugates and glutathione itself to the 
extracellular millieu in an ATP-dependent manner 
86 Cho et al., 2002; Huang et al., 2014; Park and Rho, 2002; Zhang et al., 2013  
87 Zhu et al., 2005 
88 Shih et al., 2003; Thimmulappa et al., 2002; Zhu et al., 2005 
89 Banning et al., 2005; Cho et al., 2002; Thimmulappa et al., 2002 
90 Cho et al., 2002; Shih et al., 2003; Chanas et al., 2002 
91 Jeyapaul and Jaiswal, 2000; Moinova and Mulcahy, 1999; Shih et al., 2003; Wild et al., 1999 
92 Shih et al., 2003 
93 Hayashi et al., 2003; Ji et al., 2013; Maher et al., 2007; Shih et al., 2003 
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Gamma-glutamyl transpeptidase (-GT)
94 Catalyzes the cleavage of the gamma-glutamyl bond of GSH and the transfer of 
gamma-glutamyl to water or to some amino acids and peptides 
Excitatory amino acid carrier 1 (EAAC1)
95
Mediates the cysteine uptake in cells 
Cystine/glutamate antiporter (Xc-)
96
Mediates the oxidized form of cysteine (cystine) uptake in cells 
NADPH-producing enzymes 
Glucose-6-phosphate dehydrogenase 
(G6PD)
97
Catalyzes the conversion of D-glucose 6-phosphate and NADP
+
 into  6-phospho-D-
glucono-1,5-lactone (6PGL) and NADPH 
6-Phosphogluconate dehydrogenase (6PGD)
98
Catalyzes the conversion of 6-phosphogluconate and NADP
+
 into ribulose 5-
phosphate and NADPH 
Malic enzyme
99 Catalyzes the conversion of (S)-malate and NADP
+
, into pyruvate, CO2, and
NADPH. 
Thioredoxin 
Thioredoxin (Trx)
100
 
Catalyzes the reduction of oxidized proteins by exchanging cysteine thiol and 
protein disulfides 
Thioredoxin reductase (TrxR)
101
 Catalyzes the reduction of oxidized Trxs by consuming NADPH 
Peroxiredoxin (Prdx)
102
 Catalyzes the reduction of peroxides by using Trxs 
Sulfiredoxin-1 (SRXN1)
103
 
Catalyzes the protein deglutathionylation and the reduction of Prdx-cysteine 
94 Zhang et al., 2006 
95 Escartin et al., 2011 
96 Shih et al., 2003 
97 Thimmulappa et al., 2002 
98 Thimmulappa et al., 2002 
99 Thimmulappa et al., 2002 
100
 Im et al., 2012; Kim et al., 2003; Nakaso et al., 2003 
101
 Chen et al., 2005; Suvorova et al., 2009; Tanito et al., 2007 
102
Chowdhury et al., 2009; Kim et al., 2007; Erttmann et al., 2011 
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sulfinic acid 
Detoxification 
NAD(P)H:quinone oxidoreducase (NQO1)
104 Catalyzes the two-electron reduction of endogenous quinones, using NADH or 
NADPH as reducing cofactors, and producing the redox-stable hydroquinone 
Heme oxygenase 1 (HO-1)
105 Catalyzes the degradation of toxic heme into the antioxidant biliverdin, free iron, 
and carbon monoxide 
103
Bae et al., 2009; Soriano et al., 2008 
104 Thimmulappa et al., 2002 
105 Alam et al., 1999; 2003; Thimmulappa et al., 2002 
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Figure 1.3 – Nrf2 pathway regulation upon oxidative stress conditions. Under normal conditions, Kelch-like ECH associated protein 1 (Keap1) is linked to 
the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) to promote its ubiquitination and degradation through the Keap1 binding to cullin 3 
(Cul3)-ring box protein 1 (Rbx1) ubiquitin (Ub) ligase complex. Also, glycogen synthase kinase 3 beta (GSK3-β) phosphorylates Nrf2 to promote beta-
transducin repeat-containing protein (β-TrCP) to act as a receptor substrate for the S-phase kinase-associated protein 1 (Skp1)-cullin 1 (Cul1)-Rbx1 ubiquitin 
ligase complex, leading to Nrf2 ubiquitination and degradation. Caveolin-1 (Cav-1) also recruits Nrf2 to caveolae membranes inhibiting its activation. 
However, under conditions of increased reactive oxygen species (ROS) formation, Keap1 cysteine residues are oxidized resulting in a displacement from Nrf2 
and formation of Keap1 dimers which results in Keap1 ubiquitination by the Cul3-Rbx1 ubiquitin ligase complex. Also Keap1 phosphorylation by casein 
kinase 2 (CK2), its association to the APC membrane recruitment protein 1 (Wilms tumor on the X; WTX, AMER1) or to dipeptidyl-peptidase 3 (DPP3) 
protein prevents Keap1 binding to Nrf2. Furthermore, Keap1 association with the selective autophagy substrate adaptor sequestosome1 (p62), results in 
Keap1 degradation via autophagy. Moreover, cyclin-dependent kinase inhibitor 1A (p21, Cip1, Waf1) competes with Keap1 for Nrf2 binding, and disrupts 
Keap1-dependent Nrf2 ubiquitination. Then several kinases (e.g. mitogen-activated protein (MAP) kinases (MAPKs), casein kinase 2 (CK2), protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), protein kinase C (PKC)) are able to phosphorylate Nrf2, resulting in its translocation to the nucleus. Also, 
Akt (or protein kinase B) phosphorylates and inhibits GSK3-β leading to decreased Nrf2 ubiquitination by β-TrCP-Cul1-Rbx1 complex. After Nrf2 
phosphorylation, Nrf2 is imported to the nucleus via the heterodimer nuclear import system composed by karyopherin alpha 1 (importin alpha 5) (KPNA1) 
and karyopherin (importin) beta 1 (KPNB1). Inside the nucleus, Nrf2 is acetylated by the CREB-binding protein (CBP) and associates with breast cancer 1, 
early onset (BRCA1) and p21 resulting in the enhancement of Nrf2 binding to the antioxidant response element (ARE) where it forms heterodimers with the 
receptor-associated coactivator 3 (RAC3)/AIB-1/steroid receptor coactivator-3, c-Jun, c-Jun dimerization protein 2 (JDP2), and small Mafs (MafK, MafG or 
MafF) proteins for high-affinity binding, leading to increased promoter specific DNA binding to ARE, and consequent enhancement of Nrf2-ARE 
transcription of antioxidant genes.
5
7
 
U
bU
bU
bU
b
Proteasomal 
Degradation
ARE
P
GSK3-β
Cul3
Cul1
USP15
Cul3
Keap1
Cul3
Proteasomal 
Degradation
Cul3
U
b U
b
U
b U
b
GSK3-β
βTrCP
Cul1
Src 
Kinases
5
8
 
Figure 1.4 – Nrf2 pathway regulation in the late response (post-induction of Nrf2) to oxidative stress. After oxidative stress conditions, Keap1 is 
deubiquitinated by ubiquitin specific peptidase 15 (USP15) and associates with p65, a subunit of NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) transcription factor, which leads to nuclear import of Keap1 in complex with Cul3-Rbx1 through prothymosin-alpha (PTMA) and/or 
importin alpha 7 (karyopherin alpha 6; KPNA6). In the nucleus, Nrf2 is dephosphorylated by lambda protein phosphatase (λ-PP) and deacetylated by sirtuin 1 
(SIRT1), leading to its dissociation from the antioxidant response element (ARE) and consequent association with Keap1-Cul3-Rbx1 or GSK3-β/β-TrCP-
Cul1-Rbx1 ubiquitin (Ub) complexes, resulting in Nrf2 degradation or nuclear export via exportin 1 (Exp1) and consequent degradation in the cytoplasm. 
59 
Therefore, one way that cells regulate its endogenous antioxidant capacity is 
through activation of Nrf2. In HD, the protection against ROS production may be 
affected. In fact, in the plasma and erythrocytes of HD patients, a reduction in the 
antioxidant systems correlated with disease stage (Túnez et al., 2011). The basal levels of 
striatal Nrf2 and ARE activity were significantly reduced in N171-82Q HD mice 
(Chaturvedi et al., 2010), and in STHdh
Q111/Q111 
cells (Jin et al., 2013), respectively,
whereas Nrf2 overexpression reduced the number of fragmented mitochondria in striatal 
STHdh
Q111/Q111 
cells (Jin et al., 2013). In this respect, Nrf2-deficient cells and neurons
derived from Nrf2 knockout mice were shown to be significantly more vulnerable to 
malonate or 3-NP (Calkins et al., 2005; Shih et al., 2005). Importantly, intrastriatal 
transplantation of Nrf2-overexpressing astrocytes before treatment with malonate or 3-NP 
had a strong neuroprotective effect (Calkins et al., 2005), revealing the importance of 
Nrf2 in the context of mitochondrial dysfunction associated with HD. On the other hand, 
mHtt was described to activate Nrf2-responsive genes in a PC12 model of HD (van Roon-
Mom et al., 2008). Also, although no changes in Nrf2 protein levels were detected in the 
striatum of pre-, early-, and symptomatic  R6/1 HD mice, Nrf2 protein levels were 
significantly increased in cortex at late stages of the disease, when compared to wild-type 
mice (Rue et al., 2013). Nrf2-target antioxidant proteins were also been reported to be 
modified in HD. Although, no differences were found in total superoxide dismutase 
(SOD), SOD1 (Cu/Zn-SOD) and 2 (Mn-SOD) and in glutathione peroxidase (GPx) 
activities, significantly lower specific activities for catalase were found in skin fibroblasts 
from HD patients (del Hoyo et al., 2006). In fact, reduced activities of catalase (Zanella et 
al., 1980), SOD1, and GPx (Chen et al., 2007) were also detected in HD patient’s 
erythrocytes. Moreover, GSH levels were found to be decreased in plasma (Klepac et al., 
2007) and oxidized GSH (GSSG) levels were also decreased in the CN of HD patients 
(Sian et al., 1994). Conversely, proteomic analysis of HD post-mortem striatal and 
cortical brain samples revealed increased activities of SOD2 and catalase, and an 
induction of GPx1 and 6 and peroxiredoxin (Prdx) 1, 2 and 6  (Sorolla et al., 2008). 
Moreover, increased GRed and G6PD activities were found in erythrocytes from HD 
patients, compared to control individuals (Zanella et al., 1980). Also, a significant 
increase in gamma-glutamyl transpeptidase (-GT) activity in human post-mortem HD 
CN was observed and the levels of -GT significantly increased with increasing duration 
of illness (Butterworth et al., 1985). In addition, heme oxygenase 1 (HO-1) was elevated 
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in human HD striatum and cortex as compared with age-matched control brain 
individuals (Browne et al., 1999). Also, in animal models of HD, deregulated antioxidant 
capacity has been described. A significant increase in total SOD and SOD1 activities was 
observed in the striatum of young (19 week-old) R6/1 HD mice; however, a decrease in 
total SODs activities was observed in the striatum of this HD animal model at the age of 
35 weeks, when mice exhibited a severe phenotype (Santamaria et al., 2001). Conversely, 
significant increases in mRNA levels of GPx1, catalase and SOD1 were observed in 
STHdh
Q111/Q111
 knock-in HD striatal cells (Lim et al., 2008). Although GPx transcription
was unaltered, increased GRed, SOD2, and glutamate-cysteine ligase (GCL) catalytic 
subunit (GCLc) transcription was verified in the basal ganglia of 8-week-old R6/2 HD 
mice, whereas GSH levels were increased in the forebrain of 5-6 and 11-12 week-old 
R6/2 HD mice (Fox et al., 2004). Also, GPx activity was unchanged in the striatum of 
R6/1 HD mice from 11 to 35 weeks of age (Perez-Severiano et al., 2004). In contrast, 8 
and 12 week-old R6/2 HD mice showed increased GSH levels in the striatum (Tkac et al., 
2007). Although the striatum and cortex of ~12 week-old R6/2 mice did not present any 
changes in cellular GSH, mitochondrial GSH was significantly increased compared to 
wild-type mice (Choo et al., 2005); nevertheless, GCL was reported to be actively 
decreased in both striatum and cortex of R6/2 HD mice, not explaining the increase in 
GSH levels (Choo et al., 2005). 
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1.3 Neuroprotective targets in Huntington’s disease 
Presently there is no effective protective treatment or cure for HD. Therefore, 
several approaches have been tested to prevent or delay disease progression. In this 
section some targets for neuroprotection in HD are described. 
1.3.1 Targeting Nrf2 and use of antioxidant therapies 
As delineated before in this thesis, a central role for the induction of the cellular 
antioxidant defense is carried out by the transcription factor Nrf2. Oxidative stress was 
reported as a cytotoxic mechanism in several HD models and patients, and Nrf2 pathway 
seems to be altered in HD as well as the antioxidants that are dependent of Nrf2. Thus, 
the discovery of novel drugs that increase Nrf2 activation and consequently induce the 
expression of antioxidant defenses or directly scavenge ROS might be relevant for 
delaying HD progression. Here we describe some known Nrf2 inducers as well as 
antioxidants that have shown to be protective in HD. 
Sulforaphane is a natural dietary isothiocyanate and an electrophile that can react 
with protein thiols to form thionoacyl adducts and is believed to affect the Cys residues in 
Keap1 protein, therefore releasing Nrf2 from Keap1 (Keum, 2011). Treatment with 
sulforaphane enhanced mHtt degradation, reduced mHtt cytotoxicity (Liu et al., 2014), 
and increased ARE activity in STHdh
Q111/Q111
 cells (Jin et al., 2013). tert-
Butylhydroquinone (t-BHQ) is a metabolite of the widely used food antioxidant butylated 
hydroxyanisole, approved for human use by FDA. t-BHQ possesses an oxidizable 1,4 
diphenolic structure that confers its potent ability to dissociate Keap1/Nrf2 complex (Van 
Ommen et al., 1992), and appears to have a Nrf2-specific action in vivo since dietary 
supplementation of t-BHQ attenuated 3-NP-induced toxicity in Nrf2
+/-
 but not in Nrf2
-/-
mice (Shih et al., 2005). Importantly, t-BHQ significantly increased nuclear Nrf2 protein 
levels and glutathione S-transferase (GST) activity, and prevented increased lipid 
peroxidation in rat striatal slices treated with QA or 3-NP (Tasset et al., 2010). Dimethyl 
fumarate (DMF) is an orally bioavailable fumaric acid ester that is metabolized to methyl 
hydrogen fumarate (Kees, 2013). DMF was reported to increase neuronal Nrf2 and 
promote recovery in R6/2 and YAC128 HD mouse models (Ellrichmann et al., 2011). 
Oral administration of triterpenoids upregulated Nrf2/ARE induced genes, decreased 
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oxidative stress, improved motor performance, rescued striatal atrophy and increased 
longevity in N171-82Q mice (Stack et al., 2010). Moreover, synthetic triterpenoids were 
shown to activate Nrf2 and rendered protection against 3NP-mediated increased DNA 
and protein oxidation, lipid peroxidation, and disrupted glutathione homeostasis (Yang et 
al., 2009). Lipoic acid (LA) is an essential cofactor for several enzyme complexes and is 
present in mitochondria as a cofactor for PDH and alpha-ketoglutarate dehydrogenase 
complexes. It is an effective antioxidant and has been used to treat diseases associated 
with impaired energy metabolism (Johri and Beal, 2012). LA can also increase Nrf2-
dependent transcriptional activity by forming lipoyl-cysteinyl mixed disulfides on Keap1 
(Dinkova-Kostova et al., 2002), and thus decreasing Keap1 binding to Nrf2. In both the 
R6/2 and N171-82QHD mouse models, dietary supplementation with LA resulted in 
significant extension of survival and delayed weight loss in N171-82Q transgenic mice 
(Andreassen et al., 2001). 
Ascorbic acid is a potent antioxidant which oxidizes readily to dehydroxyascorbic 
acid in the presence of ROS (Johri and Beal, 2012). Despite symptomatic R6/1 HD mice 
did not show any changes in ascorbate levels in the striatum, cortex and cerebellum 
(Petersén et al., 2001), deficits in ascorbate release in the striatum began in the 
presymptomatic phase of R6/2 HD mice (Rebec et al., 2002), which was attributed to 
dysfunctional corticostriatal pathway (Dorner et al., 2009), and in symptomatic CAG140 
knock-in HD mice (Dorner et al., 2007). Moreover, regular systemic administration of 
ascorbate in R6/2 HD mice beginning at symptom onset restored the behavior-related 
release of ascorbate in striatum and attenuated the neurological motor signs of HD (Rebec 
et al., 2003; 2006). N-acetyl-L-cysteine (NAC) is a known GSH precursor, and it has 
been widely used to increase GSH levels in several models of oxidative damage. 
Treatment with GSH ethyl ester (GSHee), a cell permeable form of GSH, or NAC 
significantly protected against mHtt-mediated cell death (Wyttenbach et al., 2002), 
disruption in mitochondrial transmembrane potential (ΔΨm) and the increase in ROS 
formation, 

NO levels and protein oxidation (Firdaus et al., 2006), in COS-7 or SK-N-SH
cells expressing mHtt exon1 with 74Q or 103Q, respectively, and completely prevented 
3-NP-mediated decrease in ΔΨm in STHdhQ111/Q111 striatal cells (Mao et al., 2006).
Indeed, it was described that expanded polyQ directly inhibit mitochondrial function by 
inducing oxidative stress, which was prevented with NAC treatment in isolated 
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mitochondria (Fukui and Moraes, 2007). Taken together, these results demonstrate that 
antioxidant therapy is beneficial to counteract mHtt-induced cytotoxicity.  
1.3.2 Targeting insulin/IGF-1/PI-3K/Akt/Erk pathway 
Insulin, insulin-like growth factor (IGF)-1 and -2 belong to the insulin-like peptide 
hormone superfamily. Insulin is mainly produced by beta-pancreatic cells, which acts to 
decrease blood glucose levels by stimulating glucose uptake after binding and activating 
the insulin receptor (IR). Insulin also promotes the transport of amino acids from the 
bloodstream into cells, increasing the rate of amino acid incorporation into proteins, and 
stimulates lipid synthesis from carbohydrates, decreases fatty acid release from tissues 
and leads to a net increase in total body lipid stores (Ghasemi et al., 2013a,b). Insulin 
present in adult CNS is mainly derived from beta-pancreatic cells, which can get across 
the blood-brain barrier by a carrier-mediated, saturable, regulatable, and temperature-
sensitive active transporter system (Banks, 2004; Burns et al., 2007). However, insulin 
and also IGF-1 can be produced in the brain, where they appear to be involved in the 
regulation of brain metabolism, neuronal differentiation and neuromodulation, after 
activating the IR and IGF-1 receptor (IGF1R) which are both expressed in neurons 
(Cardona-Gomez et al., 2001; Havrankova et al., 1978a,b; Hoyer, 2004; Rotwein et al., 
1988). Due to structural and functional homology, insulin and IGF-1 can bind to (and 
activate) both IR and IGF1R, with insulin binding to the IR with higher affinity (< 1 nM) 
than IGF-1 (100–500-fold lower affinity), whereas IGF1R preferentially binds IGF-1 (< 
1nM) as compared to insulin (100–500-fold lower affinity) (Rechler et al., 1980). 
However, the IGF1R receptor and the IR can also form functional hybrids that have 
similar affinities for IGF-1 and insulin, which is indicative of cooperation between these 
two receptors (Fernandez and Torres-Aleman, 2012).  
The IR and IGF1R are both a membrane-bound glycoprotein formed by two 
subunits held together by disulfide bridges, an extracellular alpha-subunit and a 
transmembrane beta-subunit with intracellular tyrosine kinase activity (Kuemmerle, 2003; 
Shelton et al., 2004; Torres Aleman, 2005). Insulin, IGF-1 or IGF-2 binds to the 
extracellular alpha subunit of the receptor, resulting in conformational change, which 
enables ATP to bind to the intracellular component of the receptor’s beta subunit. ATP 
binding in turn triggers phosphorylation of the beta subunit, conferring tyrosine kinase 
activity. This facilitates the recruitment of SHC (Src Homology-2 (SH2)-containing 
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protein), and insulin receptor substrate(s) (IRS), which are then tyrosine phosphorylated. 
Following activation, IRS binds and activates phosphatidylinositol 3-kinase (PI-3K) 
through its SH2 domains (Benarroch, 2012; Tseng et al., 2002; Wilcox, 2005), whereas 
SHC in turn interact with the adapter protein growth factor receptor bound protein-2 
(GRB2), recruiting the SOS (son of sevenless) to the plasma membrane for activation of 
the membrane-associated guanine nucleotide-binding protein Ras (which also requires 
stimulation of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11; or 
SHP2), through its interaction with receptor substrates such as GAB1 (GRB2 associated 
binding protein-1) or IRS1/2), which in turn stimulates a serine kinase cascade through 
the activation of Ser/Thr kinase V-Raf-1 murine leukemia viral oncogene homolog 1 
(Raf-1 or c-Raf), MEK1/2 (MAP kinase kinases 1/2) and extracellular signal-regulated 
kinases (Erk) 1 and -2 (Heinrich et al., 2006; Hu et al., 2001; Polivka and Janku, 2013; 
Yart et al., 2001). After activation, PI-3K catalyzes the conversion of PIP2 
(phosphatidylinositol-4,5-bisphosphate) to PIP3 (phosphatidylinositol-3,4,5-
trisphosphate), which is reversed by PTEN (phosphatase and tensin homolog). Elevated 
PIP3 binds to the PH (pleckstrin homology) domain of Akt (protein kinase B) and PDPK1 
(3-phosphoinositide dependent protein kinase-1) which in turn phosphorylates residue 
Thr308 on Akt, increasing cell glucose uptake by promoting the translocation of GLUT’s 
to the membrane (Mora et al., 2005; Polivka and Janku, 2013). However, Akt can also be 
phosphorylated at Ser473 by the mammalian target of rapamycin (mTOR) complex 2 
(mTORC2) (Dowling et al., 2010). Phosphorylation of these two residues (Thr308 and 
Ser473) are necessary for full activation of Akt kinase activity (Alessi et al., 1997a,b; 
Feng et al., 2004); however, it was previously described that Akt phosphorylation on 
Thr308, but not Ser473, better correlates with Akt protein kinase activity (Vincent et al., 
2011). 
Akt and Erk1/2 are considered to be crucial elements in a multiplicity of pathways 
to promote cell survival and prevent cell damage (Chong et al., 2005; de la Monte et al., 
2012; Numakawa et al., 2013). Erk1/2 promotes cell survival through preventing 
activation of the pro-apoptotic protein BAD (B-Cell CLL/Lymphoma 2 (BCL2)-
associated agonist of cell death), and through its translocation to the nucleus where it 
catalyzes the phosphorylation of transcription factors such as Elk-1 (ELK1, member of 
ETS oncogene family), initiating a transcriptional program that leads to cellular 
proliferation or differentiation (Cohen-Armon, 2007; Jin et al., 2004). Activation of PI-
3K/Akt pathway leads to activation or inactivation by phosphorylation of several 
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downstream targets, including the activation of mTORC1 (which in turn has a number of 
downstream biological effects including activation of mRNA translation via the 
phosphorylation of downstream targets (eukaryotic translation initiation factor 4E binding 
protein 1 (4E-BP1) and ribosomal protein S6 kinase, 70kDa, polypeptide 1 (RPS6KB1)), 
and suppression of autophagy through the phosphorylation and inhibition of autophagy 
related 13 (Atg13) and unc-51 like autophagy activating kinase 1 ( ULK1)), and the 
inactivation of proteins involved in apoptotic pathways, such as BAD, caspase-9, 
glycogen synthase kinase 3 beta (GSK3-β), and the members of the forkhead boxO 
(FOXO) class of transcription factors -1 and -3, (Chong et al., 2012; Dowling et al., 2010; 
Kim et al., 2001; Wu et al., 2011). Akt is also known to phosphorylate CREB at Ser133, 
promoting the recruitment of CBP, and the complex formed by CREB and its co-activator 
CBP is competent to initiate gene transcription (Du and Montminy, 1998). Moreover, it 
was previously described that Akt can accumulate in mitochondria in its active state, 
inducing neuroprotection (Bijur and Jope, 2003; Mookherjee et al., 2007). Akt 
translocation to mitochondria was associated with increased expression and activity of 
complex I. Also, within mitochondria, Akt phosphorylated alpha and beta subunits of 
ATP synthase, leading to its activation, and phosphorylated and inactivated GSK3-β 
leading to activation of PDH (Li et al., 2013).  
In HD, higher plasma IGF-1 was associated with cognitive decline in HD patients 
(Saleh et al., 2010), and genetic enhancement of IRS-2 levels in the brains of R6/2 HD 
mice significantly reduced life span and increased neuronal oxidative stress and 
mitochondrial dysfunction (Sadagurski et al., 2011). In contrast, insulin or IGF-1-induced 
IRS-2 activation caused the elimination of mHtt exon1 aggregates by macroautophagy 
(Yamamoto et al., 2006), and reduced IGF-1 mRNA levels were detected in post-mortem 
striatum and in fibroblasts of HD patients, and in STHdh
Q111/Q111
 cells (Pouladi et al.,
2010), as well as an age-dependent reduction in insulin mRNA, decreased PI-3K protein 
levels, diminished expression of key regulators of insulin gene transcription, decreased 
blood insulin and plasma IGF-1 levels, and impaired glucose tolerance in R6/2 mice 
(Andreassen et al., 2002; Duarte et al., 2011; Rajput et al., 2011). Moreover, peripheral or 
intranasal administration of IGF-1 enhanced blood insulin levels in R6/2 mice (Duarte et 
al., 2011), and enhanced IGF-1 cortical levels and improved motor activity and both 
peripheral and central metabolic abnormalities in YAC128 HD mice (Lopes et al., 2013), 
respectively. Indeed, intranasal administration IGF-1 in YAC128 HD mice activated Akt 
and concomitantly increased phosphorylation of mHtt on Ser421 (Lopes et al., 2013), 
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which was previously described to be decreased in the striatum of YAC128 HD mice 
(Warby et al., 2005), to reduce mHtt nuclear inclusions (Humbert et al., 2002), and to 
compensated anterograde and retrograde transport defects in HD cortical neurons (Zala et 
al., 2008), suggesting that mHtt phosphorylation by Akt is decreased in HD. In fact, in 
HD patients, a shorter inactive caspase-3 cleaved form of Akt was detected (Humbert et 
al., 2002; Colin et al., 2005), which can be associated with decreased p-(Ser473)Akt/Akt 
ratio in lymphoblasts and lymphocytes derived from HD patients (Colin et al., 2005), in 
STHdh
Q111/Q111 
cells (Maglione et al., 2010), in HEK293 cells expressing mHtt with 68
CAG repeats (Nagata et al., 2011), and in the striatum of 12 week-old R6/2 HD mice (Ju 
et al., 2011). Furthermore, Akt and also Erk were previously described to protect against 
mHtt toxicity (Apostol et al., 2006; Lievens et al., 2008), suggesting that besides Akt, also 
Erk could be deactivated in HD. Indeed, decreased Erk activity was observed in 
STHdh
Q111/Q111
 cells, and in the striatum of pre- and symptomatic R6/2 HD mice, whereas
striatal cholinergic interneurons, the most resistant interneuron subtype in HD, showed 
increased p-Erk (Fusco et al., 2012; Ju et al., 2011; Sarantos et al., 2012), suggesting that 
Erk activation could be a target for the delay in disease progression.  
1.3.3 Targeting energy metabolism 
Energy metabolism is deregulated in HD as described earlier in this thesis. 
Therefore, the use of stabilizers or enhancers of energy metabolism have been tested in 
HD. Here we will focus on the most studied compounds in HD that revealed an 
improvement in energy metabolism.  
Creatine has been shown to have both metabolic and antioxidant proprieties 
(Lawler et al., 2002). Althought creatine did not significantly reduce the levels of H2O2 or 
lipid peroxidation, this compound displayed a significant antioxidant scavenging capacity 
through its ability to remove 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS+) (a peroxidase substrate), O2
−, and ONOO− (Lawler et al., 2002). In early HD
patients, creatine treatment decreased 8-OHdG levels, increased serum and brain creatine 
levels and was shown to be safe and well tolerated (Hersch et al., 2006). In R6/2 and 
N171-82Q HD mouse models, creatine administration improved motor performance, 
extended mice survival, increased body and brain weight, decreased brain atrophy, 
delayed striatal neuron atrophy and the onset of diabetes, reduced the number of mHtt 
aggregates, and increased striatal ATP and creatine levels (Andreassen et al., 2001; 
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Dedeoglu et al., 2003; Ferrante at al., 2000; Yang et al., 2009), thus regulating metabolic 
dysfunction in the context of HD. The Huntington Study Group (HSG) and Massachusetts 
General Hospital (Steven M. Hersch, MD, PhD) are conducting a Phase 3 randomized, 
double-blind, placebo-controlled clinical trial in HD (CREST-E; clinicaltrials.gov). 
CoQ10 is an antioxidant and component and enhancer of respiratory chain function 
that is under phase 3 clinical trial for HD (2CARE; clinicaltrials.gov), and was reported to 
be well tolerated in HD patients (Huntington Study Group Pre2CARE Investigators, 
2010). Brain levels of CoQ10 were significantly lower in R6/2 mice, and the treatment 
with CoQ10 elevated the levels of CoQ10 and ATP in the brain, and CoQ10 levels in plasma 
while reducing 8-OHdG concentrations, significantly extended survival, improved motor 
performance and grip strength, reduced weight loss, brain atrophy, and mHtt inclusions in 
R6/2 HD mice (Smith et al., 2006). Furthermore, although creatine or CoQ10 treatment 
alone produced significant protection, combined treatment of CoQ10 and creatine showed 
an addictive effect by improving motor performance and extending survival in the R6/2 
HD mice (Yang et al., 2009). Moreover, in rats treated with 3-NP, creatine or CoQ10, or 
their combined supplementation decreased striatal volume damage, increased GSH, but 
not GSSG levels, and decreased MDA levels, whereas only creatine or CoQ10 
combination decreased 8-OHdG levels in the striatum of 3-NP treated rats (Yang et al., 
2009), suggesting that the combination treatment is more effective in reducing striatal 
damage induced by 3-NP. Therefore, targeting energy metabolism with creatine or CoQ10 
or their combination might be effective in HD. In fact, both compounds are in clinical 
trials for HD.  
1.3.4 Targeting transglutaminase 
Transglutaminases are a family of ubiquitous thiol and calcium-dependent 
enzymes that catalyze post-translational modifications and cross-linking (transamidation) 
acyl transfer reaction between Q residues and the epsilon-amino group of lysine (K) 
residues between or within proteins, leading to the formation of epsilon-(gamma-
glutamyl)-lysine isopeptide bound (Folk, 1983; Greenberg et al., 1991). They also 
catalyze a reaction between gamma-carboxamide group of a polypeptide-bound Q and a 
polyamine to form an (gamma-glutamyl)-polyamine isopeptide bound (polyamination) 
and the deamination of the gamma-carboxamide group of a Q residue within proteins 
(Folk, 1983; Greenberg et al., 1991). There are nine members of transglutaminase family, 
68 
which includes tissue transglutaminase or transglutaminase 2 (TG2) described to be 
highly active and expressed in brain, particularly in neurons (Appelt et al., 1996; Bailey 
and Johnson, 2004; Johnson et al., 1997; Lesort et al., 1999). TG2 has multiple enzymatic 
activities. Besides being a transamidating enzyme (Greenberg et al., 1991), TG2 can also 
be a signal transducing GTP-binding protein (Nakaoka et al., 1994), display protein 
disulfide isomerase activity (Hasegawa et al., 2003) and protein kinase activity (Mishra 
and Murphy, 2006). TG2 has been implicated in several cellular processes, including 
apoptosis, cell proliferation and differentiation, cell-cell and cell-extracellular matrix 
interactions, axonal growth and regeneration, signal transduction, transcription and 
regulation of mitochondrial function (Fesus and Piacentini 2002; Park et al., 2010). 
Moreover, TG2 has been implicated in several disorders, including neurodegenerative 
diseases (Grosso and Mouradian, 2012).  
In HD, increased epsilon-(gamma-glutamyl)-lysine cross-links and TG2 levels 
and activity were verified in the brain of HD patients (Dedeoglu et al., 2002; Jeitner et al., 
2001; Karpuj et al., 1999; Lesort e t al., 1999), and in the R6/2 (Dedeoglu et al., 2002), 
R6/1 (Mastroberardino et al., 2002), and YAC128 (Van Raamsdonk et al., 2005) HD 
mouse models. Moreover, polyQ repeat domains and mHtt were described to be 
substrates for TG2 (Kahlem et al., 1996; 1998; Cooper et al., 1997a,b; Zainelli et al., 
2003), which induced cross-links in mHtt leading to the formation of insoluble aggregates 
(Zainelli et al., 2003; 2004), whereas genetic deletion of TG2 improved motor 
performances and survival in R6/2 and R6/1 HD mouse models (Bailey and Johnson, 
2005; Mastroberardino et al., 2002), increased mitochondrial function in STHdh
Q111/Q111 
cells, and protected against NMDA-induced toxicity in medium-sized spiny neurons from 
YAC128 HD mice (McConoughey et al., 2010). These data clearly indicates that TG2 is 
involved in mHtt-induced cytotoxicity and that inhibition of TG2 activity might be 
significant to delay HD progression. 
One of the most used protective compounds in HD is cystamine. Cystamine is a 
linear aliphatic diamine composed of a disulfide bridge, generated from the oxidation of 
two cysteamine (HS-CH2-CH2-NH2) residues. Besides being metabolized to cysteine, 
hypotaurine and taurine, oral or systemic cystamine administration resulted in significant 
increased neuronal cysteamine levels, where it prevents the formation of TG2-catalyzed 
cross-linking of substrate proteins by acting as a competitive amine inhibitor (Bousquet et 
al., 2010; Gibrat and Cicchetti, 2011; Pinto et al., 2009). Indeed, cystamine administration 
decreased transglutaminase activity in both R6/2 and YAC128 HD mouse models 
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(Dedeoglu et al., 2002; Karpuj et al., 2002; Van Raamsdonk et al., 2005), improved motor 
performance, body and brain weight, and survival (Dedeoglu et al., 2002; Karpuj et al., 
2002), and decreased brain atrophy and the number of protein aggregates in striatal and 
cortical sections (Dedeoglu et al., 2002; Van Raamsdonk et al., 2005). However, some 
results suggest that TG2 might not be the primary target of cystamine. Cystamine-induced 
neuroprotection in R6/2 HD mice was maintained in TG2(-/-) R6/2 HD mice, reinforcing 
the hypothesis that cystamine-induced neuroprotection in HD was not related with TG2 
inhibition (Bailey and Johnson, 2006). In fact, cystamine appears to have anti-apoptotic 
and antioxidant characteristics. Cystamine was described to inhibit caspase-3 activity in 
vitro in a dose-dependent and TG2-independent manner. Cystamine also protected against 
proteasome inhibitor MG132 and the oxidative stress inducer H2O2-increased caspase-3 
activation and increased total glutathione levels in human neuroblastoma SH-SY5Y cells 
(Lesort et al., 2003). Furthermore, cystamine increased in a dose-dependent manner the 
levels of GSH and L-cysteine, but not GSSG, and decreased the number of aggregates in 
cell line models expressing mHtt (Fox et al., 2004), which can be associated with its 
ability to induce Nrf2 transcription and concomintantly protected against against 3-NP-
induced lesions (Calkins et al., 2010). The Raptor Pharmaceutical Corp. is currently 
collaborating with the Centre Hospitalier Universitaire (CHU) d'Angers in France in a 
clinical trial for the study of cysteamine bitartrate formulation (RP103) in HD named 
"CYST-HD Multicentre study of treatment of Huntington’s Disease with cysteamine, a 
randomized, controlled, double-blind multicenter phase II-III trial vs placebo" 
(http://www.raptorpharma.com).  
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1.4 Hypothesis and specific aims of the present work 
Considering the evidence of oxidative damage in HD and the controversial studies 
conducted so far, this thesis aimed to clarify the redox imbalance pathways that occur 
following expression of full-length mHtt and detail the changes in the antioxidant status, 
namely the glutathione redox system. Furthermore we aimed to evaluate the possible 
protective role of cystamine and creatine as well as insulin and IGF-1 pathways against 
oxidative stress in HD. For this purpose, we used striatal cells derived from HD knock-in 
mice expressing full-length mHtt with 111 Q (STHdh
Q111/Q111
; mutant cells) versus wild-
type striatal cells (STHdh
Q7/Q7
). Importantly, HD striatal cells may represent initial stages
of this neurodegenerative disease due to the absence of cell death or visible aggregates of 
mHtt (Trettel et al., 2000). 
The specific aims of the present work were: 
1. To thoroughly analyse the regulation of the glutathione redox system;
2. To explore the antioxidant response induced by exposure to H2O2, an oxidative
stress inducer, or STS, an apoptotic inducer, and further evaluate the protective effect of 
two compounds that are currently used in HD clinical trials, namely cystamine and 
creatine;  
3. To evaluate the role of insulin and IGF-1 signaling cascades on neuroprotection
and oxidative stress in HD knock-in striatal cells, namely through the regulation of Nrf2 
transcription factor.  
We hypothesised that glutathione redox cycle and its synthesis were disrupted and 
that decreased antioxidant response caused by stress inducers could be prevented by 
cystamine and creatine in HD striatal cells; moreover, restoration of insulin and IGF-1 
signaling pathways was hypothesized to rescue striatal cells from oxidative stress and cell 
death caused by full-length mHtt. 
The present thesis reveals important mechanisms related with the production of 
reactive oxygen species and the impact on relevant cellular antioxidants (e.g. glutathione-
dependent pathways) in HD striatal cells and determines the role of cystamine and 
creatine, as well as protective intracellular signaling pathways activated by insulin and 
IGF-1 that might help to ameliorate oxidative stress and prevent the aggravation of HD. 

Chapter 2 – Materials and 
Methods 
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2.1 Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM) culture medium, Fetal Bovine 
Serum (FBS), penicillin/streptomycin and geneticin were purchased by GIBCO (Paisley, 
UK). 5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-
dithiaoctanoic acid (MK-571) sodium salt, 5-sulfosalicylic acid dihydrate, ATP, Alamar 
Blue (resazurin sodium salt) dye, anti-β-actin, anti-α-tubulin, apocynin, calcein-AM, 
creatine monohydrate, cystamine, DL-dithiothreitol (DTT), γ-Glu-Cys, gamma-
glutamylcysteine (γ-GC), glucose-6-phosphate, GSHee, glycylglycine, GRed, GSH, 
GSSG, GST assay kit, H2O2, L-glutamic acid, L-glutamine, lucigenin, maleimide, 
NADH, NAD, NADPH, NADP, NDA (2,3-naphthalenedicarboxaldehyde), NEM (N-
ethylmaleimide), OPA (ortho-phthaldialdehyde), PMSF (phenylmethanesulfonyl 
fluoride), protease inhibitors (chymostatin, pepstatin, A, leupeptin and antipain), 
pyruvate, staurosporine from Streptomyces, and tert-butyl hydroperoxide (t-BHP) were 
from Sigma Chemical Co. (St Louis, MO, USA). γ-glutamyl-7-amino-4-methyl-coumarin 
(γ-glutamyl-AMC) was purchased from Bachem (Bubendorf, Switzerland). The 
fluorescence probes 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), Amplex® 
Red Xanthine/Xanthine Oxidase Assay Kit, dihydroethidium (DHE), Hoechst 33342, 
MitoSOX™ Red, propidium iodide, and trizol reagent were obtained from Molecular 
Probes/Invitrogen (Eugene, OR, USA). N-acetyl-Asp-Glu-Val-Asp-7-amino-4-
trifluoromethylcoumarin (Ac-DEVD-AFC) (Caspase-3 Substrate VII, Fluorogenic) and 
tetramethylrhodamine methyl ester (TMRM
+
) were obtained from Calbiochem (USA).
Anti-Akt was from BD Biosciences (USA). LY294002 and antibodies against Erk1/2 
(p44/42 MAPK) and P(Thr202/Tyr204)Erk1/2, were from Cell Signaling Technology 
(Beverly, MA, USA). Anti-Ac(K68)SOD2, anti-GCLc, anti-GRed, anti-Nrf2, anti-
P(Thr308)Akt, anti-P(Ser40)Nrf2, Anti-SOD1, anti-SOD2, and anti-TBP were from 
Abcam (Cambridge, UK). Secondary antibodies conjugated to alkaline phosphatase (anti-
mouse and anti-rabbit) were purchased from Amersham Biosciences (Buckinghamshire, 
UK). Enhanced ChemiFluorescence reagent (ECF), anti-rabbit IgG (from goat), anti-
mouse IgG+IgM (from goat) were from GE Healthcare (Little Chalfort, UK). First Strand 
cDNA Synthesis Kit (AMV) was obtained from Roche (Mannheim, Germany). GoTaq 
Flexi DNA polymerase and dNTP Mix were from Promega (Madison, WI, USA). 
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2.2 Cell culture 
Striatal cells derived from knock-in mice expressing normal Htt (STHdh
Q7/Q7
 or
wild-type cells; clone 2aA5) or homozygous to mHtt with 111 Q (STHdh
Q111/Q111 
or
mutant cells; clone 109-1A) were kindly donated by Dr. Marcy E. MacDonald 
(Department of Neurology, Massachusetts General Hospital, Boston, USA). The cells 
were maintained in an incubation chamber at 33ºC with 5% CO2, in DMEM culture 
medium supplemented with 10% FBS, 2 mM glutamine, 1% penicillin/streptomycin and 
400 µg/mL geneticin (G-418), as described previously (Trettel et al., 2000). Striatal cells 
were plated on poly-L-lysine coated glass coverslips, multiwell chambers or flasks 48 h 
before the experiments in order to allow the desired confluence. In some experiments, 
cells were incubated with cystamine (0.1 and 0.25 mM), creatine (0.1 and 1 mM), GSHee 
(0.05, 0.25 or 1 mM) or 50 µM MK-571, for 24 h. In other experiments, cells were pre-
incubated for 30 min with 25 µM LY294002 before incubation with insulin or IGF-1 
(0.1-10 nM) for 24h. Also, 15 h before some experiments, cells were incubated with STS 
(0.1-50 nM), a classic inducer of apoptosis, or H2O2 (1-100 µM) during 15 h.  
2.3 Cell extractions 
2.3.1 Total extracts and subcellular fractionation 
Nuclear-enriched fractions were obtained from cells that have been washed twice 
in ice-cold phosphate buffered saline (PBS) and scrapped in lysis buffer 1 (in mM: 10 
HEPES, 10 NaCl, 3 MgCl2, 1 EGTA, 0.1% Triton X-100, pH 7.5) supplemented with 50 
mM NaF, 1.5 mM Na3VO4, 1 mM DTT, 1 mM PMSF and 1 μg/mL protease inhibitor 
cocktail (chymostatin, pepstatin A, leupeptin and antipain). The cellular homogenate was 
incubated at 4ºC (on ice) for 40 min and then centrifuged at 4,700 rpm, for 12 min (4ºC). 
The pellet was resuspended in buffer 2 (in mM: 25 HEPES, 300 NaCl, 5 MgCl2, 1 EGTA, 
20% glycerol, pH 7.4) supplemented with 50 mM NaF, 1.5 mM Na3VO4, 1 mM DTT, 1 
mM PMSF and 1 μg/mL protease inhibitor cocktail, incubated on ice for 60 min, and 
further centrifuged at 10,600 rpm for 20 min (4°C). The resulting pellet (nuclear-enriched 
fraction) was resuspended in buffer 2. The samples were then frozen and thaw three times 
in liquid nitrogen, sonicated for 30 sec and then the samples were stored at −80 °C. To 
obtain the mitochondrial-enriched fractions, striatal cells were washed with PBS and 
lysed at 4ºC using a sucrose buffer (pH 7.5) composed by (in mM): 250 sucrose, 20 
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HEPES, 100 KCl, 1.5 MgCl2, 1 EDTA and 1 EGTA, 1 DTT, 0.1 PMSF, and 1 μg/mL 
protease inhibitor cocktail, homogenized by using a potter (120 strokes). Then, extracts 
were centrifuged at 500 g in order to remove nuclear debris and the resulting supernatant 
was centrifuged at 12,000 g for 20 min in order to obtain an enriched mitochondrial 
fraction, which was further resuspended in sucrose buffer supplemented with 0.05% 
Triton X-100. 
2.3.2 Total RNA extraction, cDNA conversion and reverse-
transcriptase PCR 
RNA from different samples was obtained with Trizol Reagent according to the 
manufacturer’s protocol. Briefly, striatal cells were lysed with Trizol and were 
homogeneized with a pipette. The RNA was precipitated with isopropyl alcohol and the 
final pellet was resuspended with water DEPC (diethylpyrocarbonate) 0.01% (v/v). 
Before performing reverse-transcriptase polymerase chain reaction (RT-PCR), the quality 
of RNA was verified through an electrophoresis in 1% agarose gel to check the ribosomal 
RNA subunits 18S and 28S. Then, the samples were incubated at 65ºC for 15 min, to 
avoid extensive secondary structure that may interfere with the annealing step and then 
were chilled on ice for 5 min. The concentration of RNA was measured and 1 g was 
used to transcribe RNA into cDNA with First Strand cDNA Synthesis Kit (AMV). The 
reaction was as follow: 10 min at +25°C and 60 min at +42°C, for primer annealing and 
cDNA synthesis, respectively, 5 min at +99°C, for the denaturation of reverse 
transcriptase and then the samples were cooled to +4°C for 5 min. 
2.4 Cell viability and death methods 
2.4.1 Alamar Blue assay 
The reducing capacity of the cells was evaluated by the Alamar Blue assay. This 
method is based on the detection of the metabolic activity of the cells, largely depending 
on the activity of dehydrogenases that produce reduced forms of coenzymes (e.g. 
NADH). The active compound of Alamar Blue (resazurin) is a nontoxic cell permeable 
compound that is reduced inside the cells to the pink fluorescent resorufin, whenever they 
are metabolically active (O’Brien et al., 2000) (Figure 2.1). After medium removal, cells 
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were incubated with 200 µL Alamar Blue (0.1 mg/ml) for 2 h at 33 ºC, and the 
absorbance was measured at 570 and 600 nm in a Spectramax Gemini EM 
spectrophotometer (Molecular Devices, Union City, CA). Cellular function based on the 
reducing capacity was calculated as a percentage of wild-type cells or control. 
Figure 2.1 – Alamar Blue Assay.  Resazurin is a cell permeable compound that has a maximum 
absorption at ~600 nm and when inside the cells is reduced by NAD(P)H dehydrogenases to the 
pink fluorescent resorufin that has a maximum absorption at ~570 nm and fluorescence 
excitation/emission of ~570/585 nm. 
2.4.2 LDH release assay 
After exposure to H2O2 or STS during 15h, striatal cells were used to determine 
cell viability by monitoring the release of LDH to the extracellular medium, which 
evaluates plasma membrane integrity, indicator of necrosis cell death. Briefly, the 
extracellular medium was collected and cells were washed twice with PBS and lysed in 
10 mM HEPES (pH 7.4) plus 0.02% Triton X-100 at 4ºC and then collected and 
submitted to 3 cycles of freezing. Then, all the samples (extra and intracellular fractions) 
were centrifugated at 14,000 rpm (Eppendorf Centrifuge 5417R), for 10 min at 4ºC. The 
pellet was discarded and LDH was determined spectrophotometrically, by following the 
rate of conversion of reduced nicotinamide adenine dinucleotide (NADH) to oxidized 
NAD
+
 at 340 nm (Bergmeyer and Bernt, 1974) (Figure 2.2). LDH released into the
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extracellular medium was expressed as a percentage of the total LDH activity in the cells 
[% of LDH released = extracellular LDH / (extracellular LDH + intracellular LDH)] and 
then expressed as percentage of wild-type cells or control. 
Figure 2.2 – LDH release assay. Under conditions of disrupted cell membrane (necrosis), lactate 
dehydrogenase (LDH) is released to the extracellular space. If substrates are given, it catalyzes the 
interconversion of lactate and NAD+ to pyruvate and NADH. NADH in turn absorbs light at 340 
nm.  
2.4.3 Caspase-3 activity assay 
Caspase-3-like activity was determined using a fluorimetric substrate Ac-DEVD-
AFC. The DEVD sequence is cleaved by caspase-3 releasing the fluorogenic AFC which 
is quantified by fluorimetry (Figure 2.3). Striatal cells were washed twice with PBS and 
then lysed at 4ºC with a lysis buffer composed by (in mM): 25 HEPES, 2 MgCl2, 1 
EDTA, 1 EGTA, 2 DTT, 0.1 PMSF, and 1:1000 protease inhibitors and 0.04% Triton X-
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100 (pH 7.5). After scraping, a reaction buffer composed by (final concentrations in the 
well) 25 mM HEPES, 10% sucrose, 0.1% CHAPS, 2 mM DTT and 15 µM Ac-DEVD-
AFC (pH 7.5), was added to the cell samples. The fluorescence was taken during 1 h at 
33ºC with 400 nm excitation and 505 nm emission. After the readings, cell samples were 
used to determine protein content by Bio-Rad protein assay. The values were obtained as 
RFU (Relative Fluorescence Units) per minute per mg protein for each condition and then 
expressed as percentage of wild-type or control cells. 
Figure 2.3 – Caspase-3 activity assay. The amino acid DEVD sequence of the caspase-3 (Casp-
3) fluorimetric substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin
(Ac-DEVD-AFC) is cleaved by caspase-3 releasing the AFC which has a fluorescence 
excitation/emission maxima of ~400/505 nm.  
2.4.4 Fluorescence microscopy 
Cells were washed with microscopy buffer (120 mM NaCl, 3.5 mM KCl, 0.4 mM 
KH2PO4, 20 mM HEPES, 5 mM NaHCO3, 1.2 mM Na2SO4 and 15 mM glucose) 
supplemented with 1.2 mM MgCl2 and 1.3 mM CaCl2, pH 7.4. Cells were further 
incubated with Hoechst 33342 (2 µg/mL, a blue permeable fluorescent dye, which binds 
to DNA, to determine fragmented/condensed nucleus) and propidium iodide (4 µg/mL, a 
non-membrane permeable red fluorescent dye that binds to DNA, for necrotic cell 
evaluation) (Figure 2.4), during 8 and 3 min, respectively, in the dark. Live cells were 
analyzed by fluorescence microscopy. Images from five different fields in each coverslip 
were acquired in a fluorescence microscope Axioskop 2 Plus (Zeiss, Jena, Germany) and 
cells were counted using ImageJ Launcher (version 1.44p, NIH). Fragmented/condensed 
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nucleus labeled with Hoechst 33342 (apoptotic-like cells) and cell nucleus labeled with 
propidium iodide (necrotic cells) were determined as a percentage of total cells (stained 
with Hoechst). 
Figure 2.4 – Cell death analysis by fluorescence microscopy. Striatal cells were incubated with 
Hoechst 33342, a blue permeable fluorescent dye, which binds to DNA, to determine 
fragmented/condensed nucleus, and has a fluorescence excitation/emission maxima of ~350/461 
nm, and propidium iodide, a non-membrane permeable red fluorescent dye that binds to DNA, for 
necrotic cell evaluation, and has a fluorescence excitation/emission maxima of ~536/617 nm.  
2.5 Analysis of mitochondrial membrane potential 
The ΔΨm was determined using the cationic fluorescent probe TMRM+, widely
used as a fluorescent probe for measuring in situ ΔΨm (Nicholls et al., 2012) (Figure 2.5). 
The experiments were performed accordingly to (Ferreira et al., 2010), with minor 
modifications. Briefly, cells were cultured in a 96-well plate during 48 h, at 33ºC. Then, 
striatal cells were washed twice in PBS and 300 nM TMRM
+
 (diluted in Krebs medium)
was incubated during 1 h, at 33ºC. After incubation, the basal fluorescence was taken 
during 5 min using a Microplate Spectrofluorometer Gemini EM (Molecular Devices, 
USA) (540 nm excitation and 590 emission). FCCP (2.5 μM) and oligomycin (2 μg/ml), 
which produced maximal mitochondrial depolarization, were added to cells and the 
fluorescence was taken during another 5 min. Results were expressed as the difference 
between the increase in TMRM
+
 fluorescence upon addition of FCCP plus oligomycin
and basal fluorescence values, and converted to percentage of wild-type (control) cells. 
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Figure 2.5 – M itochondrial membrane potential assay. The cell-permeable cationic fluorescent 
probe tetramethylrhodamine methyl ester (TMRM+) is rapidly sequestered by active 
mitochondria where it accumulates in the highly negatively charged matrix and has a fluorescence 
excitation/emission maxima of ~548/590 nm. Thus, altered fluorescence signal of TMRM+ can be 
directly co-related to changes of mitochondrial membrane portential (ΔΨm).  
2.6 Intracellular ROS levels and production measurements 
2.6.1 Total intracellular and mitochondrial ROS levels measurements 
After brief washing with PBS, striatal cells were incubated for 30 min with 20 µM 
H2DCFDA, a stable non-fluorescent cell permeable compound, at 33ºC, in modified 
Krebs medium (in mM: 135 NaCl, 5 KCl, 0.4 KH2PO4, 1.8 CaCl2, 1 MgSO4, 20 HEPES 
and 5.5 glucose) at pH 7.4. H2DCFDA is incorporated by the cells and hydrolysed by 
esterases to form H2DCF, which is then converted to dichlorofluorescein (DCF) by 
intracellular ROS (LeBel et al., 1992) (Figure 2.6). Intracellular ROS levels were 
measured by following DCF fluorescence (488 nm excitation, 530 nm emission) at 33ºC, 
continuously, for 1 h, using a Microplate Spectrofluorometer Gemini EM (Molecular 
Devices, USA). In order to correct the DCF fluorescence values for variations in total 
intracellular protein content in each well was quantified by the BioRad protein assay 
(Bradford method). The values were obtained as RFU per minute per mg protein for each 
condition and then expressed as percentage of wild-type cells. O2
•–
 formation was
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determined by using the fluorescence probe dihydroehidium (DHE) (Molecular Probes, 
Invitrogen). DHE is permeable to cell membrane and in cytoplasm it is converted to 
ethidium (E
+
) by O2
•–
. Then, E
+
 binds to DNA and emits fluorescence (Bindokas et al.,
1996) (Figure 2.7). Briefly, 5 µM DHE dissolved in Krebs medium was incubated in cells 
during 1 h at 33ºC. Fluorescence measurements were taken during 1 h (518 nm excitation; 
605 nm emission). Mitochondrial O2
•–
 levels were measured by using the fluorescent
probe MitoSOX
TM
 Red (Figure 2.7). Briefly, striatal cells were washed in PBS, and then
incubated with 2.5 µM MitoSOX
TM
 Red in Krebs medium during 10 min, at 33ºC. The
fluorescence was taken during 1 h and 30 min, at 33ºC, with 510 nm excitation and 580 
nm emission. In order to correct the DCF, DHE and MitoSOX
TM
 Red fluorescence values
for variations in total protein content in the wells, cell protein in each well was quantified 
by the BioRad protein assay. The values were obtained as RFU per minute per mg protein 
for each condition and then expressed as a percentage of wild-type cells or control. 
Figure 2.6 – Determination of ROS levels by H2DCFDA. 2',7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA), a stable non-fluorescent cell permeable compound, is hydrolysed by 
intracellular esterases to form H2DCF, which is then converted by intracellular ROS to 
dichlorofluorescein (DCF) and has fluorescence excitation/emission maxima of ~488/530 nm. 
Thus, increased fluorescence signal of DCF has been directly co-related to intracellular ROS 
levels. However, it was recently described that H2DCFDA is very inespecific probe for ROS 
detection. It can be oxidized by several oxidants, including ONOO−, •OH or hypochlorous acid, 
and redox-active metals such as iron (Kalyanaraman et al., 2012).   
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Figure 2.7 – Determination of mitochondrial ROS levels by DHE and MitoSOXTM Red. 
Dihydroethidium (DHE) is permeable to cell membrane and in cytoplasm it is converted to 
ethidium (E
+
) by O2
•–
. Then, E
+
 binds to DNA and emits fluorescence (excitation/emission:
518/605 nm). The cell-permable MitoSOX
TM
 Red reagent is a hydroethidium (HE) derivate with a 
triphenylphosphonium (TPP) moiety for mitochondrial targeting. It is rapidly oxidized by O2
•– 
and binds to mitochondrial DNA where it has a fluorescence excitation/emission maxima of 
~510/580 nm. Thus, increased fluorescence signal of DHE and MitoSOX
TM
 Red can be directly 
co-related to increased O2
•–
 levels.  However MitoSOXTM Red may also non-specifically oxidize
(Kalyanaraman et al., 2012).  
2.6.2 Cytosolic and mitochondrial ROS production measurements 
2.6.2.1 NOX activity assay 
NOX activity was determined using the chemiluminescent probe lucigenin, as 
described previously (Li et al., 1998) with some modifications (Figure 2.8). Briefly, 
striatal cells were washed twice with PBS and lysed with 25 mM Tris-HCl (pH 7.4). 
Then, 30 µg protein were added to a 96-well plate containing 100 µM NADPH and 5 µM 
lucigenin in a final volume of 200 µL (adjusted with 25 mM Tris-HCl). Luminescence 
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readings were performed during 15 min and results were calculated as relative 
luminescence units (RLU) per min per mg protein and expressed as percentage of wild-
type cells or control. Apocynin, an inhibitor of NOX was used as a control of the 
experiment.  
Figure 2.8 – NOX activity assay. The chemiluminescent probe lucigenin is oxidized by O2
•– 
that
can be produced by NADPH oxidase (NOX) after NAD(P)H supply. The final product lucigenin 
radical can emit light. Thus, increased luminescence signal of lucigenin can be directly co-related 
to increased NOX activity. 
2.6.2.2 XO activity and hypoxanthine levels 
XO activity and hypoxanthine levels were determined as described in the manual 
provided by the Amplex® Red Xanthine/Xanthine Oxidase Assay Kit (Figure 2.9). The 
results were expressed as percentage of wild-type cells or control. 
Figure 2.9 – XO activity assay. The Amplex® Red Xanthine/Xanthine Oxidase Assay is based on 
the conversion by xanthine oxidase (XO) of purine bases, hypoxanthine or xanthine, to uric acid 
and superoxide (O2
•– 
) which is spontaneously degraded to hydrogen peroxide (H2O2), which in
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the presence of horseradish peroxidase (HRP) reacts stoichiometrically with Amplex Red reagent 
to generate the red-fluorescent oxidation product, resorufin; this has absorption and fluorescence 
emission maxima of approximately 571 nm and 585 nm, respectively. 
2.6.2.3 Mitochondrial complexes I and III ROS production 
For the mitochondrial complexes I and III ROS formation, 5 µM DHE dissolved 
in Krebs medium was incubated in cells during 1 h at 33ºC. Fluorescence measurements 
were taken during 1 h (518 nm excitation; 605 nm emission) in the presence of 10 µM 
rotenone, a mitochondrial complex I inhibitor, or antimycin A, a mitochondrial complex 
III inhibitor. 
2.7 Cellular antioxidant systems measurements 
2.7.1 Measurement of antioxidant enzymes activities 
2.7.1.1 Measurement of SOD activity 
Determination of SOD activity was performed accordingly to the SOD Assay Kit 
(Sigma) (Figure 2.10). In order to measure SOD2 activity, 2 mM potassium cyanide 
(KCN) (which inhibits SOD1) was added. 
Figure 2.10 – SOD activity assay. The superoxide dismutase (SOD) Assay Kit is based on the 
conversion by superoxide (O2
•–
) of WST-1 (2-(4-iodophenyl)- 3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)- 2H-tetrazolium, monosodium salt) into a water-soluble formazan dye (WST-1 
formazan) which has an absorption maxima of ~440 nm. The rate of the WST-1 conversion to 
WST-1 formazan is linearly related to the xanthine oxidase (XO) activity, and is inhibited by 
SOD, Thus, increased SOD activity will present decreased WST-1 formazan formation. Specific 
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SOD2 activity can be measured in the presence of potassium cyanide (KCN) , since it inhibits 
SOD1 activity.  
2.7.1.2 Measurement of GRed and GPx activities 
The cells were washed twice in PBS and lysed in 25 mM Tris-HCl (pH 7.4) and 
then centrifuged at 20,800×g for 10 min, at 4ºC (Eppendorf Centrifuge 5417R). The 
supernatant was used for protein quantification using the BioRad protein assay (Bradford 
method) and for measuring GRed and GPx activities, spectrophotometrically, at 340 nm, 
through the analysis of NADPH oxidation, as described previously (Paglia and Valentine, 
1967) with some modifications (Figure 2.11). Briefly, the activity of GPx in samples was 
measured upon a 5 min incubation, in the dark, with phosphate buffer containing 0.25 M 
KH2PO4, 0.25 M K2HPO4 and 0.5 mM EDTA, pH 7.0, 10 mM GSH and GRed (1 unit). 
The reaction occurred after the addition of 2.5 mM NADPH and 12 mM t-BHP. For the 
activity of GRed, each sample was incubated with a phosphate buffer containing 0.2 M 
K2HPO4 and 2 mM EDTA, pH 7.0, plus 2 mM NADPH. The measurements were 
initiated with the addition of 20 mM GSSG. GRed and GPx activities were determined 
using a Microplate Spectrophotometer SpectraMax Plus
384
 (Molecular Devices, USA).
Results were calculated milliunits (mU) per mg protein and expressed as percentage of 
wild-type cells or control. 
Figure 2.11 – Determination of GPx and GRed activities. Glutathione peroxidase (GPx) activities 
measured in the presence of glutathione reductase (GRed), NADPH, the reduced form of 
glutathione (GSH), and tert-butyl hydroperoxide (t-BHP). GRed activity is measured in the 
presence of NADPH and the oxidized form of glutathione (GSSG). The conversion of NADPH 
(which absorbs at 340 nm) into NADP
+
 is linearly related to GPx and GRed activities.  
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2.7.1.3 Measurement of G6PD and 6PGD activities 
G6PD activity was determined according to Choo and collaborators (2005), with 
some minor modifications (Figure 2.12). Briefly, the cells were washed twice in PBS and 
lysed in 25 mM Tris-HCl (pH 7.4) and then centrifuged at 20,800×g for 10 min, at 4ºC 
(Eppendorf Centrifuge 5417R). The supernatant was used for protein quantification using 
the BioRad protein assay (Bradford method) and cell samples (30 µg) were mixed with a 
reaction buffer containing (in mM): 0.38 NADP, 6.3 MgCl2, 3.3 G6P, and 5 maleimide 
(an inhibitor of 6-phosphogluconate dehydrogenase (6PGD) activity) in 50 mM Tris-HCl 
(pH 7.5). For 6PGD activity determination, experiments were performed in the absence of 
maleimide, corresponding, therefore, to the total NADPH production (G6PD + 6PGD) by 
the pentose phosphate pathway; thus 6PGD activity = total NADPH production – G6PD 
activity. The NADPH production was continuously monitored at 340 nm using a 
Microplate Spectrophotometer SpectraMax Plus
384
 (Molecular Devices, USA) at 37ºC
and the results were calculated in milliunits (mU) per mg protein and expressed as 
percentage of wild-type cells. 
Figure 2.12 – Determination of G6PD and 6PGD activities. Since both glucose-6-phosphate 
dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) activities can produce 
NADPH, maleimide, which inhibits 6PGD activity, is used to measure G6PD activity. Besides 
maleimide, G6PD is measured after addition of glucose-6-phosphate (G6P), and NADP
+
, both 
substrates of G6PD, resulting in NADPH and 6-phospho-D-glucono-1,5-lactone (6PGL) 
formation; the latter is a substrate for 6-phosphogluconolactonase (6PGLase), producing 6-
phosphogluconate (6PG), which is then converted to ribulose-5-phosphate (R5P) by 6PGD. The 
rate of NADPH formation is followed at 340 nm. 6PGD activity is measured without maleimide 
supply.  
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2.7.1.4 Determination of GCL and GS activities 
GCL and glutathione synthetase (GS) activities were measured according to White 
and collaborators (2003), with some minor modifications (Zhu et al., 2006) (Figure 2.13). 
Cells were washed twice with PBS and lysed with 25 mM Tris-HCl (pH 7.4) plus 0.1 mM 
EDTA. Cellular extracts were centrifuged at 20,800×g for 10 min at 4ºC, and protein 
content analysed by the BioRad protein assay (Bradford method). For GCL activity, 50 
µL of sample was added to 50 µL of GCL reaction buffer containing (in mM): 100 Tris, 
10 ATP, 20 L-glutamic acid, 2 EDTA, 20 sodium borate, 2 serine, and 40 MgCl2, and 
incubated at 37ºC during 5 min. The GCL reaction was initiated by adding 50 µL of 2 
mM L-cysteine. For GS activity, L-glutamic acid and L-cysteine were replaced with 30 
mM glycine and 3 mM γ-GC, respectively. After 20 min incubation, the GCL and GS 
reactions were stopped by adding 50 µL of 200 mM 5-sulfosalicylic acid. Samples were 
vortexed, incubated on ice for 20 min, and centrifuged at 660×g at 4°C, for 5 min. Then, 
20 µL of supernatant were transferred into a 96-well plate and 180 µL of NDA 
derivatization solution (50 mM Tris, pH 10, 0.5 M NaOH and 10 mM NDA in dimethyl 
sulfoxide (DMSO), v/v/v 1.4/0.2/0.2, respectively) was then added to each well to form 
NDA-γ-GC or NDA-GSH fluorescent complexes. The fluorescence was detected at 472 
nm (excitation) and 528 nm (emission), using a Microplate Spectrofluorometer Gemini 
EM (Molecular Devices, USA). The results were calculated as RFU per mg protein and 
expressed as percentage of wild-type cells. 
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Figure 2.13 – Determination of GCL and GS activities. Glutamate-cysteine ligase (GCL) activity 
is measured after addition of the substrates ATP, L-cysteine and L-glutamate producing γ-
glutamylcysteine (γ-GC), which forms fluorescent adducts with 2,3-naphthalenedicarboxaldehyde 
(NDA) (excitation/emission: 472/528 nm). Glutathione synthetase (GS) activity is measured after 
addition of the substrates γ-GC and L-glycine, producing the reduced form of glutathione (GSH) 
that also forms fluorescent adducts with NDA (excitation/emission: 472/528 nm). 
2.7.1.5 Measurement of GST activity 
Determination of GST activity was performed accordingly to the manual provided 
by the GST Assay kit (Sigma). Briefly, after a washing step in PBS cell samples were 
mixed in a 96-well plate with a substrate solution containing 1-chloro-2,4-dinitrobenzene 
(CDNB) and GSH and the absorbance was followed at 340 nm during 6 min (Figure 
2.14). The results were calculated in µmol per min per mg protein and expressed as 
percentage of wild-type cells. 
2.7.1.6 Measurement of -GT activity 
The cells were lysed at 4ºC in 100 mM Tris-HCl, 1 mM EDTA and 0.1% Triton 
X-100; pH 7.6 and -glutamyl transpeptidase (-GT) activity was measured accordingly 
to Zhu and collaborators (2006) with some modifications (Figure 2.14). Briefly, 50 µL of 
cell samples  were added to 50 µL of a reaction mixture containing 100 mM Tris–HCl 
(pH 7.6), 40 mM glycylglycine, 40 μM -glutamyl-7-amino-4-methyl-coumarin (-
glutamyl-AMC), and 0.1% (v/v) Triton X-100, in a 96-well plate. The fluorescence was 
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measured with excitation at 370 nm and emission at 440 nm, for 45 min at 33ºC. The 
values were obtained as RFU per minute per mg protein for each condition and then 
expressed as percentage of wild-type cells. 
Figure 2.14 – Determination of GST and -GT activities. Glutathione S-transferase (GST) 
activity assay is based on the GST-catalyzed reaction between the reduced form of glutathione 
(GSH) and the GST substrate, CDNB (1-chloro-2,4-dinitrobenzene), producing DNB-GS, which 
absorbs at 340 nm. -Glutamyl transpeptidase (-GT) activity is measured in the presence of 
glycylglycine and gamma-glutamyl-7-amino-4-methyl-coumarin (-glutamyl-AMC), producing -
glutamyl-glycylglycine and AMC that has a fluorescence excitation/emission maxima of 
~370/440 nm. 
2.7.1.7 Analysis of Mrp1 activity based on calcein fluorescence 
Mrp1 activity was determined based on calcein fluorescence, since Mrp1 is 
involved in the transport of calcein to the extracellular space (Dogan et al., 2004) (Figure 
2.15). Striatal cells were cultured during 24 h and then briefly washed in PBS. After the 
washing step, the cells were incubated with 5 µM calcein-AM in modified Krebs medium 
during 1 h, at 33ºC. Calcein-AM diffuses into cells where it is cleaved by intracellular 
esterases, resulting in fluorescent calcein. After incubation, striatal cells were washed 
twice in PBS and intracellular calcein fluorescence was analysed using excitation at 494 
nm and emission at 517 nm. The results were calculated as RFU per mg protein and 
expressed as a percentage of wild-type cells. 
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Figure 2.15 – Mrp1 activity assay. Multidrug resistance-associated protein 1 (Mrp1) activity is 
determined based on calcein fluorescence, since Mrp1 is involved in the transport of calcein to the 
extracellular space. Calcein-AM diffuses into cells where it is cleaved by intracellular esterases, 
resulting in fluorescent calcein (excitation/emission: 494/517 nm). MK-571 is an inhibitor of 
Mrp1 activity and is used as a positive control. 
2.7.1.8 Analysis of Nrf2/ARE activity based on luciferase gene reporter 
assay 
Nrf2 transcription activity was measured based on its capability of binding ARE 
region, promoting luciferase gene transcription. Striatal cells plated on 12-well plates 
(90,000 cells/well) were transfected with the reporter construct 
[pGL4.37[luc2P/ARE/Hygro] (Promega) using Fugene 6 (Promega) by adding 1.1 µg 
plasmid. After 24 h, cells were exposed to insulin (0.1 nM) for another 24 h. 3 days after 
transfection, cells were washed with PBS and incubated at -80ºC for 2 h in Lysis Buffer 
(1.15 M Tris, 1 mM EDTA, 8 mM MgCl2, 15% glycerol, 1 mM DTT, 1% Triton X-100, 
pH 7.4). Cells were then scraped and samples were centrifuged (5 min, 4ºC at 14,000 
rpm). 50 µl of the supernatant were transferred to a white opaque 96-wells plate. The 
luciferase activity was measured in a Microplate Luminometer Reader LMax 384 
(Molecular Devices, USA) using two different buffers: Reading Buffer (1.15 M Tris, 1 
mM EDTA, 8 mM MgCl2, 15% glycerol, 1 mM DTT, 2 mM ATP, pH 7.4) and 
Luciferase Buffer (167 µM; prepared in water with pH 8). In order to correct the 
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luciferase activity, the protein content in each well was measured by the Bio-Rad protein 
assay (Bradford method). The percentage of luciferase activity was then normalized to 
controls (wild-type cells transfected without any treatment). 
2.7.2 Measurement of antioxidant systems levels 
2.7.2.1 Measurement of glutathione and protein levels 
2.7.2.1.1 Measurement of glutathione levels by fluorimetry 
The levels of GSH and GSSG were measured as previously described (Hissin and 
Hilf, 1976) (Figure 2.16). Briefly, striatal cells were cultured during 48h at 33ºC.  After 
incubation, the cells were washed twice in PBS and lysed in 15 mM Tris, pH 7.4, with 
0.2% Triton X-100. GSH levels were measured in samples after the addition of OPA (1 
mg OPA/ml methanol) and 100 mM NaH2PO4. After 15 min incubation, the fluorescence 
was measured using an excitation wavelength of 350 nm and an emission wavelength of 
420 nm. The experimental procedure for GSSG was similar, although the samples were 
mixed during 30 min with NEM (5 mg NEM/ml methanol) which forms adducts with 
GSH. Then, the mixture was incubated for 15 min in 100 mM NaOH plus OPA (1 mg 
OPA/ml methanol), and the fluorescence was measured with excitation at 350 nm and 
emission at 420 nm in a Microplate Spectrofluorometer Gemini EM (Molecular Devices, 
USA). The results were calculated as RFU per mg protein and expressed as percentage of 
wild-type cells, control, or as a percentage of control (untreated) conditions in the case of 
MK-571 incubation.  
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Figure 2.16 – Determination of GSH and GSSG levels by fluorimetry. The levels of the reduced 
form of glutathione (GSH) are determined based on the capacity of GSH to form fluorescent 
adducts with ortho-phthaldialdehyde (OPA) (excitation/emission: ~350/420 nm) at neutral pH. 
The levels of the oxidized form of glutathione (GSSG) are based on the capacity of GSSG to form 
fluorescent adducts with OPA at pH 12. N-ethylmaleimide (NEM), which forms non-fluorescent 
adducts with GSH, is added to the samples to prevent GSH-OPA fluorescent adducts formation.  
2.7.2.1.2 Measurement of intra- and extracellular levels of total glutathione 
by HPLC 
Extracellular cultured medium was collected, whereas the cells were washed with 
PBS and further lysed in 1 M NaOH for determination of intra- and extracellular levels of 
total glutathione (GSH+GSSG). Both fractions were centrifuged at 20,800×g, at 4ºC for 
10 min, to remove cell debris, and the supernatants were used for total glutathione 
analysis in a Gilson-ASTED HPLC system. Samples were separated on a Hichrom ACE 
type column (150 × 4.6 mm, 5 µM C18) at a flow rate of 2.5 mL/min for 45 min, using a 
ternary solvent system consisting of solvent A [37.5 mM sodium phosphate, 50 mM 
propionic acid, 7% acetonitrile, and 3% DMSO (pH 6.2)], solvent B (40% acetonitrile, 
33% methanol, and 7% DMSO), and solvent C [62.5 mM sodium phosphate, 50 mM 
propionic acid, 7% acetonitrile, and 3% DMSO (pH 5.5)]. Total glutathione was detected 
as a fluorescent derivative after precolumn derivatization with OPA/2-mercaptoethanol 
(MCE), using a Gilson fluorescent detector model 121, with excitation at 340 nm and 
emission at 410 nm. Total glutathione levels were determined by comparison with peak 
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areas of GSH standards, calculated in nanomoles per milligram of protein and expressed 
as a percentage of wild-type cells. Protein levels were determined by the BioRad protein 
assay (Bradford method). 
2.7.2.1.3 Western Blotting 
Striatal cells were washed twice in PBS and extracted with lysis buffer containing 
20 mM Tris-HCl (pH 7), 1% Triton X-100, 100 mM NaCl, 2 mM EDTA, 2 mM EGTA, 
0.1 mM PMSF, 50 mM NaF, 1.5 mM Na3VO4 and 1 μg/mL protease inhibitor cocktail. 
Total extracts were centrifuged at 14,000 rpm for 10 min in order to discard debris, and 
protein content determined by the Bio-Rad method. Samples were denaturated in 50 mM 
Tris-HCl, pH 6.8, 2% sodium dodecyl sulphate (SDS), 5% glycerol, 0.01% bromophenol 
blue and 100 mM DTT at 95ºC, for 5 min. Equivalent amounts of 30-60 μg of protein 
were separated on 12% SDS-PAGE and electroblotted onto polyvinylidene difluoride 
(PVDF) membranes. The membranes were further blocked with 5% fat-free milk and 
incubated with anti-GCLc (1:1000), anti-GRed (1:2,000), anti-SOD1 (1:1000), anti-
Ac(Lys68)SOD2 (1:1000), anti-SOD2 (1:1000), anti-Akt (1:1000), anti-p-(Thr308)Akt 
(1:1000), anti-Erk (1:1000), anti-p-(Thr202/Tyr204)Erk (1:1000), anti-Nrf2 (1:1000) and 
anti-p-(Ser40)Nrf2 (1:1000). Anti-α-tubulin (1:1000) or anti--actin (1:5000) were used 
as loading controls for total cellular fractions, and anti-TBP (TATA binding protein) 
(1:1000) was used as loading control of nuclear fractions. Immunoreactive bands were 
visualized by alkaline phosphatase activity after incubation with ECF reagent, by using a 
BioRad Versa Doc 3000 Imaging System.  
2.7.2.2 Measurement of mRNA levels 
2.7.2.2.1 Quantification of G6PD, GCLc, HO-1 and Mrp1, NQO1 mRNA levels 
The concentration of the resulting single-stranded cDNA was determined, and 10 
ng was used to each further reaction. The cDNA of each sample was amplified using 
sequence-specific primers to to G6PD, forward (5’-3’) ATG GCA GAG CAG GTG 
GCC; reverse (5’-3’) GCA CTG TTG GTG GAA GAT G; GCLc: forward (5’-3’) ATG 
GGG CTG CTG TCC CAA G; reverse (5’-3’) GTA TGA GAG GAT CAC CCT AG; 
HO-1: forward (5’-3’) GCT CAC GGT CTC CAG TCG CC; reverse (5’-3’) CAC TGC 
96 
CAC TGT TGC CAA C; Mrp1, forward (5’-3’) CTG CAC AAC CTG CGC TTC; 
reverse (5’-3’) GGT GCC AGA GGC CAG AC; NQO1: forward (5’-3’) AGG CTC AGC 
TCT TAC TAG C; reverse (5’-3’) ATT CAT TTT GTT GTT ATG GCA G. The 
normalization of the amplified product was performed in relation to the product of actin 
obtained in the same samples using as primers (5’-3’) GGA GAC GGG GTC ACC CAC 
AC and (5’-3’) AGC CTC AGG GCA TCG GAA CC, forward and reverse respectively. 
All reactions were performed using GoTaq Flexi DNA Polymerase (5x kit) and 10 mM 
dNTP Mix. The amplification reaction mixture (50 l) contained 10 l of the cDNA 
template, 1.5 mM of MgCl2, 0.2 M of each primer, 0.05 U Taq Pol. The thermal cycling 
conditions included 3 min at 94ºC, proceeding with 40 cycles of 94ºC for 30 s, 57ºC for 
30 s and 72ºC for 45 s, followed by 72ºC for 10 min. The size of the PCR products was 
visualized in a 1.7% agarose gel and analyzed afterwards using a BioRad Gel Doc 3000 
Imaging System. G6PD, GCLc, HO-1, Mrp1, or NQO1 mRNA levels were expressed in 
relation to actin. 
2.8 Statistical analysis 
Statistical significance was determined by one-way or two-way ANOVA followed 
by the Bonferroni post-hoc test for multiple groups or by the Student’s t-test for 
comparison between two Gaussian populations, as described in figure legends. Data were 
expressed as the mean ± S.E.M. of the number of experiments indicated in figure legends. 
Significance was accepted at p<0.05. 
Chapter 3 – Results 
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3.1 Glutathione redox cycle dysregulation in Huntington’s 
disease knock-in striatal cells106 
3.1.1 Summary 
HD is a CAG repeat disorder affecting the HTT gene, which encodes for Htt and is 
characterized by prominent cell death in the striatum. Oxidative stress was previously 
implicated in HD neurodegeneration, but the role of the major endogenous antioxidant 
system, the glutathione redox cycle, has been less studied following expression of full-
length mHtt. Thus, in this work we analysed the glutathione system in striatal cells 
derived from HD knock-in mice expressing mHtt versus wild-type cells. Mutant cells 
showed increased intracellular ROS and caspase-3 activity, which were significantly 
prevented following treatment with GSHee. Interestingly, mutant cells exhibited an 
increase in intracellular levels of both GSH and GSSG, and enhanced activities of GPx 
and GRed. Furthermore, GST and γ-glutamyl transpeptidase (-GT) activities were also 
increased in mutant cells. Nevertheless, GCL and GS activities and levels of GCLc were 
decreased in cells expressing full-length mHtt, highly suggesting decreased de novo 
synthesis of glutathione. Enhanced intracellular total glutathione, despite decreased 
synthesis, could be explained by decreased extracellular glutathione in mutant cells. This 
occurred concomitantly with decreased mRNA expression levels and activity of the 
multidrug resistance-associated protein 1 (Mrp1), a transport protein that mediates 
cellular export of glutathione disulfide and glutathione conjugates. Additionally, 
inhibition of Mrp1 enhanced intracellular GSH in wild-type cells only. These data suggest 
that full-length mHtt affects the export of glutathione by decreasing the expression of 
Mrp1. Data further suggest that boosting of GSH-related antioxidant defence mechanisms 
induced by full-length mHtt is insufficient to counterbalance increased ROS formation 
and emergent apoptotic features in HD striatal cells. 
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3.1.2 Introduction 
Oxidative stress is one of several dysfunctional mechanisms described in HD 
(Browne et al., 1997; 1999; Chen et al., 2007; Goswami et al., 2006; Stoy et al., 2005), 
which may result from impaired mitochondrial function, namely due to interaction of the 
organelle with mHtt (Panov et al., 2002) and/or imbalanced levels of antioxidants. 
Altered oxidative parameters have been observed in both central and peripheral samples 
of HD patients and in some animal models of the disease. In HD post-mortem tissues, 
levels of 8-OHdG, a DNA oxidative damage marker, and MDA, a lipid peroxidation 
marker, were increased in CN and parietal cortex (Browne et al., 1997; Polidori et al., 
1999). In HD patients blood plasma, elevated levels of 8-OHdG were observed (Chen et 
al., 2007; Hersch et al., 2006). Also, increased levels of 8-OHdG (Chen et al., 2007) and 
MDA (Stoy et al., 2005) were previously observed, respectively, in leukocytes and serum 
of HD patients. Concordantly, in R6/2 HD mice (expressing the exon-1 of the human 
HTT gene), 8-OHdG levels were shown to be increased in striatum, urine and plasma 
(Bogdanov et al., 2001).  
The levels of antioxidants also vary depending on the type of tissue and possibly 
the stage of HD pathology. In striatum and cortex of HD post-mortem samples a 
proteomic analysis revealed an induction of antioxidant proteins Prdx’s 1, 2 and 6 and 
GPx1 and -6, and an increase in SOD2 and catalase activities, when compared to control 
individuals (Sorolla et al., 2008). Furthermore, increases in mRNA levels of GPx1, 
catalase and SOD1 were observed in striatal cells expressing full-length mHtt (Lim et al., 
2008); however these studies did not analyze the enzymatic activities of the antioxidant 
systems. Conversely, in erythrocytes from HD patients, GPx and SOD1 activities were 
found to be decreased, compared to unaffected subjects (Chen et al., 2007), suggesting an 
impairment of the antioxidant defenses in HD peripheral samples. 
Concordantly with increased levels of antioxidant proteins in HD human brain, a 
significant increase in the levels of GSH was observed in striatum of 8 to 12 week-old 
R6/2 HD mice (Tkac et al., 2007). Enhanced GSH levels were also detected in isolated 
mitochondria from both cortex and striatum of R6/2 HD mice; however, GCL, an enzyme 
involved in the synthesis of GSH, was reported to be actively decreased in both striatum 
and cortex of R6/2 HD mice, not explaining the increase in GSH levels (Choo et al., 
2005). Moreover, in the same study, G6PD activity, an enzyme that produces NADPH 
essential for GRed activity, was also reported to be decreased in the striatum of R6/2 HD 
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mice (Choo et al., 2005). Together, these observations show some discrepancies in the 
antioxidant redox systems in HD, namely associated with the glutathione redox cycle, 
evidencing the need to clarify the regulation of antioxidant levels in striatal cells 
expressing full-length mHtt. Thus, in this study, we detailed the changes in GSH 
antioxidant system in striatal cells derived from HD knock-in mice. Our results indicate 
that expression of full-length mHtt is accompanied by heightened of GSH-related 
antioxidant levels and activity due to reduced functional activity of Mrp1, although they 
appear to be insufficient, as HD cells exhibit increased ROS generation and cell death 
features.  
3.1.3 Results 
3.1.3.1 ROS production and caspase-3 activation in HD striatal mutant 
cells – influence of GSHee 
In order to investigate ROS production in HD striatal cells derived from knock-in 
mice, we used the fluorescent probe H2DCFDA which has been reported to measure 
ROS, including H2O2, ONOO− and HOCl in viable cells (LeBel et al., 1992; Whiteman et 
al., 2005). A significant increase in ROS formation was observed in mutant cells when 
compared to wild-type cells (Figure 3.1.1A). Treatment with GSHee, a cell permeable 
ester of GSH (0.05, 0.25 and 1 mM) significantly decreased ROS levels in mutant cells to 
similar values of wild-type (control) cells (Figure 3.1.1A). Moreover, an increase in 
caspase-3 activity was observed in mutant cells (Figure 3.1.1B), which might be related to 
the increase in ROS formation, as described previously by Gil and Rego, (2008). GSHee 
treatment also decreased caspase-3 activity in mutant cells (Figure 3.1.1B), which was 
significant for 0.25 mM GSHee. These results suggested that intracellular levels of GSH 
might be insufficient to deal with ROS produced in cells expressing mHtt. Thus, in the 
following experiments we determined the changes in components of the glutathione redox 
cycle in HD striatal cells. 
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Figure 3.1.1 – Effect of GSH ethyl ester on ROS generation and caspase-3 activity in HD knock-
in striatal cells. ROS formation and caspase-3 activity were measured in wild-type and mutant 
cells before and after incubation with 0.05, 0.25 or 1 mM GSH ethyl ester (GSHee) for 24 h. (A) 
DCF fluorescence shows that mutant cells produce significant more peroxides than wild-type cells 
(696.6 ± 54.9 RFU/min/mg protein); GSHee supplementation significantly reduced ROS 
formation in mutant cells, when compared to non-treated conditions. (B) Caspase-3 activity is 
increased in mutant cells and 0.25 mM GSHee protected against caspase-3 activation (caspase-3 
activity in untreated wild-type cells: 404.1 ± 19.2 RFU/min/mg protein). Data are presented as 
mean ± S.E.M. of 3 to 5 independent experiments performed in duplicates, triplicates or 6 
replicates. Statistical analysis was performed by two-way ANOVA followed by Bonferroni post-
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test for analysis of multiple groups: ***P<0.0001 when compared to wild-type cells; 
#
P<0.05 and 
###
P<0.0001 when compared to non-treated conditions. 
3.1.3.2 Glutathione redox cycle is affected upon expression of mutant 
huntingtin 
GSH has been shown to be essential to detoxify cells against H2O2. In order to 
investigate the levels of the glutathione antioxidant defense systems present in striatal 
mutant and wild-type cells, we measured the intracellular levels of GSH and GSSG. 
Surprisingly, a significant increase in the levels of GSH (Figure 3.1.2A,B) and GSSG 
(Figure 3.1.2C,D) were found in total (cellular) and mitochondrial fractions of mutant 
cells, compared to wild-type cells. These data suggested an alteration of the glutathione 
redox cycle enzymes in HD knock-in striatal cells. Thus, we further determined GPx and 
GRed activities. GPx converts GSH and H2O2 into GSSG and H2O, respectively. GRed 
uses GSSG and NADPH to produce GSH and NADP
+
. Concomitantly with the alterations
in GSH and GSSG, we observed a significant increase in total and mitochondrial GPx 
activity in mutant
 
cells, when compared to wild-type cells (Figure 3.1.2E and F). 
Moreover, we observed that total and mitochondrial GRed activities were increased in 
mutant cells, as compared to wild-type cells (Figure 3.1.2G and H).  
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Figure 3.1.2 – Glutathione redox cycle upon expression of full-length mutant huntingtin. Striatal 
cells were cultured during 48 h and then used to determine reduced (GSH) and oxidized (GSSG) 
glutathione levels, and the activities of glutathione peroxidase (GPx) and glutathione reductase 
(GRed). Levels of total (A,C) and mitochondrial (B,D) GSH (A,B) and GSSG (C,D) were 
significantly increased in mutant cells, when compared to wild-type cells (cellular  GSH: 464600 
± 12140 RFU/mg protein; mitochondrial GSH: 53586 ± 3693 RFU/mg protein; cellular GSSG: 
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63805 ± 2350 RFU/mg protein; mitochondrial GSSG: 8965 ± 590 RFU/mg protein). GPx (E,F) 
and GRed (G,H) activities were also examined in total (E,G) and mitochondrial (F,H) fractions. 
Data show significantly increased GPx and GRed activities in mutant cells, when compared to 
wild-type cells (in wild-type cells: cellular GPx activity: 110.2 ± 17.1 mU/mg protein; 
mitochondrial GPx activity: 61.2 ± 18.3 mU/mg protein; cellular GRed activity: 36.1 ± 3.2 
mU/mg protein; mitochondrial GRed activity: 21.4 ± 2.7 mU/mg protein). Results are expressed 
as the mean ± S.E.M. of 3 to 4 independent experiments performed in triplicates. Statistical 
analysis was performed by Student’s t-test: *P<0.05; **P<0.01 and ***P<0.0001 when compared 
to wild-type cells. 
3.1.3.3 NADPH and pentose-phosphate NADPH producing enzymes are 
increased in mutant cells 
In order to explain the increase in activity of GRed in mutant cells we further 
measured the activities of the pentose phosphate pathway enzymes, which are mainly 
responsible for producing the NADPH necessary for GRed activity, namely G6PD and 
6PGD. Our results showed significant increases in G6PD and in 6PGD activities in HD 
mutant cells, compared to wild-type cells (Figure 3.1.3A and B), corroborating our 
previous findings. However, no changes in mRNA levels of G6PD were found in striatal 
cells (Figure 3.1.3C).  
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Figure 3.1.3 – NADPH-producing pentose phosphate pathway enzyme activities in striatal 
mutant cells. HD mutant striatal cells from knock-in mice and wild-type cells were used for 
analysis of glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase 
(6PGD) activities and G6PD mRNA levels. G6PD (A) and 6PGD (B) activities were significantly 
increased in mutant cells, when compared to wild-type cells, whereas G6PD mRNA levels (C) 
were unchanged in mutant cells (G6PD activity in wild-type cells:89.4 mU ± 11.2 mU/mg 
protein; 6PGD activity in wild-type cells: 52.3 ± 10.1 mU/mg protein). The results are expressed 
as the mean ± S.E.M. from 3 to 4 independent experiments performed in triplicates. Statistical 
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analysis was performed by the Student’s t-test: *P<0.05 and ***P<0.0001 when compared to 
wild-type cells. 
3.1.3.4 Decreased GSH producing enzymes and increased activities of 
gamma-glutamyl transpeptidase and glutathione S-transferase in 
mutant cells 
Because increased glutathione levels could result from increased GSH synthesis, 
we also studied GCL and GS activities and analyzed the protein expression levels of 
GCLc. Unexpectedly, we observed a significant decrease in GCL and GS activities in 
mutant cells, compared to wild-type cells (Figure 3.1.4A and B), suggesting decreased 
GSH synthesis. We also observed a slight, although significant, decrease in the protein 
levels of GCLc in mutant cells when compared to wild-type cells (Figure 3.1.4C), 
contributing to the observed decrease in GCL activity (Figure 3.1.4A). Since these results 
did not explain the higher GSH levels observed in Figure 3.1.2A and B, we measured the 
activities of -GT, an enzyme involved in GSH degradation, and GST, which also 
participates in glutathione metabolism. Our results demonstrate an increase in the activity 
of -GT in mutant cells when compared to wild-type cells (Figure 3.1.5A). Moreover, 
GST activity was also increased in total and mitochondrial (although not significant) 
fractions obtained from mutant cells, compared to wild-type cells (Figure 3.1.5B and C), 
thus not explaining the intracellular accumulation of GSH. 
Wild-type Mutant
0
20
40
60
80
100
120
**
G
C
L
 a
c
ti
v
it
y
(%
 o
f 
w
il
d
-t
y
p
e
 c
e
ll
s
)
A
108 
Figure 3.1.4 – Activity and protein expression levels of enzymes involved in GSH synthesis in 
mutant cells. GSH synthesis was determined through the analysis of (A) glutamate-cysteine ligase 
(GCL) and (B) glutathione synthetase (GS) activities, and (C) catalytic subunit of GCL (GCLc) 
protein levels, which were decreased in mutant versus wild-type cells (GCL activity: 3981 ± 
138.4 RFU/mg protein; GS activity: 5764 ± 223.7 RFU/mg protein). The results are expressed as 
the mean ± S.E.M. from 3 to 6 independent experiments performed in duplicates. Statistical 
analysis was performed by Student’s t-test: *P<0.05 or **P<0.01 when compared to wild-type 
cells. 
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Figure 3.1.5 – Activities of gamma-glutamyl transpeptidase and glutathione S-transferase in HD 
knock-in striatal cells. Gamma-glutamyl transpeptidase (-GT) (A) and glutathione-S-transferase 
(GST) (B,C) were measured in total lysates (A,B) and mitochondrial fractions (C) obtained from 
HD mutant and wild-type striatal cells. -GT and GST activities were increased in mutant cells 
when compared to wild-type cells, although statistically significant results compared to wild-type 
cells were observed in total fractions only (-GT activity in wild-type cells: 372 ± 29.5 
RFU/min/mg protein; cellular and mitochondrial GST activity in wild-type cells: 78.2 ± 5.6 
µmol/min/mg protein and 42.4 ± 2.3 µmol/min/mg protein, respectively). The results are 
expressed as the mean ± S.E.M. from 3 independent experiments performed in duplicates. 
Statistical analysis was performed by Student’s t-test: ***P<0.0001 when compared to wild-type 
cells. 
3.1.3.5 Decreased extracellular glutathione levels and Mrp1 mRNA 
levels upon expression of mutant huntingtin 
In order to explain the higher levels of GSH in mutant cells, we also evaluated the 
levels of glutathione by HPLC, which gives information about total glutathione (GSH 
plus GSSG) levels. Concordantly with data shown in Figure 3.1.2, we also observed a 
significant increase in the intracellular total glutathione levels in mutant cells (Figure 
3.6A). Because the activities of GSH metabolizing and converting enzymes, -GT and 
GST, were increased (Figure 3.1.5), the rise in GSH in mutant cells was still unexplained. 
Thus, we analyzed whether enhanced intracellular GSH pool resulted from cellular 
retention by evaluating the extracellular levels of total glutathione in the culture medium 
of striatal cells maintained for 72 h in culture. Data in Figure 3.1.6B show a slight, but 
significant, decrease in the accumulation of extracellular total glutathione (about 8% 
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decrement of GSH plus GSSG levels present in the culture medium, containing FBS) in 
the mutant striatal cells, suggesting a deficit in its release.  
In order to explain the decrease in glutathione release we determined the mRNA 
expression of Mrp1, a transport protein that mediates cellular export of glutathione and 
glutathione conjugates (e.g. Müller et al., 1994). Importantly, Mrp1 expression was 
largely and significantly decreased in mutant cells (Figure 3.1.6C), suggesting that 
expression of full-lenght mHtt induces alterations in the glutathione dynamics due to 
altered expression of Mrp1. This result was supported by a significant increase in 
intracellular GSH levels in wild-type cells after Mrp1 inhibition with MK-571 (at 50 µM, 
for 24 h), whereas no changes were detected in mutant cells (Figure 3.1.6D). 
Additionally, we determined the activity of Mrp1 based on the fluorescence of calcein. 
Mrp1 is involved in the cellular export of calcein and therefore an increase in calcein 
fluorescence may correlate to decreased Mrp1 activity (Dogan et al., 2004). In accordance 
with decreased expression of the protein, we determined a significant increase in 
intracellular calcein fluorescence in mutant cells, when compared to wild-type cells, 
indicating a decrease in Mrp1 activity (Figure 3.1.6E). 
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Figure 3.1.6 – Intracellular and extracellular glutathione and Mrp1 mRNA levels upon expression 
of mHtt. Striatal cells were incubated and the culture medium was collected after 72 h in culture 
for analysis of extracellular glutathione. Cells were lysed and extra- and intracellular total 
glutathione (GSH+GSSG) levels were determined by HPLC. (A) Intracellular glutathione levels 
were increased, whereas (B) extracellular glutathione levels were significantly decreased in 
mutant cells (intracellular glutathione levels in wild-type cells: 24.82 ± 4.854 nmol/mg protein; 
extracellular glutathione levels in wild-type cells: 26.06 ± 4.955 nmol/mg protein). In (C) mRNA 
levels of Mrp1 were also significantly reduced in mutant cells, when compared to wild-type cells. 
(D) Intracellular GSH levels (in wild-type cells: 482354 ± 9859 RFU/mg protein) measured 
before and after incubation with 50 µM MK-571; exposure to MK-571 increased GSH levels in 
wild-type cells only. (E) Mrp1 activity based on cellular export of fluorescent calcein (Mrp1 
activity: 76790 ± 2548 RFU/mg protein in wild-type cells). Results are expressed as the mean ± 
S.E.M. from 3 to 4 independent experiments performed in duplicates. Statistical analysis was 
performed by Student’s t-test: *P<0.05 or **P<0.01 when compared to wild-type cells. For 
analysis of multiple groups (D) statistical analysis was performed by two-way ANOVA followed 
by Bonferroni post-test: **P<0.01 when compared to wild-type cells; 
###
P<0.0001 when 
compared to non-treated conditions. 
3.1.4 Discussion 
In this work we found evidences for oxidative stress in cells expressing full-lenght 
mHtt. Increased ROS occurs concomitantly with enhanced intracellular glutathione levels 
and activity of the glutathione redox cycle, despite the downward effects of mHtt on the 
activity and expression of enzymes involved in GSH synthesis. Importantly, decreased 
expression of Mrp1 favours the intracellular accumulation of glutathione. 
Previous studies reported significantly higher ROS formation in the striatum of 
R6/1 HD mice expressing the exon-1 of mHtt compared to control mice (Perez-Severiano 
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et al., 2004). In HD knock-in striatal cells, mitochondrial dysfunction (Milakovic and 
Johnson, 2005; Oliveira et al., 2006; Quintanillaet al., 2008) may related to increased 
formation of O2
−
 and other cellular ROS, as shown in this study. Moreover, in Wistar
rats subjected to the mitochondrial complex II inhibitor 3-NP, known to mimic some 
characteristics of HD, higher peroxide formation was detected when compared to 
untreated rats (Tunez et al., 2006). Although HD knock-in striatal cells evidence 
increased ROS generation, they do not exhibit massive cell death and large or visible 
mHtt aggregates (Trettel et al., 2000), thus mimicking initial HD cytopathological 
features. Nevertheless, these cells exhibit features of apoptosis, as demonstrated by 
increased caspase-3 activation (Lim et al., 2008; Rosenstock et al., 2011).  
We further show that striatal cells expressing full-lenght mHtt present higher 
levels of GSH compared to wild-type cells, although this is not sufficient for preventing 
the rise in ROS. Indeed, treatment with GSHee was effective in preventing ROS 
generation, revealing that mutant cells are under a reversible state of oxidation. Also, 
caspase-3 activation was ameliorated by treatment of mutant striatal cells with GSHee, 
further suggesting that increased intracellular accumulation of GSH is insufficient to 
rescue HD cells from features of apoptotic cell death. Previously, treatment of HD striatal 
cells with GSHee significantly prevented 3-NP-mediated decrease in ΔΨm (Mao et al., 
2006). 
Although HD knock-in striatal cells, expressing full-lenght mHtt, showed 
increased levels of glutathione, a decrease in GSH levels was previously described in the 
cortex of HD patients (Beal et al., 1992). In addition, decreased GSH levels and higher 
lipid peroxidation were observed in the plasma of HD symptomatic and asymptomatic 
individuals, compared to age and sex-matched controls, suggesting that oxidative stress 
may occur before the onset of HD symptoms (Klepac et al., 2007). Conversely, the levels 
of mitochondrial GSH were increased in the striatum and cortex of R6/2 HD mice 
compared to wild-type animals, suggesting a compensatory mechanism to counteract the 
increase in mitochondrial ROS generation (Choo et al., 2005), which may also help to 
explain our data. R6/2 mice are one of the most studied models of HD. However, R6/2 
mice present a rapid progression of the disease due to only express the exon-1 of mHtt 
and present some phenotypes not typically associated with HD (Gil and Rego, 2008). 
Therefore, studies with models that express full-length mHtt are important to understand 
the mechanisms associated with the occurrence of oxidative stress in the disease. 
115 
Despite increased intracellular glutathione, here we demonstrate, for the first time, 
a decrease in GCL and GS activities in striatal cell lines expressing full-lenght mHtt, 
largely suggesting a decrease in GSH synthesis. Additionally, GCLc protein (Figure 
3.1.4C) and mRNA (author’s unpublished data) expression levels are significantly 
decreased in mutant cells. In agreement, a decrease in GCL activity was previously 
shown in the cortex and striatum of R6/2 HD, compared to wild-type mice (Choo et al., 
2005). In the present work we show that this defect is also observed following expression 
of full-lenght mHtt.  
Along with increased cellular GSH in HD striatal cells, we observed an increase in 
GSSG levels. In contrast, a significant decrease in GSSG (by about 50%) was detected in 
the CN of HD patients (Sian et al., 1994). We also observed an increase in GPx activity. 
In accordance with these data, GPx1 transcription levels were shown to be increased in 
three clones of striatal cells expressing mHtt, compared to wild-type cells (Lim et al., 
2008). Nevertheless, decreased GPx activity was found in erythrocytes of HD patients 
compared to control individuals (Chen et al., 2007), whereas in striatal tissue of R6/1 HD 
mice GPx activity was not different (Perez-Severiano et al., 2004), and GPx transcription 
was unaltered in R6/2 HD mice (Fox et al., 2004), compared with wild-type mice. 
Concordantly with our study, an increase in GRed activity was found in erythrocytes from 
HD patients, compared to control individuals (Zanella et al., 1980) and increased GRed 
transcription was found in the basal ganglia of R6/2 HD mice (Fox et al., 2004), 
suggesting a repository mechanism of GSH levels. We also observed increased activity of 
NADPH producing-enzymes of the pentose-phosphate pathway (G6PD and 6PGD), 
which is relevant since NADPH is an important cofactor of GRed. Changes in G6PD 
activity in HD models are controversial. G6PD activity was found to be increased in 
erythrocytes from HD patients (Zanella et al., 1980), but decreased in the striatum from 
R6/2 mice (Choo et al., 2005). Moreover, hexokinase, a prime enzyme in glycolysis and 
in the pentose-phosphate pathway upstream G6PD, was found to be actively increased in 
the brain of 3-NP-treated and in the HD transgenic N171-82Q mouse models (Olah et al., 
2008). 
Despite decreased GSH synthesis in HD striatal cells, we show that glutathione 
was accumulated intracellularly; this was not explained by alterations in GST or -GT 
(both involved in glutathione metabolism), since their activities were increased in mutant 
cells. Conversely, increased intracellular glutathione could be due to decreased release of 
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the endogenous antioxidant to the extracellular milieu by Mrp1, which mediates the 
export of GSH and GSH conjugates in an ATP-dependent manner (Müller et al., 1994; 
Rappa et al., 1997), thus also requiring a functional metabolic status of the cells. Mrp1 is 
a 190 kDa protein involved in cellular xenobiotics metabolite detoxification, namely 
carcinogens, pesticides, herbicides or metalloids. Mrp1 is highly overexpressed in many 
drug-resistant tumour cell lines and expressed at moderate levels in most normal tissues. 
In the brain it is part of the drug permeability barrier between blood and the cerebrospinal 
fluid (Cole and Deeley, 2006). No data describing the Mrp1 involvement in HD has been 
reported until now. Here, we show that mRNA levels of Mrp1 are decreased in mutant 
HD striatal cells, which may be related to the negative effects of mHtt on transcription 
regulation (Cha, 2000). Indeed, mHtt interacts with and sequesters CBP, a co-activator of 
transcription that forms a complex with CREB to initiate gene transcription (Mayr and 
Montminy, 2001), within protein aggregates (Steffan et al., 2000) leading to decreased 
transcription of PGC-1α, a transcriptional regulator of mitochondrial biogenesis and 
antioxidant enzymes (Cui et al., 2006). Therefore, mHtt may be interacting and/or altering 
transcription and thus modifying normal Mrp1 expression. 
In astrocytes, Mrp1 was previously reported to mediate 60% of the GSH export 
and to be exclusively responsible for GSSG export (Minich et al., 2006). Moreover, due 
to its role in the transport of glutathione S-conjugates and GSSG into the extracellular 
space, proteins of the Mrp family may play an important function in defense mechanisms 
against oxidative stress (Keppler, 1999). Concordantly with the decreased expression of 
Mrp1, we observed that Mrp1 activity is affected in mutant cells. Furthermore, we 
observed a significant increase in intracellular GSH levels in wild-type cells, but not in 
mutant striatal cells after inhibition of Mrp1 with MK-571, largely evidencing the 
dysfunction in this transport protein in HD cells. No changes of intracellular GSH levels 
were observed in mutant cells, reinforcing the hypothesis of decreased Mrp1 function 
upon expression of full-lenght mHtt. In this perspective, fragments of mHtt may be 
involved in altering the activity of Mrp1, more studies are required to test this possibility. 
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3.2  Oxidizing effects of exogenous stressors in Huntington’s 
disease knock-in striatal cells – protective effect of 
cystamine and creatine107 
3.2.1 Summary 
HD is a polyQ-expansion disease associated to degeneration of striatal and cortical 
neurons. Previously, we showed that oxidative stress occurs in HD knock-in striatal cells, 
but little is known regarding cell antioxidant response against exogenous stimuli. 
Therefore, in the present study we analysed cellular antioxidant profile following H2O2 
and STS exposure, and tested the protective effect of cystamine and creatine in striatal 
cells expressing mHtt with 111 Q (STHdh
Q111/Q111
; mutant cells) versus wild-type cells
(STHdh
Q7/Q7
). Mutant cells displayed increased mitochondrial ROS and decreased NOX
and XO activities, reflecting lower O2
−
 cytosolic generation, along with increased SODs
and components of glutathione redox cycle. Exposure to H2O2 and STS enhanced ROS in 
mutant cells and largely increased XO activity; STS further boosted the generation of 
mitochondrial ROS and caspase-3 activity. Both stimuli slightly increased SOD1 activity, 
without affecting SOD2 activity, and decreased GRed with a consequent rise in GSSG in 
mutant cells, whereas H2O2 only increased GPx activity. Additionally, creatine and 
cystamine increased mutant cells viability and prevented ROS formation in HD cells 
subjected to H2O2 and STS. These results indicate that elevation of the antioxidant 
systems accompanies mitochondrial-driven ROS generation in mutant striatal cells and 
that exposure to noxious stimuli induces a higher susceptibility to oxidative stress by 
increasing XO activity and lowering the antioxidant response. Furthermore, creatine and 
cystamine are efficient in preventing H2O2- and STS-evoked ROS formation in HD 
striatal cells. 
107 Based on the following publication: Ribeiro, M.; Silva, A. C.; Rodrigues, J.; Naia, L.; Rego, A. C. Oxidizing effects 
of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine. 
Toxicol Sci 136:487-499; 2013. 
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3.2.2 Introduction 
The selective death of striatal and cortical neurons is not completely understood. 
Several cytotoxic mechanisms have been described in HD, including oxidative stress 
(Browne et al., 1997, 1999; Chen et al., 2007; Goswami et al., 2006; Stoy et al., 2005). 
Oxidation markers, such as 8-OHdG and MDA were increased in leukocytes and plasma 
of HD patients, respectively (Chen et al., 2007). Impairment in antioxidant defenses may 
also underlie enhanced oxidative stress in HD. In erythrocytes from HD patients, GPx and 
SOD1 activities were decreased (Chen et al., 2007). Conversely, increased levels of 
Prdx’s 1, 2 and 6 and GPx 1 and 6, and increased activities of SOD2 and catalase were 
observed in HD post-mortem striatal and cortical brain samples (Sorolla et al., 2008). 
Increased levels of GSH were also detected in the striatum of 8 week-old (early 
symptomatic) R6/2 HD mice (Tkac et al., 2007) and in STHdh
Q111
 striatal cells derived
from HD knock-in mice (Ribeiro et al., 2012), which may represent early phases of HD 
due to the absence of visible protein aggregates and overt cell death (Trettel et al., 2000). 
Therefore, treatment with compounds that can inhibit or prevent the oxidation of proteins, 
lipids and DNA in HD might be a potential target for alleviating disease progression.  
PolyQ repeat domains and mHtt are substrates for TG2 (Kahlem et al., 1996; 
1998). Cystamine is a competitive inhibitor of TG2, which may inhibit mHtt cross-links 
induced by TG2, reducing mHtt aggregates. Cystamine administration in R6/2 HD mice 
increased motor performance, body and brain weight, and survival (Dedeoglu et al., 2002; 
Karpuj et al., 2002), and decreased brain atrophy and the number of protein aggregates in 
striatal and cortical sections (Dedeoglu et al., 2002). Cystamine also increased GSH and 
decreased the number of aggregates in cell lines expressing mHtt (Fox et al., 2004). 
Cystamine-induced neuroprotection R6/2 HD mice was maintained in TG2(-/-) R6/2 HD 
mice, suggesting that TG2 inhibition is not the sole target of cystamine in HD (Bailey and 
Johnson, 2006). Indeed, cystamine was described to inhibit caspase-3 activity (Lesort et 
al., 2003). Moreover, cystamine protected against H2O2-increased caspase-3 activation 
and increased total glutathione levels in human neuroblastoma SH-SY5Y cells (Lesort et 
al., 2003). 
Energy metabolism is also impaired in HD. Increased lactate levels were 
previously described in occipital cortex and in striatum of HD patients (Jenkins et al., 
1998). Furthermore, impaired mitochondrial respiration and ATP production were 
reported in STHdh
Q111
 HD striatal cells (Milakovic and Johnson, 2005) and ATP
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depletion was also demonstrated in brain tissues of R6/2 mice (Mochel et al., 2012). 
Creatine is a substrate of cytosolic and mitochondrial CK’s (Woznicki and Walker 1979), 
which catalyze the reversible phosphorylation of creatine, using ATP as a phosphate 
donor. Creatine can thereby modulate ATP metabolism by increasing the phosphocreatine 
content (Woznicki and Walker 1979). Apart from counterbalancing energy metabolism, 
creatine has been shown to have direct antioxidant proprieties (Lawler et al., 2002). In 
early HD patients, creatine decreased 8-OHdG levels, increased serum and brain creatine 
levels and was shown to be safe and well tolerated (Hersch et al., 2006). Creatine is 
presently under phase III clinical trial for HD (clinicaltrials.gov). 
Although some proteins involved in antioxidant defense system have been 
described to be dysregulated in HD models, namely in striatal cells derived from knock-in 
mice (e.g. Ribeiro et al., 2012), the efficacy of cell response against exogenous toxic 
injuries in cells expressing full-length mHtt is not well known. Therefore, in this study we 
used HD knock-in-derived striatal cell lines, which express endogenous and comparable 
levels of both wild-type and mHtt, and represent early phases of HD (Trettel et al., 2000), 
to test the cellular response against exogenous stressors, H2O2 and STS, and to evaluate 
the potential antioxidant effect of cystamine and creatine. We demonstrate that cells 
expressing mHtt are more susceptible to increased ROS formation after exposure to 
exogenous stressors by increasing XO activity and lowering the antioxidant response, 
namely SOD2 and GRed, the latter promoting the levels of GSSG, and that both creatine 
and cystamine are able to decrease ROS levels, protecting HD striatal cells. 
3.2.3 Results 
3.2.3.1 Hydrogen peroxide and staurosporine decrease cell viability and 
increase ROS formation in mutant cells 
Striatal cells viability was measured by Alamar Blue (Figure 3.2.1A) and by LDH 
release (Figure 3.2.1B). A slight decrease in viability was observed by both methods in 
mutant cells when compared to wild-type cells (Figure 3.2.1A,B). Cell death was 
analysed by Hoechst 33342 (Figure 3.2.1C) and propidium iodide (Figure 3.2.1C) 
staining to determine fragmented/condensed nucleus and necrotic cell death, respectively. 
Mutant cells exhibited significant apoptotic cell death compared to wild-type cells (Figure 
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3.2.1C), however no significant changes in necrotic cell death were observed between 
both striatal cell lines (Figure 3.2.1D). In order to analyze the influence of exogenous 
stressors on striatal cell viability, we incubated striatal cells with different concentrations 
of H2O2 or STS during 15 h followed by LDH release measurement, and compared with 
non-treated cells (control) (Figure 3.2.1E-H). H2O2 induced cell death at concentrations of 
50 µM and 100 µM in both striatal cells (Figure 3.2.1E,F). STS induced cell death in 
wild-type cells only at concentrations of 25 and 50 nM (Figure 3.2.1G,H). For each stress 
inducer, we chose a concentration that did not cause necrotic cell death, namely 25 µM 
H2O2 and 10 nM STS.  
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Figure 3.2.1 – mHtt-induced decreased cellular viability - influence of H2O2 and STS. Cell 
viability was assessed by Alamar Blue reduction (A) and LDH release (B,E-H). Alamar blue 
reduction was decreased in mutant compared to wild-type cells (A) which indicates loss of 
metabolic function induced by mHtt. LDH release, which indicates loss of cell membrane 
integrity or necrosis, was increased in mutant (% of total LDH released= 29.28 ± 0.95) versus 
wild-type cells (% of total LDH released 25.21 ± 1.14) (B). Cell death was determined by 
Hoechst 33342 (C) and propidium iodide (D) staining. Hoechst 33342 staining was increased in 
mutant compared to wild-type cells (C) which indicates increased apoptosis induced mHtt 
expression. Propidium iodide staining was unchanged between between both striatal cells (D) 
which indicates that necrotic cell death is unchanged in mutant cells. A cellular dose-response 
effect for H2O2 (1-100 µM) (E,F) and STS (0.1-50 nM) (G,H) was performed during 15h and 
analysed by LDH release. Wild-type (E) and mutant (F) cells presented loss of cell viability in the 
presence of 50 and 100 µM H2O2. 25 and 50 nM STS-induced loss of viability in wild-type (G) 
but not in mutant (H) cells. Data are the mean ± S.E.M. of 3 independent experiments performed 
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in duplicates. Statistical analysis: 
t
P<0.05 and 
ttt
P<0.0001 by Student’s t-test when comparing 
mutant versus wild-type cells; 
ϕ
P<0.05, 
ϕϕ
P<0.01 and 
ϕϕϕ
P<0.0001 by one-way ANOVA when 
comparing treated versus non-treated (control) cells; 
+
P<0.05 and 
+++
P<0.0001 by one-way 
ANOVA when comparing 50 versus 100 µM H2O2. 
We measured intracellular ROS by using the fluorescent probe H2DCFDA, which 
can be oxidized by ROS, including ONOO−, OH or HOCl, among other oxidants, and
redox-active metals such as iron (e.g. Kalyanaraman et al., 2012). Under basal conditions, 
overall ROS formation was significantly higher in mutant cells when compared to wild-
type cells (Figure 3.2.2A-insert). After exposure to H2O2 or STS, we observed a 
potentiation effect on ROS formation in mutant cells (Figure 3.2.2A). We also measured 
the generation of O2
•–
 using the fluorescent probe DHE (Figure 3.2.2B). The red
fluorescence formed from the two-electron oxidation product, E
+
, is usually used to
measure intracellular O2
•–
 formation. However, DHE is oxidized by O2
•– 
to form
 
2-
hydroxyethidium (2-OH-E
+
)
 
and also with ONOO− and OH to form E+ and dimers,
which difficult a specific analysis (e.g. Kalyanaraman et al., 2012). A significant increase 
in O2
•–
 levels were observed in mutant cells, when compared to wild-type cells (Figure
3.2.2B-insert). Incubation with H2O2 or STS provoked a similar but more pronounced 
increase in O2
•–
 formation in mutant cells (Figure 3.2.2B). We evaluated if the O2
•– 
production was mitochondrial-dependent using the selective mitochondrial O2
•–
fluorescent probe MitoSOX Red, a triphenylphosphonium (TPP) cation conjugated with 
hydroethidine, which appears to readily react with O2
•–
 (Robinson et al, 2008), although it
may also non-specifically oxidize (Kalyanaraman et al., 2012). We observed a 2-fold rise 
in mitochondrial O2
•–
 in mutant cells, when compared to wild-type cells (Figure 3.2.2C-
insert), revealing a high susceptibility of mutant cells to produce mitochondrial ROS. 
When treated with H2O2 or STS, mitochondrial O2
•–
 levels increased in both striatal cells
following STS exposure only. Caspase-3 activation was previously observed in HD 
striatal cells (Lim et al., 2008; Ribeiro et al., 2012; Rosenstock et al., 2011) and can be 
activated via the intrinsic mitochondrial apoptotic pathway, which was described to be 
activated in HD patients and in R6/2 HD mice (Kiechle et al., 2002). Therefore, we tested 
if mutant striatal cells were more vulnerable to apoptosis after incubation with the stress 
inducers H2O2 and STS (Figure 3.2.2D). We observed a significant increase in caspase-3-
like activity in mutant cells under basal conditions, when compared to wild-type cells 
(Figure 3.2.2D-insert). A slight increase in caspase-3-like activity was observed after 
H2O2 (25 µM) treatment in mutant cells when compared with untreated/control cells 
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(P<0.01 by Student’s t-test). On the other hand, STS induced a significant rise in caspase-
3-like activity in both striatal cells, particularly in mutant cells when compared to wild-
type cells (Figure 3.2.2D), coincident with a higher susceptibility of HD striatal cells to 
apoptotic cell death (e.g. Rosenstock et al., 2011). These data suggest that the major 
source of ROS induced by mHtt might be driven by mitochondria; indeed, STS seems to 
stimulate both mitochondrial and cytosolic ROS generation, whereas H2O2 appears to 
stimulate cytosolic ROS formation in HD striatal cells. 
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Figure 3.2.2 – Increased ROS formation and caspase-3 activity in striatal cells expressing mHtt – 
effects of H2O2 and STS. ROS formation is increased in HD knock-in striatal cells compared to 
wild-type cells under basal conditions (insert graphs show basal conditions only) or after exposure 
to H2O2 or STS during 15h, as measured by (A) DCF fluorescence using H2DCFDA and (B) 
Ethidium (E
+
)-DNA fluorescence using DHE, showing significant O2
•–
 generation. (C)
MitoSOX
TM
 Red fluorescence, which evaluates the generation of mitochondrial O2
•–
,  increases
under basal conditions in mutant cells and after exposure to 10 nM STS in both striatal cells. (D) 
Caspase-3-like activity is increased in mutant cells compared to wild-type cells and 10 nM STS 
induced caspase-3 activation in both striatal cells with a greater increase in mutant cells compared 
to wild-type cells. Data are the mean ± S.E.M. of 3-10 independent experiments. Statistical 
analysis: 
ttt
P<0.0001 by Student’s t-test when comparing mutant versus wild-type cells; *P<0.05 
and 
***
P<0.0001 by two-way ANOVA when comparing mutant versus wild-type cells; 
#
P<0.05, 
##
P<0.01 and 
###
P<0.0001 by two-way ANOVA when comparing treated versus non-treated 
(control) cells. 
3.2.3.2 Hydrogen peroxide and staurosporine modify NADPH oxidase 
and xanthine oxidase activities in mutant cells 
To verify if the higher ROS formation in mutant cells was dependent on cytosolic 
oxidase activities, we measured NOX and XO activities, two major sources of O2
•– 
in the
cytosol. A significant decrease in NOX and XO activities was observed in untreated 
mutant cells, when compared to wild-type cells (Figure 3.2.3A and B-inserts). 
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Considering the decrease in XO activity in mutant cells, we also measured the levels of 
hypoxanthine, a XO substrate. However, no significant changes in hypoxanthine levels 
were observed (Figure 3.2.3C-insert), suggesting that altered enzyme activity may not be 
caused by insufficient substrate levels. These results suggested lower cytosolic ROS 
formation in HD mutant cells, as a result of decreased NOX and XO activities, 
emphasizing the contribution of mitochondria under control conditions.  
However, after exposure to H2O2 or STS, NOX activity decreased (Figure 3.2.3A), 
while XO activity largely increased (Figure 3.2.3B) in mutant cells, suggesting that XO 
contributes to ROS formation induced by the stress inducers. Interestingly, hypoxanthine 
levels increased significantly in wild-type cells after H2O2 and STS stimulation, but 
decreased following STS exposure in mutant cells, when compared to untreated 
conditions (Figure 3.2.3C), implicating that the loss of substrate accompanies enhanced 
XO activity. 
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Figure 3.2.3 – Cytosolic oxidase activities in HD mutant striatal cells under basal conditions and 
after exposure to H2O2 and STS. NADPH oxidase (NOX) (A) and xanthine oxidase (XO) (B) 
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activities were measured in wild-type and mutant striatal cells, under basal conditions (basal 
conditions shown in insert graphs) and after exposure to H2O2 or STS during 15h, to evaluate their 
contribution in generating cytosolic O2
•–
. NOX and XO activities were significantly decreased in
mutant when compared to wild-type cells under basal conditions. After exposure to 25 µM H2O2 
or 10 nM STS NOX activity decreased, whereas XO activity increased in mutant cells. (C) 
Hypoxanthine levels are unaltered in mutant cells under basal conditions. However hypoxanthine 
levels increased in wild-type cells after incubation with 25 µM H2O2 or 10 nM STS (15h), and 
decreased in mutant cells after 10 nM STS exposure only. Results are the mean ± S.E.M. of 4 
independent experiments. Statistical: 
ttt
P<0.0001 by Student’s t-test when comparing mutant 
versus wild-type cells; 
***
P<0.0001 by two-way ANOVA when comparing mutant versus wild-
type cells; 
#
P<0.05 and 
###
P<0.0001 by two-way ANOVA when comparing treated versus non-
treated cells. 
3.2.3.3 Differential response of antioxidant systems between mutant and 
wild-type cells against exogenous stress stimuli 
In order to determine if increased ROS levels, and in particular O2
•–
, induced by
H2O2 or STS was dependent on antioxidant modifications in mutant cells, we determined 
SOD1, SOD2 and total intracellular SOD activities. A significant increase in SOD1, 
SOD2 and total intracellular SOD activities was observed in untreated mutant cells, 
compared to wild-type cells (Figure 3.2.4A ,B and C-inserts), suggesting a compensatory 
mechanism against higher levels of O2
•–
. Incubation with H2O2 or STS induced a large
decrease in SOD1 activity (Figure 3.2.4A) and an increase in SOD2 (Figure 3.2.4B) and 
total intracellular SOD (Figure 3.2.4C) activities in wild-type cells. Conversely, STS 
exposure only moderately enhanced SOD1 activity (Figure 3.2.4A), without significantly 
affecting SOD2 or total SOD activities (Figure 3.2.4B) in mutant cells. These results 
indicate that HD mutant cells are less able to stimulate SOD activity following stress 
stimuli. 
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Figure 3.2.4 – Altered SOD 1 and 2 activities in basal mutant cells and after exposure to H2O2 
and STS. Under basal conditions (shown in insert graphs), SOD1, SOD2 and total intracellular 
SOD activities increased significantly in HD knock-in striatal cells (A,B,C). After exposure to 25 
µM H2O2 or 10 nM STS during 15h, (A) SOD1 activity decreased and (B) SOD2 and total 
intracellular SOD (C) increased in wild-type cells. In mutant cells, only STS increased SOD1 
activity (A) with no effects in SOD2 (B) and total intracellular SOD (C) activities. Data are the 
mean ± S.E.M. of 4 independent experiments. Statistical analysis: 
t
P<0.05; 
tt
P<0.01 and 
ttt
P<0.0001 by Student’s t-test when comparing mutant versus wild-type cells; *P<0.05 and 
***
P<0.0001 by two-way ANOVA when comparing mutant versus wild-type cells. 
#
P<0.05, 
##
P<0.01 and 
###
P<0.0001 by two-way ANOVA when comparing treated versus non-treated cells. 
We have previously shown that glutathione redox cycle is dysregulated in HD 
striatal cells (Ribeiro et al., 2012). Therefore, to verify the capacity of response against 
exogenous stress in mutant cells, we next analysed the levels of GSH and GSSG and the 
activities of GPx and GRed after exposure to H2O2 or STS. Under basal conditions, GSH 
(Figure 3.2.5A-insert) and GSSG (Figure 3.2.5B-insert) levels and GPx (Figure 3.2.5C-
insert) and GRed (Figure 3.2.5D-insert) activities were increased in mutant cells when 
compared to wild-type cells, as shown by us (Ribeiro et al., 2012). After exposure to STS, 
mutant cells displayed an increase in GSH levels with no changes observed in wild-type 
cells (Figure 3.2.5A). Exposure to H2O2 slightly affected wild-type cells only, with a 
decrease in GSH levels (Figure 3.2.5A). GSH oxidation augmented significantly in the 
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presence of H2O2 and STS in mutant cells (Figure 3.2.5B), confirming the higher 
susceptibility of mutant cells to undergo oxidative stress following exposure to a noxious 
stimulus. In the order to evaluate the changes in GSH oxidation after H2O2 and STS 
stimuli in mutant cells, we also measured the activities of GPx and GRed. We observed 
an increase in GPx activity in wild-type cells after STS or H2O2 treatment and only with 
H2O2 in mutant cells (Figure 3.2.5C). GRed activity greatly decreased in mutant cells 
after H2O2 or STS treatment, and a significant rise was detected in STS-treated wild-type 
cells (Figure 3.2.5D). These results indicate that the increase in ROS formation evoked by 
H2O2 and STS in mutant cells is linked to a striking increase in GSH oxidation possibly 
due to the large reduction in GRed activity, suggesting that the glutathione defense 
system is largely compromised in mutant cells exposed to H2O2 or STS.  
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Figure 3.2.5 – Glutathione redox cycle is affected by mutant huntingtin expression and after 
stress stimuli. Striatal cells were cultured in the absence (basal conditions shown in insert graphs), 
or in the presence of 25 µM H2O2 or 10 nM STS during 15h and then used to determine reduced 
(GSH) and oxidized (GSSG) glutathione levels, and the activities of glutathione peroxidase (GPx) 
and glutathione reductase (GRed). (A) GSH levels are increased in mutant cells under basal 
conditions. STS exposure increased GSH levels in mutant cells. (B) GSSG levels are increased in 
basal mutant cells. After exposure to H2O2 or STS, GSSG levels largely increased in mutant cells. 
(C) GPx activity is increased in mutant cells under basal conditions. Incubation with H2O2 
increased GPx activity in both striatal cells, whereas STS exposure only increased GPx activity in 
wild-type cells. (D) GRed activity is increased in mutant cells under basal conditions. After H2O2 
and STS exposure GRed activity greatly decreased in mutant cells. Data are the mean ± S.E.M. of 
4 independent experiments. Statistical analysis: 
tt
P<0.01 and 
ttt
P<0.0001 by Student’s t-test when 
comparing mutant versus wild-type cells; 
**
P<0.01 and 
***
P<0.0001 by two-way ANOVA when 
comparing mutant versus wild-type cells; 
#
P<0.05, 
##
P<0.01 and 
###
P<0.0001 by two-way 
ANOVA when comparing treated versus non-treated cells. 
3.2.3.4 Creatine and cystamine protect against increased ROS levels 
induced by STS or H2O2 in mutant cells 
Creatine has been shown to have direct antioxidant proprieties (Lawler et al., 
2002) and decreased 8-OHdG levels in serum of HD patients (Hersch et al., 2006), while 
cystamine increased GSH and L-cysteine, but not GSSG in cells expressing mHtt (Fox et 
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al., 2004). Therefore, we tested whether both compounds affect striatal cells viability and 
caspase-3 activation and could prevent against ROS formation in HD striatal cells under 
basal conditions and after exposure to STS or H2O2. We observed that creatine (0.1 mM 
and 1 mM) (Figure 3.2.6A,B) induced a slight and significant increase in mutant cells 
viability. Also, cystamine (250 µM) induced a slight and significant increase in the 
viability in mutant cells (Figure 3.2.6C,D). However, no significant changes in caspase-3-
like activity were observed after creatine or cystamine treatment in both striatal cell 
models (Figure 3.2.6E).  
In basal conditions neither creatine nor cystamine altered ROS levels in both 
striatal cell models (Figure 3.2.6F, G). Nevertheless, both 1 mM creatine and 250 µM 
cystamine significantly decreased ROS levels evoked by H2O2 (Figure 3.2.6H) or STS 
(Figure 3.2.6I) in mutant cells, suggesting a protection of these compounds against 
oxidative stress in HD striatal cells.  
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Figure 3.2.6 – Creatine and cystamine increase cell viability and protect from H2O2 or STS-
induced ROS formation in HD striatal cells. Creatine (0.1 and 1 mM) treatment did not affect 
wild-type cells viability (A), but increased mutant cells (B) viability, as assessed by alamar blue 
reduction assay. Cystamine (100 and and 250 µM) treatment did not alter wild-type cells viability 
(C) but cystamine (250 µM) increased mutant cells viability (D). (E) Caspase-3-like activity was 
not changed by 1 mM creatine or 250 µM in both striatal cells. Creatine (0.1 and 1 mM) (F) or 
cystamine (100 and 250 µM) (G) treatment during 24h did not influence ROS formation in both 
striatal cells under basal conditions. After exposure to 25 µM H2O2 (H) or 10 nM STS (I), during 
15h, 1 mM creatine and 0.25 mM cystamine decreased ROS formation in mutant cells. Data are 
the mean ± S.E.M. of 5 independent experiments. Statistical analysis: 
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ϕϕϕ
P<0.0001 by one-way ANOVA when comparing treated versus non-treated (control) cells; 
*
P<0.05 by two-way ANOVA when comparing mutant versus wild-type cells; 
#
P<0.05 and 
##
P<0.01 by two-way ANOVA when comparing treated versus non-treated cells; 
ɵ
P<0.05 and 
ɵɵ
P<0.01 by two-way ANOVA when comparing H2O2 or STS condition with creatine or 
cystamine plus H2O2 or STS conditions. 
3.2.4 Discussion 
In this study we analysed the formation of ROS and related defense systems 
against stress stimuli, H2O2 and STS. Striatal cells expressing mHtt presented higher ROS 
formation, namely O2
•–
, potentiated by H2O2 or STS through XO activity, and decreased
antioxidant profile. We also show that exposure to H2O2 or STS potentiated mHtt-induced 
O2
•–
 formation in mutant cells, but only STS was able to increase mitochondrial-driven
O2
•–
, indicating different cytotoxic mechanisms between H2O2 and STS. We previously
showed that O2
•– 
formation was higher in HD cybrid lines following exposure to 3-NP or
STS (Ferreira et al., 2010). Higher levels of peroxides were also detected in R6/1 mice 
striatum (Pérez-Severiano et al., 2004) and in whole brain of rats subjected to 3-NP 
(Túnez et al., 2006). 
Heightened NOX activity was described in human HD post-mortem cortex and 
striatum, and in cortical and striatal neurons and synaptosomes from HD(140Q/140Q) 
mice. Moreover, NOX was involved in striatal damage evoked by QA in adult rats 
(Maldonado et al., 2010). In contrast, we report that NOX activity is decreased in mutant 
cells, which is further decreased by H2O2 or STS. XO activity, another cytosolic producer 
of O2
•–
, was decreased in mutant cells, which could potentially equilibrate mitochondrial
O2
•–
 formation. Concordantly, uric acid levels were reduced in human HD cerebral cortex
(Beal et al., 1992). Here we further show that H2O2 or STS significantly increased XO 
activity in mutant cells, contributing for increased ROS formation.  
We previously reported that HD striatal cells exhibited features of intrinsic 
apoptosis (Ribeiro et al., 2012; Rosenstock et al., 2011). Caspase-3 activation can be 
triggered via the intrinsic mitochondrial apoptotic pathway, which was described to be 
activated in HD patients and in R6/2 HD mice (Kiechle et al., 2002). STS induced 
pronounced caspase-3 activation, compared with H2O2, which may be linked to STS-
evoked mitochondrial ROS generation, as cytochrome c release may cause ROS 
formation (Cai and Jones, 1998). Indeed, both mitochondrial and cytosolic ROS underlie 
STS-induced retinal cell death involving caspase-3 activation and DNA fragmentation 
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(Gil et al., 2003). Moreover, we showed that 10 nM STS induced cytochrome c and 
apoptosis-inducing factor (AIF) release and DNA fragmentation in STHdh
Q111/Q111
 cells
(Rosenstock et al., 2011). STS is a potent inhibitor of protein kinase C (PKC) (Tamaoki et 
al., 1986) (which is known to phosphorylate and promote the nuclear translocation of 
Nrf2), abrogating the expression of antioxidant and detoxifying proteins (e.g. Huang et 
al., 2002). Previous studies showed that treatment of STHdh
Q111/Q111
 cells with H2O2
enhanced the number of apoptotic and necrotic cells, and increased poly(ADP-ribose) 
polymerase (PARP) cleavage, a hallmark of apoptosis (Ruiz et al., 2012). H2O2 also 
induced caspase-independent apoptosis through AIF release in a PARP1-dependent 
manner in fibroblast cultures (Yu et al., 2002). Moreover, H2O2 was described to enhance 
mHtt-induced cell death and promote ubiquitin-labeled mHtt aggregates by decreasing 
proteasome activity (Goswami et al., 2006). 
Higher O2
•–
 formation in HD appears concomitantly with increased antioxidant
defenses. Increased total SOD and SOD1 activities were observed in 19 week–old R6/1 
mice, although older (35 week-old) mice exhibited decreased SODs activities (Santamaria 
et al., 2001), suggesting that a failure in antioxidant system occurred with disease 
progression in HD mice. On the contrary, SOD1 levels remained unchanged in HD 
patient’s brains (Sorolla et al., 2008). Interestingly, overexpression of SOD1 protected 
against H2O2-induced decrease in proteasome activity, and reduced mHtt aggregation and 
cell death (Goswami et al., 2006). We show increased SOD1/2 and total SOD activities in 
untreated mutant cells. SOD2 activity and protein levels were increased in both striatum 
and cortex of HD patients, evidencing an increase in antioxidant defenses as a result of 
mitochondrial ROS generation (Sorolla et al., 2008), as occurs in untreated mutant striatal 
cells. SOD2 mRNA was increased in the CN of HD patients, again suggesting a 
compensatory mechanism against higher ROS (Kim et al., 2010). Moreover, SOD2 
mRNA increased in the basal ganglia of R6/2 HD mice (Fox et al., 2004). Wild-type cells 
exhibited increased total SOD/SOD2 activities in response to stress stimuli, suggesting an 
adaptive response to stress of mitochondrial antioxidant defenses. In mutant cells 
subjected to STS, SOD1 activity increased significantly, probably in response to 
enhanced mitochondrial O2
•–
 levels, as SOD1 is also located in mitochondria.
Nevertheless, SOD2/total SOD activities remained unchanged after H2O2 or STS 
treatment in mutant cells, suggesting a defect in stress response and increased 
susceptibility of HD striatal cells. Increased ROS formation was reported to stimulate 
sirtuin (SIRT)3 transcription, causing SOD2 deacetylation and activation (Chen et al., 
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2011). However, SIRT3 protein levels were reduced in STHdh
Q111/Q111
 cells (e.g. Fu et al.,
2012), which may result in unchanged SOD2 activity in the presence of exogenous 
stressors. Interestingly, heterozygous SOD2 knockout (SOD2+/−) mice showed large 
striatal lesions produced by 3-NP (Andreassen et al., 2001), whereas upregulation of 
SOD2 was neuroprotective against 3-NP (Madhavan et al., 2008). 
Previously we showed increased glutathione levels despite decreased GCLc 
activity in HD striatal cells. We demonstrated that increased GSH was due to a decrease 
in the capacity of the Mrp1 to export GSH, along with increased ROS formation (Ribeiro 
et al., 2012). In agreement, the levels of mitochondrial GSH were increased in the 
striatum and cortex of R6/2 HD mice (Choo et al., 2005) and total GSH levels increased 
with age in R6/2 HD mice forebrain (Fox et al., 2004). Increased GSH was also detected 
in the striatum of 8-week old (early symptomatic) R6/2 HD mice (Tkac et al., 2007). In 
contrast, a decrease in GSH was observed in HD patient’s post-mortem brain cortex (Beal 
et al., 1992). Here we show that GSH levels increased in mutant cells after STS treatment; 
however, GSSG levels have risen in a great extent after STS and H2O2 exposure in mutant 
cells, indicating a high level of oxidation in HD cells. We previously demonstrated that 
the activity of enzymes of the glutathione redox cycle, GPx and GRed, was increased in 
mutant cells (Ribeiro et al., 2012). Concordantly, GPx1 transcription levels were 
increased in the same HD model (Lim et al., 2008), suggesting mHtt-induced stress 
response. Moreover, GPx1 and 6 were increased in the striatum of HD patients, and GPx 
and catalase activities were elevated in HD striatum and cortex (Sorolla et al., 2008). 
Here we show an increase in GPx activity in wild-type cells subjected to STS or H2O2, 
whereas GPx activity was only increased in mutant cells exposed to H2O2, indicating a 
lower ability of mutant cells to stimulate antioxidant activity when exposed to STS. In 
agreement with our data, an increase in GRed activity was found in HD patient’s 
erythrocytes (Zanella et al., 1980); also, increased GRed transcription was found in the 
basal ganglia of R6/2 HD mice (Fox et al., 2004), suggesting an induction at antioxidant 
defenses by mHtt. However, diminished GRed activity was observed after exposure to 
stress stimuli in mutant cells. Concordantly, QA administration in rats caused a loss of 
GRed activity (Cruz-Aguado et al., 2000). 
We also show that cystamine increased mutant cells viability and protected 
against H2O2 and STS-induced ROS formation in mutant cells. Cystamine may act as an 
antioxidant by increasing GSH levels. Indeed, cystamine increased the GSH and L-
cysteine, but not GSSG, in cells expressing mHtt (Fox et al., 2004). Furthermore, 
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cystamine protected against 3-NP lesions via induction of Nrf2 (Calkins et al., 2010); 
importantly, impaired Nrf2 signaling was recently described in STHdh
Q111/Q111
 cells (Jin
et al, 2013). By inhibiting TG2, cystamine protected from oxidative stress-induced cell 
death in cortical neurons (Basso et al., 2012). Additionally, cystamine may inhibit 
caspase-3 activity (Lesort et al., 2003) in a TG2-independent manner. Cystamine 
protected against H2O2-increased caspase-3 activation and increased glutathione levels in 
human neuroblastoma SH-SY5Y cells (Lesort et al., 2003). Nevertheless, we show that 
cystamine was not able to decrease caspase-3 activity in both striatal cells. A randomized, 
controlled double-blind multicenter phase II/III clinical trial of cysteamine (FDA-
approved reduced form of cystamine) for the potential treatment of HD is currently being 
conducted using BDNF as a biomarker (www.raptorpharma.com).  
Creatine also increased mutant cells viability and protected against H2O2 and STS-
induced ROS levels in mutant cells. Creatine can have direct antioxidant proprieties by 
decreasing 8-OHdG levels in serum of HD patients (Hersch et al., 2006), increasing GSH 
and decreasing MDA levels in rats treated with 3-NP (Yang et al., 2009). Moreover, 
creatine increased brain phosphocreatine, and protected against 3-NP-induced increase in 
lactate and 3-NT and decreased phosphocreatine and ATP levels (Matthews et al., 1998). 
Creatine is currently under phase III clinical trial for HD (clinicaltrials.gov). 
The present study shows that striatal cells expressing full-length mHtt exhibit high 
ROS, at least partially produced by mitochondria, and that exposure to H2O2 or STS 
potentiate oxidative stress by increasing XO activity and lowering the antioxidant 
response, namely SOD2 and GRed, the later promoting GSSG levels. Moreover, 
cystamine and creatine protected against H2O2 or STS-induced ROS formation in HD 
striatal cells. Thus, a better understanding of the mechanisms involved in this 
neuroprotection may contribute to delay striatal cell degeneration in HD. 
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3.3 Insulin and IGF-1 reduce mitochondrial-driven oxidative 
stress in Huntington’s disease knock-in striatal cells108 
3.3.1 Summary 
Oxidative stress and mitochondrial dysfunction have been described in HD, caused by 
expression of mHtt. We have previously shown that mHtt-induced enhanced glutathione 
redox cycle and that this antioxidant accumulates intracellularly due to decreased Mrp1 
activity. We also have shown that despite enhanced antioxidant activities, HD knock-in 
striatal cells presented lower response capacity to exogenous stressors, and that creatine 
and cystamine treatment prevented ROS formation. However, neither creatine nor 
cystamine were able to revert the effects provoked by mHtt. Therefore, taken into account 
that IGF-1 was previously shown to protect HD cells, whereas insulin prevented neuronal 
oxidative stress, in this work we analysed the role of insulin/IGF-1 in striatal cells derived 
from HD knock-in mice against ROS production and related antioxidant and signaling 
pathways. Insulin and IGF-1 decreased mitochondrial-driven ROS formation induced by 
mHtt, without changing superoxide dismutase 2 activity or glutathione (GSH and GSSG) 
levels. Insulin and IGF-1 promoted Akt and Erk phosphorylation, respectively, and 
increased nuclear levels of phosphorylated Nrf2; however, this was not correlated with 
Nrf2 transcriptional activity or changes in mRNA levels of Nrf2 target genes. Insulin and 
IGF-1 treatment also ameliorated mitochondrial function in HD cells. In the case of 
insulin, this occurred in a PI-3K/Akt-dependent manner, concomitantly with reduced 
caspase-3 activation evoked by mHtt. Hence, insulin and IGF-1 improve mitochondrial 
function and reduce mitochondrial-driven ROS caused by mHtt, along with differential 
stimulation of Akt and Erk, in a process independent of Nrf2 transcriptional activity.  
108 Based on the following manuscript submission: Ribeiro, M.; Rosenstock, T. R.; Cunha-Oliveira, T.; Ferreira, I. L.; 
Oliveira, C. R.; Rego, A. C. Insulin and IGF-1 reduce mitochondrial-driven oxidative stress in Huntington’s disease 
knock-in striatal cells. Free Radic Biol Med. 2014. 
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3.3.2 Introduction 
Elevated levels of DNA oxidation were previously detected in blood plasma, 
serum and leukocytes from HD patients (Chen et al., 2007; Hersch et al., 2006; Tunez et 
al., 2011) and in striatum and cortex of HD post-mortem tissues (Browne et al., 1997; 
Polidori et al., 1999; Shirendeb et al., 2011). Moreover, DNA oxidation markers were 
detected in the striatum, urine and plasma of R6/2 HD mice (Bogdanov et al., 2001). 
Increased lipid peroxidation markers were also detected in HD patient’s blood serum and 
plasma, correlating with disease severity (Chen et al., 2007; Stoy et al., 2005), in the 
striatum and cortex of post-mortem HD human brains (Browne et al., 1999; Lee et al., 
2011), and in total brain and striatum of R6/2 mice co-localizing with mHtt inclusions 
(Lee et al., 2011; Tabrizi et al., 2000). Indeed, intracellular aggregates of mHtt exon-1 
were directly linked to increased production of ROS, in a polyQ length-dependent 
manner, preceding cell death (Hands et al., 2011).  
Impairment in antioxidant defenses also underlies oxidative stress in HD. In 
erythrocytes from HD patients, GPx and SOD1 activities were decreased (Chen et al., 
2007). Moreover, proteomic analysis of HD post-mortem striatal and cortical brain 
samples revealed an induction of Prdx’s 1, 2 and 6 and GPx 1 and 6, along with increased 
activities of SOD2 and catalase (Sorolla et al., 2008). More recently, we demonstrated 
increased ROS formation and deregulated glutathione redox cycle in HD striatal cells 
(Ribeiro et al., 2012), which presented lower response capacity to exogenous stressors 
(Ribeiro et al., 2013).  
ROS formation in HD has been also attributed to impaired mitochondrial function. 
Evidences for mitochondrial dysfunction in HD include, among many other reports, 
decreased activity of mitochondrial complexes I-IV in caudate and putamen, and in 
muscle and platelets of HD patients (Ehrlich et al., 2012; Silva et al., 2013), reduced 
activities of complexes I, IV and V in progenitor and differentiated neuron-like 
STHdh
Q111/Q111
 cells (Napoli et al., 2013), or mitochondrial membrane depolarization and
decreased mitochondrial Ca
2+
 retention (Panov et al., 2002; Oliveira et al., 2006).
STHdh
Q111/Q111
 striatal cells also showed higher levels of mitochondrial ROS, mtDNA
damage and a lower spare respiratory capacity compared to wild-type cells (Siddiqui et 
al., 2012). Importantly, treatment with a mitochondria-specific antioxidant improved 
function in isolated mitochondria from HdhQ150 knock-in mice and restored the mtDNA 
copy number in vivo to levels similar to the controls (Xun et al., 2012). These results 
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suggest oxidative stress-induced mitochondrial abnormalities upon expression of mHtt. 
Moreover, mHtt binding at the outer mitochondrial membrane was demonstrated in 
mitochondria from YAC72 transgenic mice, STHdh
Q111/Q111
 striatal cells and in mouse
liver mitochondria, inducing MPT pore opening (Panov et al., 2002; Choo et al., 2004). 
Neuronal survival largely depends on growth factors through activation of kinases, 
namely Akt. IGF-1 levels are decreased in HD mutant striatal cells, in human HD striatal 
post-mortem tissues and in plasma of 11 week-old R6/2 mice (Pouladi et al., 2010). IGF-
1-mediated Akt activation was previously described to be neuroprotective in HD and to 
reduce nuclear inclusions through phosphorylation of mHtt at Ser421 (Humbert et al., 
2002); moreover, activation of Akt was described to reflect early striatal pro-survival 
response in HD knock-in HdhQ111 mice and STHdh
Q111/Q111 
cells (Gines et al., 2003).
Furthermore, we recently showed that intranasal administration IGF-1 in YAC128 HD 
mice activated Akt and concomitantly increased phosphorylation of mHtt on Ser421 
(Lopes et al., 2013). We also showed that peripheral administration of IGF-1 protected 
against HD-associated impaired glucose tolerance, namely by enhancing blood insulin 
levels in R6/2 mice (Duarte et al., 2011), and that intranasal administration of IGF-1 
enhanced IGF-1 cortical levels and improved motor activity and both peripheral and 
central metabolic abnormalities in YAC128 HD mice (Lopes et al., 2013). We also 
demonstrated that insulin (which shares structural and signaling properties with IGF-1) 
protects against oxidative stress in cortical neurons through Akt activation (Duarte et al., 
2008). Interestingly, insulin was described to induce expression of GCLc through the 
transcription factor Nrf2 (Langston et al., 2008), directly interfering with cellular 
antioxidant profile in endothelial cells. Importantly, impaired Nrf2 signaling pathway was 
recently described in striatal STHdh
Q111/Q111 
cells
 
(Jin et al., 2013).
In this work we examine the role of insulin and IGF-1 on mitochondrial ROS 
generation and depolarization, and Nrf2 transcriptional activity related with antioxidant 
profile in HD knock-in striatal cells. We show that insulin and IGF-1 increase Akt and 
Erk activation and nuclear levels of phosphorylated Nrf2, as well as heighten 
mitochondrial function, precluding mitochondrial ROS formation induced by mHtt. 
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3.3.3 Results 
3.3.3.1 Insulin and IGF-1 prevent increased ROS generation in HD 
mutant striatal cells 
ROS levels in striatal cells were assessed with the fluorescent redox probe 
H2DCFDA, which can be oxidized by ROS, including ONOO−, 

OH or hypochlorous
acid, among other oxidants, and redox-active metals such as iron (Kalyanaraman et al., 
2012). A significant increase in DCF fluorescence was observed in HD knock-in striatal 
cells expressing full-length mHtt (STHdh
Q111/Q111 
or mutant cells), when compared to
STHdh
Q7/Q7
 cells (wild-type cells) (Figure 3.3.1A,B), largely suggesting enhanced ROS
production.  
Since IGF-1 expression levels are largely decreased in mutant striatal cells 
(Pouladi et al., 2010), and both insulin (Duarte et al., 2005; 2006; 2008) and IGF-1 
(Duarte et al., 2011; Humbert et al., 2002; Lopes et al., 2013) were neuroprotective 
following oxidative stress or expression of mHtt, respectively, we determined the effect 
of both insulin and IGF-1 on ROS formation in STHdh
Q111/Q111
 cells. Due to structural
and functional homology, insulin and IGF-1 can bind to (and activate) both IR and 
IGF1R, with insulin binding to the IR with higher affinity (< 1 nM) than IGF-1 (100–500-
fold lower affinity), whereas IGF1R preferentially binds IGF-1 (< 1nM) as compared to 
insulin (100–500-fold lower affinity) (Rechler et al., 1980); therefore, striatal cells were 
exposed to insulin or IGF-1 in the low nM range (0.1-10 nM). Interestingly, both insulin 
and IGF-1 significantly precluded ROS generation in mutant cells (Figure 3.3.1A,B).  
We also measured the levels of mitochondrial O2
−
 using MitoSOX Red, a TPP
cation conjugated with hydroethidine, which may readily react with O2
−
 (Robinson et al.,
2008), although it may also non-specifically oxidize (Kalyanaraman et al., 2012). 
Importantly, a significant increase in mitochondrial O2
−
 (Figure 3.3.1C) was observed in
mutant cells, when compared to wild-type cells. Mitochondrial O2
−
 production in mutant
cells was further revealed with DHE following exposure to rotenone (complex I inhibitor) 
or antimycin A (complex III inhibitor) (Figure 3.3.1D), thereby confirming increased 
susceptibility to mitochondrial ROS. When exposed to insulin or IGF-1, mutant cells 
presented a significant decrease in mitochondrial O2
−
 formation (Figure 3.3.1C).
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These data show that both insulin and IGF-1 (at low nM) protect from mHtt-
induced oxidative stress, by precluding ROS production and in particular mitochondrial 
O2
−
 formation.
Because caspase-3 activation was previously observed in HD striatal cells (Lim et 
al., 2008; Ribeiro et al., 2012; Rosenstock et al., 2011), we determined the effect of 
insulin and IGF-1 on caspase-3 activation in mutant versus wild-type cells. Insulin (0.1 
nM) significantly protected against caspase-3 activation induced by expression of mHtt 
(Figure 3.3.1E). 
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Figure 3.3.1 – Insulin and IGF-1 protects from ROS formation and caspase-3 activation in HD 
striatal cells. ROS formation, measured using (A,B) H2DCFDA, (C) MitoSOX Red and (D) DHE, 
increases in mutant cells, compared to wild-type cells, whereas treatment with (A) insulin or (B) 
IGF-1 (0.1-10 nM) during 24h precludes ROS formation in mutant cells. (C) Mitochondrial and 
(D) total intracellular O2
−
 formation rises in mutant cells, which is prevented by (C) 0.1 nM
insulin or IGF-1 (24h) and exacerbated by (D) mitochondrial complex I (rotenone) and III 
(antimycin A) inhibitors (10 µM, for 1h). (E) Caspase-3 activity is prevented by insulin treatment 
(0.1 nM) in mutant cells. Data are the mean ± S.E.M. of 3-6 independent experiments. Statistical 
analysis: 
ttt
P<0.0001 when comparing mutant versus wild-type cells by Student’s t-test; *P<0.05, 
**
P<0.01 and 
***
P<0.0001 by two-way ANOVA for multiple groups using Bonferroni as post-hoc 
test, when comparing mutant versus wild-type cells; or 
##
P<0.01, 
###
P<0.0001 by two-way 
ANOVA when comparing treated versus non-treated (control) cells. 
3.3.3.2 Full-length mHtt modifies SOD1/2, GCLc and glutathione levels 
– influence of insulin and IGF-1
In order to examine whether higher ROS levels in mutant cells were due to 
alterations in antioxidant activities, we determined SOD1/2 activities and protein levels. 
A significant increase in SOD2 activity was observed in total cell extracts from mutant, 
compared to wild-type cells (Figure 3.3.2A), suggesting a compensatory mechanism 
against higher levels of O2
−
. Concordantly, SOD2 activity was increased in
mitochondrial fractions from mutant cells (Figure 3.3.2B). Since SOD2 can be acetylated 
at Lys68 leading to a decrease in its activity (Chen et al., 2011), we measured the 
acetylation levels of SOD2 in striatal cells. In agreement with increased SOD2 activity, 
we detected a decrease in Ac-SOD2/SOD2 ratio in mutant cells (Figure 3.3.2C). 
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However, a decrease in SOD2 protein levels were also verified in mutant cells (Figure 
3.3.2D). Although IGF-1 increased SOD2 protein levels in mutant cells (Figure 3.3.2D), 
neither insulin nor IGF-1 significantly changed SOD2 acetylation in mutant cells (Figure 
3.3.2C). We also observed an increase in total (Figure 3.3.2E) and mitochondrial (Figure 
3.3.2F) SOD1 activities, however no differences in SOD1 protein levels were detected in 
mutant versus wild-type cells (Figure 3.3.2G). These results indicate that increased ROS 
caused by expression of full-length mHtt largely correlate with increased SOD1 and 2 
activities and that treatment with insulin or IGF-1 do not interfere with SOD2 activity. 
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Figure 3.3.2 – Enhanced SOD1 and 2 activities in HD striatal cells. (A) Total and (B) 
mitochondrial SOD2 activities are increased, correlating with decreased (C) 
Ac(Lys68)SOD2/SOD2 ratio in mutant cells; (C) 0.1 nM insulin or IGF-1 treatment (24h) does 
not affect Ac(Lys68)SOD2/SOD2 ratio, but (D) 0.1 nM IGF-1 increases SOD2 protein levels in 
mutant cells. (E) Total and (F) mitochondrial SOD1 (Cu/Zn-SOD) activities increases 
significantly in mutant cells, but (G) SOD1 protein levels do not change in mutant, compared to 
wild-type cells. Data are the mean ± S.E.M. of 3-4 independent experiments. Statistical analysis: 
t
P<0.05, 
tt
P<0.01 and 
ttt
P<0.0001 by Student’s t-test comparing mutant versus wild-type cells; 
*
P<0.05, 
**
P<0.01 and 
***
P<0.0001 by two-way ANOVA when comparing mutant versus wild-
type cells;
 ##
P<0.01 by two-way ANOVA when comparing treated versus non-treated (control) 
cells. 
We previously showed that the activity of enzymes of the glutathione redox cycle 
were enhanced, whereas GCL and GS activities and protein levels of GCLc were 
decreased in HD mutant striatal cells (Ribeiro et al., 2012). Therefore, in the present 
study, we determined the effect of insulin and IGF-1 on GCLc protein levels by western 
blotting. A significant decrease in GCLc levels were observed in mutant cells, when 
compared to wild-type cells (Figure 3.3.3A,B). Furthermore, treatment with 0.1 nM 
insulin increased GCLc levels in mutant cells, whereas IGF-1 (0.1-1 nM) increased GCLc 
levels in wild-type cells only, compared to non-treated conditions (Figure 3.3.3A,B).  
We further demonstrated a rise in glutathione levels in mutant cells despite 
decreased GCL activity (Ribeiro et al., 2012). Therefore, we tested if insulin or IGF-1 
could change GSH and GSSG levels. Despite an increase in GCLc levels in mutant cells 
induced by insulin, neither insulin nor IGF-1 altered GSH or GSSG levels in mutant cells 
(Figure 3.3.3C,D); nevertheless, insulin slightly increased GSH and GSSG levels in wild-
type cells (Figure 3.3.3C,D). These data suggest that insulin ameliorate GCLc protein 
levels, although not affecting GSH or GSSG levels in cells expressing mHtt. 
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Figure 3.3.3 – Insulin increases GCLc protein levels in mutant cells. (A,B) GCLc protein levels 
decrease but (C) GSH and (D) GSSG levels increase in mutant compared to wild-type cells. 0.1 
nM insulin (24h-treatment) rises (A) GCLc protein levels in mutant cells and (C) GSH and (D) 
GSSG levels in wild-type cells. 0.1 and 1 nM IGF-1 treatment (24 h) increase (B) GCLc protein 
levels in wild-type cells, but not in mutant cells, and do not change (C) GSH or (D) GSSG levels 
in both striatal cells. Data are the mean ± S.E.M. of 4 independent experiments. Statistical 
analysis: 
*
P<0.05, 
**
P<0.01 and 
***
P<0.0001 by two-way ANOVA when comparing mutant 
versus wild-type cells; 
#
P<0.05 and 
##
P<0.01 by two-way ANOVA when comparing treated 
versus non-treated (control)
 
cells. 
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3.3.3.3 Insulin and IGF-1 enhance phosphorylated Nrf2 nuclear levels, 
but do not affect its transcriptional activity in HD striatal cells 
We have previously shown that despite enhanced antioxidant activities, HD 
knock-in striatal cells presented lower response capacity to H2O2 or STS, which might be 
due to decreased activation of antioxidant enzyme transcription (Ribeiro et al., 2013). In 
order to evaluate whether antioxidant response was induced by insulin and/or IGF-1, we 
analysed the levels of the transcription factor Nrf2, which is responsible for the 
transcription of many antioxidant enzymes, including SOD1 and GCLc, and thus is 
directly implicated in cellular detoxifying systems (Langston et al., 2008; Nakaso et al., 
2003). Human Nrf2 contains 605 amino acids with a predicted relative molecular mass 
(Mr) of 66 kDa (57 kDa in mice). However, it was shown that transcription and 
translation of the full-length Nrf2 cDNA produces a band at 66 kDa and a higher Mr band 
at approximately 96 kDa, likely due to the abundance of acidic residues in Nrf2 (Moi et 
al., 1994). Lau and collaborators (2013) have recently reported that the biologically 
relevant Mr of Nrf2 ranges from ~95-110 kDa. Therefore, in our experiments we 
quantified the Nrf2 Mr band between ~95-110 kDa. Phosphorylated p-(Ser40)-Nrf2 in 
total cell fractions did not differ significantly between both cell types (wild-type and 
mutant) (Figure 3.3.4A). However, under basal conditions, cellular Nrf2 levels decreased 
significantly in mutant cells (Figure 3.3.4B). Moreover, in nuclear-enriched fractions 
derived from mutant cells, p-Nrf2 levels decreased (Figure 3.3.4C), relatively to wild-
type cells. Decreased nuclear p-Nrf2 by full-length mHtt suggests reduced efficiency of 
the antioxidant defense system through inhibition of gene transcription, most likely 
promoting cellular ROS generation (Figure 3.3.1). Indeed, Nrf2 transcriptional activity 
decreased significantly in mutant cells when compared to wild-type cells (Figure 3.3.4D). 
Incubation with 0.1 nM insulin or IGF-1 in wild-type cells significantly increased cellular 
Nrf2 levels (Figure 3.3.4B) and insulin further enhanced Nrf2 activity (Figure 3.3.4D). 
Moreover, in mutant cells nuclear p-Nrf2 levels were rescued by insulin or IGF-1 (Figure 
3.3.4C). Despite this, insulin did not change Nrf2 transcriptional activity in mutant striatal 
cells (Figure 3.3.4D). 
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Figure 3.3.4 – Insulin and IGF-1 increase nuclear levels of phosphorylated Nrf2 in mutant cells. 
Striatal cells were treated with 0.1 nM insulin or IGF-1 during 24h for determination of cellular 
(A) p-(Ser40)Nrf2 and (B) Nrf2 levels and nuclear (C) p-(Ser40)Nrf2 levels and (D) Nrf2/ARE 
transcriptional activity by the luciferase reporter assay. (A) Cellular levels of p-Nrf2 are not 
changed, but decreased (B) cellular Nrf2, (C) nuclear p-(Ser40)Nrf2 levels and (D) Nrf2 
transcriptional activity are observed in mutant, compared to wild-type cells. 0.1 nM insulin 
increases (B) total Nrf2 levels and (D) transcriptional activity, but decreases (C) nuclear p-
(Ser40)Nrf2 levels in wild-type cells; insulin increases (C) nuclear p-(Ser40)Nrf2 levels in mutant 
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cells only. 0.1 nM IGF-1 increases (C) nuclear p-(Ser40)Nrf2 levels in mutant cells, but does not 
alter cellular (A) p-(Ser40)Nrf2 or (B) Nrf2 levels in both striatal cells. Results are the mean ± 
S.E.M. of 4-7 independent experiments. Statistical analysis: 
*
P<0.05 and 
***
P<0.0001 by two-way 
ANOVA when comparing mutant versus wild-type cells; 
#
P<0.05, 
##
P<0.01 and 
###
P<0.0001 by 
two-way ANOVA when comparing treated versus non-treated (control) cells. 
p-Nrf2 is known to translocate to the nucleus where it activates the transcription of 
genes involved in antioxidant defense, including GCLc, NQO1, HO-1, among others 
(Nakaso et al., 2003). In order to further examine the importance of Nrf2 in regulating the 
oxidant status in mutant cells, we determined the levels of mRNA of some Nrf2 targets, 
namely GCLc, NQO1 and HO-1 under basal conditions and after exposure to insulin and 
IGF-1 (Figure 3.3.5). In agreement with the decrease in nuclear p-Nrf2, Nrf2 
transcriptional activity and GCLc protein levels in untreated mutant cells, we observed a 
significant reduction in GCLc mRNA levels in HD knock-in cells, when compared to 
wild-type cells (Figure 3.3.5A). Nevertheless, no significant changes were observed upon 
treatment with 0.1 nM insulin or IGF-1 (Figure 3.3.5B), in accordance with the 
inefficiency of insulin to promote Nrf2 transcriptional activity (Figure 3.3.4D). No 
significant changes in NQO1 and HO-1 mRNA levels were detected in untreated mutant 
versus wild-type cells or after exposure to insulin or IGF-1 either (Figure 3.3.5C,D,E,F).  
Our data indicate that although insulin and IGF-1 induced translocation of p-Nrf2 
to the nucleus in mutant cells, its activity and the transcription of related proteins was not 
changed, suggesting that insulin- and IGF-1-induced protection against ROS formation in 
HD striatal cells is independent of Nrf2-regulated antioxidant response. 
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Figure 3.3.5 – Decreased mRNA levels of GCLc in mutant cells. 0.1 nM insulin or IGF-1 
treatment during 24h was tested for analysis of mRNA levels of (A,B) GCLc, (C,D) NQO1, and 
(E,F) HO-1 in striatal cells. Decreased (A) GCLc without changes in (C) NQO1 or (E) HO-1 
mRNA levels are verified in mutant versus wild-type cells. 0.1 nM insulin and IGF-1 (24h) do not 
significantly affect (B) GCLc, (D) NQO1 or (F) HO-1 mRNA levels in both striatal cells. Data are 
expressed as the mean ± S.E.M. of 3-7 independent experiments. Statistical analysis: 
t
P<0.05 by 
Student’s t-test comparing mutant versus wild-type cells.  
3.3.3.4 Insulin prevent mitochondrial depolarization via PI-3K/Akt 
pathway 
Because insulin and IGF-1 are able stimulate intracellular signaling pathways, we 
next investigated an upstream pathway of cell transcription and survival. We measured 
total and phosphorylated levels of Akt, and Erk42/44 in the absence or presence of 0.1 
nM insulin or IGF-1 (Figure 3.3.6). In the present work we analysed p-(Thr308)Akt, 
phosphorylated by PDPK1, since it was described to better correlate with Akt protein 
kinase activity (Vincent et al., 2011). 
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Expression of mHtt per se significantly decreased the ratio of phosphorylated p-
(Thr308)Akt/total Akt, total Akt/actin and p-(Thr202/Tyr204)Erk(42/44)/total Erk(42/44) 
(Figure 3.3.6A,B,C), largely suggesting decreased activation of both PI-3K/Akt and 
MEK/Erk signaling pathways. On the other hand, Erk(42/44) levels were only slightly 
affected in mutant cells (see representative blot in Figure 3.3.6C), as the increase in 
Erk(42/44)/tubulin levels (Figure 3.3.6D) were largely due to the decrease in tubulin 
levels in mutant cells, compared to wild-type cells; notably, tubulin was used as a loading 
control for normalizing Erk(42/44) protein levels because Erk and actin have similar Mr. 
Exposure to 0.1 nM insulin, but not 0.1 nM IGF-1, significantly increased Akt 
phosphorylation (p-(Thr308)Akt/Akt), whereas total Akt levels did not change with either 
insulin or IGF-1 stimuli in mutant cells (Figure 3.3.6A,B). On the other hand, 0.1 nM 
IGF-1 significantly increased p-Erk(42/44)/Erk(42/44) in both striatal cells, whereas 0.1 
nM insulin did not significantly affect p-Erk(42/44)/Erk(42/44) ratio (Figure 3.3.6C). 
These results suggest that insulin and IGF-1 may differentially regulate pro-survival 
responses in mutant striatal cells by activating Akt and Erk, respectively. 
Taking into account that insulin and IGF-1 protected from mitochondrial O2
−
formation induced by expression of mHtt (Figure 3.3.1), we next tested whether insulin 
and IGF-1 influenced mitochondrial function. ΔΨm, measured using TMRM+ after
complete depolarization with FCCP plus oligomycin, was decreased by almost 50% in 
mutant cells when compared to wild-type cells (Figure 3.3.6E), revealing higher 
mitochondrial depolarization induced by mHtt. Insulin (0.1 nM) significantly increased 
ΔΨm and IGF-1 ameliorated the changes observed in mutant cells (Figure 3.3.6E). These 
data showed that insulin and IGF-1 improve mitochondrial function, which appears to be 
in accordance with the decrease in mitochondrial ROS formation observed in HD striatal 
cells (Figure 3.3.1C). 
Because insulin induced the activation of Akt and significantly decreased 
mitochondrial depolarization, compared to untreated mutant cells, we further tested if the 
PI-3K/Akt pathway was involved in improving mitochondrial function of mutant cells, by 
testing the effect of LY294002 (25 µM), a highly selective inhibitor of PI-3K (Vlahos et 
al., 1994). We observed that insulin-evoked increase in ΔΨm was completely abrogated 
by LY294002 (Figure 3.3.6F), whereas non-significant tendencies were observed in the 
case of IGF-1. Thus, insulin largely improves mitochondrial function through the PI-
3K/Akt pathway in HD mutant cells. 
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Figure 3.3.6 – Insulin and IGF-1 promote Akt and Erk activation, and insulin increases 
mitochondrial transmembrane potential (ΔΨm) in HD striatal cells. Striatal cells were treated with 
0.1 nM insulin or IGF-1 during 24h for determination of (A) p-(Thr308)Akt/Akt, (B) Akt/actin, 
(C) p-(Thr202/Tyr204)Erk1/2, and (D) Erk/tubulin ratio and analysis of mitochondrial 
transmembrane potential (ΔΨm) with TMRM+ (E,F). Decreased (A) p-(Thr308)Akt/Akt, (B) 
Akt/actin, and (C) p-(Thr202/Tyr204)Erk1/2, increased (D) Erk/tubulin and decreased (E) 
mitochondrial transmembrane potential (ΔΨm) are verified in mutant cells. 0.1 nM insulin 
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significantly increases (A) p-(Thr308)Akt/Akt ratio and (E,F) mitochondrial transmembrane 
potential (ΔΨm) in mutant cells, and decreases (D) Erk/tubulin ratio in wild-type cells, without 
changing (B) Akt/actin, and (C) p-(Thr202/Tyr204)Erk1/2 ratio in both striatal cells. IGF-1 (0.1 
nM) increases (C) p-(Thr202/Tyr204)Erk1/2, and decreases (D) Erk/tubulin ratio, without altering 
(A) p-(Thr308)Akt/Akt or (B) Akt/actin ratio in both striatal cells; (E,F) mitochondrial 
transmembrane potential (ΔΨm) is ameliorated by IGF-1 in both striatal cells. Exposure to 25 µM 
LY294002, a PI-3K/Akt inhibitor, 30 min before insulin or IGF-1 treatment during 24h 
significantly blocks elevated (D) mitochondrial transmembrane potential (ΔΨm) induced by 0.1 
nM insulin in mutant cells. Data are the mean ± S.E.M. of 4 independent experiments. Statistical 
analysis was performed by one-way or two-way ANOVA for multiple groups using Bonferroni as 
post-test: 
*
P<0.05, 
**
P<0.01 and 
***
P<0.0001 when comparing mutant versus wild-type cells; 
#
P<0.05 and 
##
P<0.01 when comparing treated versus non-treated (control) cells; 
§§§
P<0.0001 
when comparing insulin versus LY294002 plus insulin treatment in mutant striatal cells. 
3.3.4 Discussion 
In this study we show that treatment of striatal cells expressing full-length mHtt 
with insulin and IGF-1 stimulate Akt and Erk pathways, respectively, which may promote 
phosphorylated Nrf2 in the nucleus, a transcription factor that acts at the ARE regulating 
the expression of detoxifying and antioxidant genes. Nevertheless, insulin-mediated rise 
in GCLc protein levels was not accompanied by enhanced Nrf2 transcriptional activity, 
GCLc mRNA or glutathione levels in mutant cells. Importantly, insulin and IGF-1 
decreased mitochondrial-driven ROS formation and mitochondrial depolarization induced 
by mHtt. In the case of insulin, rescued mitochondrial function was dependent on PI-
3K/Akt pathway, which may further underlie protection against mHtt-evoked caspase-3 
activity. 
In HD striatal cells we showed increased mitochondrial generation of ROS, 
accompanied by increased activities of SOD1/2, which was confirmed by reduced SOD2 
acetylation. An increase in SOD activity was previously observed in R6/1 HD mice at 19 
weeks of age, although older mice exhibited decreased SOD activity (Santamaria et al., 
2001). Reduced activity of SOD1 was observed in cortex and cerebellum of post-mortem 
human brain tissues (Browne et al., 1997) and in erythrocytes (Chen et al., 2007) of HD 
patients. Interestingly, insulin- and IGF-1-induced protection against ROS formation in 
HD striatal cells was independent of changes in SOD2 activity. In a previous study we 
demonstrated increased ROS levels and a decrease in GCLc activity, despite increased 
glutathione levels in HD striatal cells, which occurred as a result of a lower capacity of 
Mrp1 to export GSH to the extracellular space (Ribeiro et al., 2012). While insulin 
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moderately enhanced GCLc protein levels in mutant striatal cells, no changes in GCLc 
mRNA were observed and glutathione levels remained unchanged, largely suggesting that 
ROS protection induced by insulin is also independent on glutathione antioxidant 
response. Moreover, the transcription of other Nrf2-target genes, such as HO-1 and 
NQO1, was not affected either. Surprisingly, this occurred despite insulin and IGF-1-
induced translocation of phosphorylated Nrf2 to the nucleus in mutant cells. In contrast to 
van Roon-Mom and collaborators (2008), we did not detect activation of Nrf2-responsive 
genes upon expression of mHtt under non-stimulated conditions. Indeed, p-Nrf2 nuclear 
levels were decreased in HD knock-in striatal cells, underlying reduced ARE 
transcriptional activity and thus decreased mRNA and protein levels of GCLc. In 
agreement with our data, the striatum of the NLS-N171-82Q transgenic mice showed 
reduced levels of Nrf2 (Chaturvedi et al., 2010). Moreover, neurons derived from Nrf2 
KO mice were greatly sensitive to mitochondrial complex II inhibitors (Calkins et al., 
2005), used to model mitochondrial dysfunction in HD. In the present study, although 
insulin/IGF-1 could act as indirect antioxidants in HD cells via increased translocation of 
phosphorylated Nrf2 to the nucleus, the peptide was not able to affect ARE transcriptional 
activity. Acetylation of Nrf2 by CBP was previously described to increase Nrf2 promoter-
specific DNA binding (Sun et al., 2009). Therefore, we hypothesize that insulin or IGF-1 
may not be able to increase Nrf2 acetylation and promote its activity and/or may not 
efficiently bind to ARE due to the presence of mHtt in the nucleus. 
We previously showed that HD striatal cells exhibit features of intrinsic apoptosis 
(Rosenstock et al., 2011). Enhanced caspase-3 activation has been linked to increased 
mitochondrial ROS formation. Indeed, we showed that there is a close interplay between 
endogenous ROS generation and caspase-3 activation in apoptotic neurons (Ferreira et al., 
2010; Gil et al., 2003). Interestingly, although both insulin and IGF-1 prevented ROS 
generation in mutant cells, only insulin was able to significantly prevent caspase-3 
activation in cells expressing mHtt. This may account for by differential activation of pro-
survival signaling pathways in knock-in HD striatal cells exposed to insulin or IGF-1. In a 
previous study we demonstrated that insulin (at higher concentrations, potentially acting 
on IR and IGF1R) can act as an antioxidant in cortical neurons, under conditions 
involving Akt activation and GSK3-β inhibition (Duarte et al., 2005; 2008). In 
unstimulated HD knock-in striatal cells showed reduced activation of MEK/Erk1/2 and 
PI-3K/Akt signaling pathways, which were stimulated by and IGF-1 and insulin, 
respectively. Erk was previously described to protect against mHtt toxicity (Apostol et al., 
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2006); thus, decreased Erk activation in mutant cells may contribute to increase mHtt 
cytotoxicity. In agreement with our work, STHdh
Q111/Q111
 cells displayed significant
decreased p-Erk/Erk (Sarantos et al., 2012). Decreased p-Erk levels were also observed in 
the striatum of 8-week old R6/2 HD mice (Fusco et al., 2012). Reduced Akt was 
previously reported in HD patients, appearing as a shorter inactive caspase-3-cleaved 
form (Colin et al., 2005; Humbert et al., 2002). Corroborating our study, p-
(Ser473)Akt/Akt levels were significant decreased in STHdh
Q111/Q111
 cells (Maglione et
al., 2010), in HEK293 cells expressing mHtt with 68 CAG repeats (Nagata et al., 2011) 
and in HD patient’s lymphoblasts and lymphocytes (Colin et al., 2005). Akt activation is 
an early pro-survival striatal response in knock-in HdhQ111 mice and STHdh
Q111/Q111
cells (Gines et al., 2033); importantly, activation of IGF-1/Akt pathway caused Htt 
phosphorylation at Ser421, decreasing mHtt nuclear inclusions and mHtt toxicity 
(Humbert et al., 2002), further regulating anterograde and retrograde transport defects in 
HD cortical neurons (Zala et al., 2008). Another study demonstrated that p-(Ser473)Akt 
was unchanged in YAC128 and in R6/2 HD mice, but the levels of p-(Ser421)Htt were 
decreased in the striatum of YAC128 HD mice and in cells expressing mHtt (Warby et 
al., 2005). In contrast, IRS-2, which activates PI-3K/Akt and mTOR cascade, promoted 
mitochondrial dysfunction and oxidative stress in R6/2 mice (Sadagurski et al., 2011). In 
this respect, plasma IGF-1 was correlated with cognitive decline in HD patients (Saleh et 
al., 2010). However, reduced IGF-1 mRNA was demonstrated in striatum and skin 
fibroblasts of HD patients and HD knock-in striatal cells (Pouladi et al., 2010). Moreover, 
IRS-2 was reported to be necessary for the elimination of mutant exon1htt aggregates. 
IRS-2 knockdown inhibited aggregate clearance, while IRS-2 activation induced by 
insulin, IGF-1 and interleukin-4 enhanced exon1htt clearance in a dose-dependent manner 
(Yamamoto et al., 2006). Additionally, we previously showed that IGF-1 rescued 
peripheral metabolic abnormalities linked to diabetes in R6/2 mice (Duarte et al., 2011), 
and recently, we also showed that intranasal administration of recombinant human IGF-1 
(rhIGF-1) for 2 weeks, in order to promote IGF-1 delivery to the brain, enhanced IGF-1 
cortical levels and improved motor activity and both peripheral and central metabolic 
abnormalities in YAC128 HD mice. Moreover, rhIGF-1 administration in YAC128 HD 
mice activated Akt and concomitantly increased phosphorylation of mHtt on Ser421, 
suggesting that intranasal administration of rhIGF-1 ameliorates HD-associated glucose 
metabolic brain abnormalities and mice phenotype (Lopes et al., 2013). Moreover, insulin 
stimulated neuronal glucose metabolism, restoring phosphocreatine and ATP levels upon 
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oxidative stress in primary cortical neurons (Duarte et al., 2006). These data are 
consistent with the stimulation of Akt and Erk signaling in insulin and IGF-1-treated HD 
striatal cells. 
Mitochondria of HD striatal cells were recently described to be altered and more 
vulnerable to oxidative stress (Jin et al., 2013). Indeed, elevated mitochondrial O2
−
generation in HD knock-in striatal cells has been linked to mitochondrial dysfunction 
(Milakovic and Johnson, 2005; Quintanilla et al., 2008). In HD striatal neurons, ROS 
formation may be a consequence of mitochondrial dysfunction through defects of 
mitochondrial respiratory complexes (Lim et al., 2008), which occur very early in disease 
progression, as recently shown by us (Silva et al., 2013). Indeed, the striatum is highly 
susceptible to dysfunction of mitochondrial oxidative phosphorylation (Pickrell et al., 
2011). ROS formation in HD can further damage mitochondria, by dissipating the ΔΨm, 
dysregulating ATP production and leading to oxidation of mtDNA (Acevedo-Torres et 
al., 2009; Polidori et al., 1999; Siddiqui et al., 2012), which is highly vulnerable to 
oxidative damage due to its proximity to the respiratory chain, limited repair mechanisms, 
few non-coding sequences and lack of histones (Richter et al., 1988). We have previously 
shown that O2
−
 formation also rises in HD human cybrids following exposure to 3-NP or
STS (Ferreira et al., 2010). In this work, insulin and IGF-1 decreased mitochondrial O2
−
formation in mutant cells. Interestingly, we also showed that insulin and IGF-1 improve 
mitochondrial function, evaluated through increased ΔΨm, which was largely PI-3K/Akt-
dependent in cells exposed to insulin. Interestingly, it was previously described that Akt 
can accumulate in mitochondria in its active state (Bijur and Jope, 2003) and this 
accumulation is dependent on the activity of heat shock protein 90 (Hsp90) (Barksdale 
and Bijur, 2009). Although the role of Akt in mitochondria is not well understood, active 
mitochondrial Akt has been shown to be neuroprotective (Mookherjee et al., 2007). In 
hepatocytes lacking PTEN which is an endogenous inhibitor of PI-3K/Akt pathway, 
activation of PI-3K/Akt pathway by IGF-1 induced anaerobic glycolysis and 
mitochondrial respiration (Li et al., 2013). Activated Akt is translocated to mitochondria, 
where it phosphorylates α and β subunits of ATP synthase leading to its activation. 
Furthermore, Akt translocation to mitochondria was associated with increased expression 
and activity of complex I (Li et al., 2013). Therefore, a better knowledge about the role of 
Akt in mitochondria of HD striatal cells might be essential to describe the role of insulin 
on mitochondrial function. 

Chapter 4 – Conclusions 
and Future Perspectives 
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In the first part of our work we showed that striatal cells expressing full-lenght 
mHtt exhibit raised antioxidant defense profile through increased activity of the 
glutathione redox cycle and related metabolic enzymes, namely GST and -GT, despite 
decreased GSH synthesis. Interestingly, our work gives evidence that decreased 
expression and activity of Mrp1 results in decreased release of glutathione, leading to its 
intracellular accumulation (Figure 4.1). Although this is apparently insufficient to prevent 
oxidative stress and apoptotic features, it may result from an attempt of HD striatal cells 
that do not exhibit massive cell death or visible mHtt aggregates to counterbalance initial 
generation of ROS evoked by mHtt.  
Figure 4.1 – Increased glutathione redox cycle in HD knock-in striatal cells. Despite decreased 
activities of glutamate-cysteine ligase (GCL) and glutathione synthetase (GS), both involved in 
the synthesis of glutathione, the levels of reduced (GSH) and oxidized (GSSG) forms of 
glutathione are significant increased in HD knock-in striatal cells, concomitantly with increased 
reactive oxygen species (ROS), including hydrogen peroxide (H2O2) levels, and increased 
activities of glutathione peroxidase (GPx), reductase (GRed), S-transferase (GST), γ-glutamyl 
transpeptidase (-GT), and glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate 
dehydrogenase (6PGD) which are essential to produce NADPH, a cofactor used by GRed in the 
regeneration of GSH.  
In the second part of our work we showed that striatal cells expressing full-length 
mHtt exhibit high ROS formation, at least partially produced by mitochondria, and that 
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exposure to H2O2 or STS potentiate oxidative stress by increasing XO activity and 
lowering the antioxidant response, namely SOD2 and GRed, the later promoting 
increased GSSG levels. Moreover, cystamine and creatine protected against H2O2 or STS-
induced ROS formation in HD striatal cells (Figure 4.2). Thus, a better understanding of 
the mechanisms involved in this neuroprotection may contribute to delay striatal cell 
degeneration in HD. 
Figure 4.2 – Increased vulnerability of striatal cells expressing mHtt to exogenous stressors and 
the protective effect of cystamine and creatine. Exposure to noxious stimuli, staurosporine (STS) 
and hydrogen peroxide (H2O2), resulted in the exacerbation of mutant huntingtin (mHtt)-induced 
reactive oxygen species (ROS) formation and caspase-3 (Casp3) activation. STS and H2O2 
exposure in mutant cells also decreased glutathione reductase (GRed) activity and increased the 
levels of the oxidized form of glutathione (GSSG) with minor changes in glutathione peroxidase 
(GPx), superoxide dismutase (SOD) 1 and 2 activities and in the levels of the reduced form of 
glutathione (GSH), indicating lower capacity of striatal cells expressing mHtt to reduce oxidative 
damage provoked by exogenous stress. mHtt expression also induced decreased activities of 
NADPH oxidase (NOX) and xanthine oxidase (XO) which were differentially affected by H2O2 or 
STS exposure. H2O2 and STS treatments exacerbated mHtt-induced decreased NOX activity, 
whereas XO activity was enhanced by the exogenous stressors. Creatine and cystamine treatment 
did not affect caspase-3 activity, but decreased ROS formation after exposure to H2O2 and STS. 
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In the third and last part of our work, we showed that expression of full-length 
mHtt promotes mitochondrial-driven oxidative stress, associated to compensatory 
enhanced SOD1/2 activities. Insulin and IGF-1 (at low nM) activated intracellular 
signaling pathways, Akt and Erk, respectively, and nuclear phosphorylated Nrf2 levels, 
but not its transcriptional activity. Insulin and IGF-1 further decreased mitochondrial 
ROS production and decreased mitochondrial depolarization in HD striatal cells. Insulin 
also induced cytoprotection through decreased caspase-3 activation, which might be due 
to its positive effect on mitochondria occurring through the PI-3K/Akt pathway (Figure 
4.3). This work shows differential cellular effects exerted by insulin and IGF-1 under low 
nM concentrations, suggesting that insulin and/or IGF-1-mediated intracellular signaling 
pathways may constitute important therapeutic targets for pharmacological intervention 
as a way to ameliorate mitochondrial function and decrease oxidative stress and apoptotic 
features in HD.  
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Figure 4.3 – Insulin and IGF-1 induces protection against mitochondrial-driven oxidative stress 
in HD knock-in striatal cells. (A) Under basal conditions, mutant huntingtin (mHtt) induces 
decreased phosphorylation and activation of protein kinase B (Akt) and extracellular-signal-
regulated kinase 1/2 (Erk1/2), which can be both activated via stimulation of insulin receptor (IR) 
and/or insulin-like growth factor 1 (IGF-1) receptor (IGF1R). Also, Nrf2 phosphorylated levels, 
which can be dependent on Akt or Erk1/2 activities, are decreased in the nucleus of HD striatal 
cells, which correlated with decreased Nrf2-antioxidant response element (ARE) activity and 
decreased expression of the Nrf2-ARE target genes glutamate-cysteine ligase (GCL) (involved in 
the synthesis of the reduced form of glutathione (GSH)) and superoxide dismutase (SOD) 2, but 
not SOD1. Despite decreased Nrf2 activation and GCL and SOD2 expression, GSH levels and 
SOD1 and 2 activities are increased, but this is not sufficient to decrease mitochondrial reactive 
oxygen species (ROS) formation, to ameliorate the changes in mitochondrial membrane potential 
(ΔΨm), or to reduce caspase-3 (Casp3) activation upon expression of mHtt. (B) Insulin treatment 
induces Akt activation, increases nuclear phosphorylated levels of Nrf2 and total levels of GCL, 
reduces mitochondrial ROS formation, increases mitochondrial membrane potential (ΔΨm), and 
reduces caspase-3 activity, without changing GSH or GSSG levels and SOD2 activity in HD 
striatal cells. (C) IGF-1 treatment induces Erk1/2 activation, increases nuclear phosphorylated 
levels of Nrf2 and total levels of SOD1, reduces mitochondrial ROS formation, without changing 
GSH and GSSG levels, or SOD2 and caspase-3 activities. 
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In summary, in this work we demonstrate that striatal cells expressing mHtt 
exhibit enhanced ROS formation mainly via mitochondria, altered activities and levels of 
antioxidant defense systems, and decreased antioxidant response to exogenous stressors 
which may be correlated with impaired Nrf2 activation. Despite mHtt-induced decrease in 
Nrf2/ARE activation, HO-1, NQO1, and G6PD mRNA, and SOD1 protein levels were 
not changed; conversely, GCLc and Mrp1 mRNA, and also GCL and SOD2 protein 
levels, which expression is also regulated by Nrf2, were decreased following expression 
of mHtt. Therefore, it would be interesting to test the specificity of Nrf2 for these genes in 
the striatal cells and in the context of mHtt expression and evaluate whether other 
transcription factors may be involved in regulating the expression of these proteins in HD 
cells or tissues derived from HD transgenic mice (e.g. YAC128 or R6/2 mice). On the 
other hand, SOD2 activity was increased despite decreased protein levels, as revealed by 
a decrease in SOD2 acetylation at Lys68 (K68), which is a target residue for the 
mitochondrial NAD-dependent deacetylase SIRT3 (e.g. Chen et al., 2011; Qiu et al., 
2010). Indeed, SIRT3 protein levels were reduced in STHdh
Q111/Q111
 cells (Fu et al.,
2012), which may contribute to decrease SOD2 acetylation and thus increase SOD2 
activity. Moreover, G6PD and SOD1 activities were increased in mutant cells; however, 
no changes were observed in mRNA or protein levels, respectively. It is known that Src 
tyrosine kinase phosphorylates G6PD, enhancing its activity (Pan et al., 2009). Therefore, 
analysis of Src levels and activity (by following its phosphorylation) would be relevant 
upon expression of mHtt, and measurement of G6PD phosphorylated levels and activity 
after both silencing or overexpressing Src would reveal how G6PD activity might be 
regulated in HD cells. Relatively to SOD1, it was previously described that SOD1 can be 
phosphorylated at Thr-2 and -58, and at Ser-59 (by unknown kinase(s)); however it was 
not shown how phosphorylation may affect SOD1 activity. SOD1 is also glutathionylated 
at Cys111, which promotes SOD1 dimer dissociation, resulting in its decreased activity 
(Wilcox et al., 2009). Thus, it would be interesting to measure SOD1 glutathionylated and 
phosphorylated levels upon expression of mHtt. Moreover, we observed reduced 
activities of GCL (and also GS) and Mrp1, which are involved in the control of the 
glutathione system, oppositely contributing for a decrease in GSH synthesis or an 
increase in intracellular accumulation of GSH, respectively, in mutant striatal cells. 
Indeed, increased GSH levels seemed to boost both -GT and GST activities, although 
cellular detoxification associated with the formation of GSH conjugates with toxic 
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products might be compromised due to decreased Mrp1, potentially accumulating toxins 
intracellularly. Another feature that involves Mrp1 is the decrease in extracellular GSH 
levels, which might result in lower extracellular antioxidant capacity to decrease damage 
at the external part of cell membrane and also decrease the uptake of L-cysteine (which is 
essential for GSH biosynthesis) by neighboring cells. Therefore, and in order to determine 
whether mHtt affects cysteine uptake in striatal cells, it would be relevant to measure 
extracellular L-cysteine levels and uptake, and also the activities and levels of the 
excitatory amino acid carrier 1 (EAAC1) (mediates the cysteine uptake in cells) and 
cystine/glutamate antiporter (Xc-) (mediates the oxidized form of cysteine (cystine) 
uptake in cells), which can be both regulated by Nrf2. As a result, the overall cell defense 
appears to be largely compromised by mHtt expression. In fact, exposure to stress stimuli, 
such as H2O2 and STS, interfered with an adequate response of the antioxidant systems, 
potentiating ROS formation and cell death in striatal cells expressing mHtt.  
We also observed that cell survival signaling pathways, namely Akt and Erk, were 
decreased by mHtt, which might contribute for a decrease in Nrf2 activation and 
consequent decreased transcription of target genes. However, the mechanism that leads to 
Akt and Erk inactivation still needs to be investigated. In this respect, IR and IGF1R 
expression levels and activities, as well as PI-3K, and PDPK1 activities could be affected 
in mutant striatal cells. Moreover, both Akt and Erk were described to be targets for 
oxidative or nitrosative modifications, leading to protein kinase inactivation (Durgadoss 
et al., 2012; Feng et al., 2013); thus, we might verify if mHtt expression induces oxidative 
changes in both proteins. In the present study we showed that insulin and IGF-1 induced 
the activation of Akt and Erk, respectively, and increased nuclear phosphorylated Nrf2; 
however, this was not accompanied by increased activity of Nrf2/ARE, nor by a 
consequent rise in mRNA levels of target genes. Nevertheless, insulin and IGF-1 
protected against ROS formation, mitochondrial dysfunction and cell death. Indeed, 
inhibition of PI-3K/Akt pathway blocked insulin-induced protection against 
mitochondrial depolarization; nonetheless the specific mechanism(s) involved in such 
protection still need to be investigated. Therefore, it would be interesting to analyse the 
levels of total and phosphorylated Akt induced by insulin in isolated mitochondrial 
fractions. Recently, Akt was described to phosphorylate subunits of ATP synthase, 
increasing its activity (Li et al., 2013), thus analysis of phosphorylated levels of Akt-
target subunits of ATP synthase, in the presence or absence of insulin and also in the 
presence of a specific Akt inhibitor would help to complement this study. Moreover, it 
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was previously reported that Akt phosphorylates mHtt on Ser421, decreasing its toxicity 
(Humbert et al., 2002), and that mHtt interacts with mitochondria, leading to the 
formation of mitochondrial mHtt aggregates, increasing mitochondrial fission, MPT pore 
opening and contributing for the occurrence of intrinsic apoptotic cell death pathway, and 
impaired vesicular and mitochondrial fast axonal trafficking (see Chapter 1.2.3.3). 
Therefore, determining whether phosphorylation of mHtt Ser421 could affect its direct 
interaction with mitochondria and consequent mitochondrial destabilization and function, 
by mutating Ser421 to Asp (mimicking the phosphorylated residue) or Ala (to mimick the 
non-phosphorylated form) on mHtt would rather complement our study.  
Additionally, we observed protection of striatal cells expressing mHtt following 
treatment with GSHee, creatine or cystamine. GSHee and also insulin treatment were able 
to revert the effects of mHtt expression per se on ROS formation and caspase-3 activity, 
whereas creatine and cystamine offered protection against ROS formation when the cells 
were exposed to stress stimuli only. IGF-1 treatment also offered protection against ROS 
formation, which may be due to its capacity to increase Erk1/2 activation and SOD2 
protein levels. However, in previous studies higher plasma IGF-1 levels were shown to 
correlate with cognitive decline in HD patients (Saleh et al., 2010). In another study 
plasma IGF-1 levels were shown to be reduced in HD patients compared with controls 
(Mochel et al., 2007), and IGF-1 mRNA levels were reduced in the striatum an in skin 
fibroblasts from HD patients (Pouladi et al., 2010); moreover, plasma IGF-1 levels 
correlated with decreased body weight in R6/2 HD mice (Pouladi et al., 2010). 
Importantly, we previously showed that IGF-1 rescued peripheral metabolic abnormalities 
linked to diabetes in R6/2 mice (Duarte et al., 2011), and recently, we showed that 
intranasal administration of recombinant human IGF-1 (rhIGF-1) improved motor activity 
and both peripheral and central metabolic abnormalities in YAC128 HD mice (Lopes et 
al., 2013). Therefore, treatment with IGF-1 at low doses may be highly relevant and 
protective to the striatum.  
Considering that the model used in our work represents initial stages of HD, our 
results indicate that oxidative stress might be an early feature of the disease. Indeed, this 
may constitute an important biomarker of disease progression that can be tested by using 
YAC128 HD transgenic mice at different ages, namely at presymptomatic versus 
symptomatic stages, and follow striatal specific alteration of proteins investigated in this 
study.  
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In conclusion, our results defined new targets and strategies for investigation of 
mHtt-induced striatal neurodegeneration demonstrating that insulin or IGF-1 treatment 
might be benefic against striatal cytotoxicity induced by mHtt. Therapeutics targets 
include the overexpression of Mrp-1 to regulate glutathione levels, the selective activation 
of Nrf2 to protect against mHtt-induced oxidative damage and the stimulation of 
insulin/IGF-1 intracellular signaling pathways, which may ameliorate mitochondrial 
function and decrease oxidative damage in HD. Taking into account present and previous 
studies, it would be relevant to conduct further studies that might support evaluating the 
tolerability and efficacy of intranasal insulin or IGF-1 treatments in HD patients. While 
intravenous application of insulin is a highly invasive technique that leads to 
hypoglycemia, which itself has detrimental effects on brain function (Freiherr et al., 
2013), clinical trials have demonstrated that intranasal insulin improves both memory 
performance and metabolic integrity of the brain in patients suffering from Alzheimer’s 
disease or its prodrome, mild cognitive impairment. Additionally, creatine and cystamine 
have been tested in HD clinical trials and may be used as preventive treatments 
(clinicaltrials.gov; http://www.raptorpharma.com) by precluding oxidative stress. 
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"It is good to have an end to journey toward; but 
it is the journey that matters, in the end” 
Ernest Hemingway 
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